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REPORTABLE OUTCOMES 
The data, troubleshooting procedures, and research findings presented in this 
dissertation have achieved or directly contributed to: 
 elucidation of the effects of fluorophore bulkiness and substrate length on the 
proteolytic cleavage and MMP selectivity of designed MMP substrates with 
FRET-paired fluorophores for optical sensing of MMP activity. 
 modification and application of an inhibitor titration assay using GM6001 
tight binding inhibitor of MMPs to characterize active MMP concentrations. 
 development of a robust synthesis scheme for solid phase synthesis of FRET-
equipped substrate peptides with attachment of folic acid to N-termini and 
functional groups at C-termini for bioconjugation with nanoparticles. This 
strategy is adaptable to the production of any number of peptides with no 
fewer than 4 covalent attachment sites for linking to fluorophores, 
therapeutics, targeting ligands and/or particles or surfaces. Such peptides may 
be designed as substrates for any proteolytic enzymes of interest by modifying 
the central primary amino acid sequence. 
 reporting on the modification of the optical properties of TAMRA dye by 
exposure to 2% hydrazine solution or para-phenylenediamine (pPDA), 
rendering the modified TAMRA unsuitable for FRET with fluorescein-based 
dyes at physiologic pH. 
 elucidation of the causes for interference with bioconjugation chemistry for 
attaching FRET peptides to nanoparticles or surfaces including absence of 
vi 
 
functional groups, modification of functional groups by chemical adducts, and 
steric hindrance of the reaction. A strategy to overcome these interferences 
was designed and executed successfully. 
 successful conjugation of folate-linked,  FRET-equipped MMP substrate 
peptides to PAMAM nanoparticles to produce folate-targeted proteolytic 
nanobeacons (FTPNBs) and subsequent validation of the MMP-
responsiveness of FTPNBs. 
 preliminary in vitro characterization of the dependence of cellular 
internalization of FTPNBs on folate-targeting and MMP activation. 
 development of a new cell line variant of MDA-MB-468 human metastatic 
breast cancer cells expressing decreased levels of folate receptor, i.e. 40-75% 
of control. 
 development of methods to manipulate folate receptor expression in cells by 
culture in folate-deficient medium and to assess folate binding capacity by 
indirect flow cytometry. 
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CHAPTER I 
 INTRODUCTION 
It goes almost without saying that cancer, a group of over 200 different diseases that 
are classified as malignant neoplasms, presents a world health concern that demands the 
attention of biomedical researchers and clinicians. These diseases altogether comprise the 
second leading cause of death in the United States trailing heart disease by less than one 
percent and outpacing the next most prevalent cause by nearly eighteen percent
1
. The 
death rate due to cancer is not declining as quickly as heart disease
1
, though, and may 
therefore become the overall most common cause of death in the near future. This is 
especially concerning as the average life expectancy continues to increase
1
, and deaths 
from cancer are more prevalent in persons over age 45
2
. Excluding basal cell and 
squamous cell skin cancers and most in situ carcinomas, an estimated 1.66 million new 
cancer diagnoses and 586,000 cancer deaths will be counted in 2014 in the United States 
alone
3
. 
Many of these cancer cases will present as solid tumor malignancies in bodily organ 
tissues such as breast, prostate, lung, colon, kidney, or liver, among others. Despite 
success stories of modern chemotherapies and even newer molecularly-targeted 
treatments for some hematologic malignancies such as imatinib (marketed by Novartis 
Pharmaceuticals as Gleevec) for chronic myelogenous leukemia
4
, equally effective 
chemotherapeutic interventions for most non-resectable solid tumors have remained 
elusive. The anatomies and physiologies of these dysplastic growths present significant 
challenges to treatment, often owing to difficulty in selectively delivering diagnostic or 
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cytotoxic reagents to tumors primarily because they arise by clonal evolution from 
normal cells and tissues. The ultimate goal in cancer chemotherapy is the specific 
eradication of malignant cells while sparing normal ones. However, despite the currently 
available menu of tumoricidal compounds, many chemotherapy approaches fail to halt or 
reverse tumor progression due to dose-limiting off-target or systemic toxicities. Even 
targeted therapies have failed in this respect either because of a lack of true tumor 
specificity, ineffective delivery to solid tumors, or both. For example, monoclonal 
antibodies, which may have great specificity and affinity for a biomarker of interest, 
succumb to the physiological barriers that prevent systemic delivery of many potentially 
therapeutic agents to tumors. Studies have found that systemically administered 
antibodies fail to accumulate in solid tumors, resulting in tumor retention of less than 1% 
of the injected dose in rodents and less than 0.01% in humans
5,6
. As explained by Dvorak 
et al, the target tumor cells are generally some distance removed from leaky tumor blood 
vessels, separated by stromal cells and other tumor cells that collectively constitute 
significant barriers to tumor penetration by extravasated monoclonal antibodies
5
. 
Therefore a global research objective must be to understand and exploit the emergent 
properties of tumor cells and the solid tumor microenvironment. Mortality from cancer is 
strongly associated with metastatic disease rather than with primary lesions. For example, 
the 5-year survival rate of women diagnosed with localized breast cancer is 99% whereas 
for women diagnosed with distant metastases this rate is only 24%
3
. But which molecules 
are important at which stages of tumor progression and metastasis? Are these molecules 
clinically relevant therapeutic targets? Such questions have provided the impetus for 
entire fields of cancer and disease research that have provided vast amounts of 
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knowledge in recent decades about the biomolecular mechanisms of carcinogenesis and 
cancer progression. An improved understanding of who, what, and when with respect to 
biomarker expression, cellular secretions, enzymatic activities, and host-tumor 
interactions in the tumor microenvironment is leading to development of new strategies 
to target diagnostic and therapeutic agents to solid tumor malignancies. 
I.1. MATRIX METALLOPROTEINASES IN CANCER RESEARCH  
The first of the strategies our research seeks to employ in order to target solid tumors 
is to exploit the proteolytic activities of tumor-associated matrix metalloproteinases 
(MMPs). MMPs are a family of at least 24 different zinc-dependent endopeptidases, 
altogether capable of degrading all components of the extracellular matrix (ECM) as well 
as other cell surface substrates important in tumor progression
7,8
. Likely because of their 
great diversity of substrates and the roles of MMPs in normal physiology such as 
embryogenesis, tissue remodeling, angiogenesis, inflammation, and wound healing, 
MMPs are tightly regulated at multiple biological levels. Transcription of MMP genes is 
modulated by transcription factors downstream of extracellular and intracellular signaling 
networks which are in some cases themselves influenced by MMP activity
9
. Upon 
transcription and translation, MMPs are expressed as zymogens requiring proteolytic 
processing to become active and exert their own specific proteolytic activities
10
. These 
enzymes are then further regulated by an endogenous class of inhibitors known as tissue 
inhibitors of metalloproteinases (TIMPs)
10
. Interestingly, TIMPs also have roles in 
facilitating the activation of MMPs, such as activation of pro-MMP2 by the complex of 
MMP14 and TIMP-2
10,11
. Given the myriad intermolecular interfaces and regulatory 
components involved, it is not surprising that dysregulation or altered expression of 
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MMPs is associated with many different disease states including atherosclerosis
12
, 
arthritis
13
, emphysema
14
, and cancer 
15,16
. 
The expression patterns and enzymatic activities of MMPs have been used to 
distinguish benign from malignant tumors and to identify aggressive tumors associated 
with poor outcome, as reviewed extensively elsewhere
15,17
. Identification of the ECM-
degrading functions of MMPs and association of MMP expression with invasion and 
metastasis in some malignancies led to rapid development and clinical testing of small 
molecule matrix metalloproteinase inhibitors (MMPIs) in the 1990s. The unexpected and 
disappointing failure of most MMPI clinical trials, particularly those employing non-
selective MMPIs, resulted in the abandonment of MMPs as therapeutic targets by many 
pharmaceutical companies, though it also gave researchers pause to develop new 
perspectives about the roles of MMPs in cancer. MMP experts have since posited that 
perhaps the most important roles for MMPs in tumor progression have not to do with 
ECM degradation but instead with the plethora of other substrates and signaling cascades 
with which MMPs interact
8,18,19
. Furthermore, different MMP family members have been 
shown to have either positive or negative prognostic significance in different diseases at 
various phases of tumor development
19,20
. In combination with follow-up studies that 
indicated that treatment with marimastat could improve survival of an appropriately 
selected population of gastric cancer patients
21
, these insights suggest that MMPs may yet 
be viable therapeutic targets in the diagnosis and treatment of cancer. A better 
understanding of which MMPs play what roles at which stages of disease progression, 
along with development of reagents that are selective for those enzymes, is imperative in 
the development of effective anti-cancer therapies. However, in vivo assessment of the 
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efficacy of MMPIs both as inhibitors of MMPs and as tumor cell cytostatic agents has 
been a challenge. The lack of appropriate endpoints and surrogate markers was criticized 
following reports of the MMPI clinical trial outcomes
18,19
. In the time since, though, 
advances in biomedical and molecular imaging in parallel with bioconjugate chemistry 
have shown a promising potential to develop tools that enable the requisite measurement 
of MMP activity and response to therapy in vivo. 
The development of probes to noninvasively visualize and quantify MMP activity in 
vivo has steadily progressed for over a decade, now encompassing several imaging 
modalities including optical imaging
22–28
, magnetic resonance imaging (MRI)
29,30
, 
positron emission tomography (PET)
31–33
, and single-photon emission computerized 
tomography (SPECT)
34
, as reviewed by Scherer et al (2008)
35
. Importantly, in 2001 
following the development of a protease-activated near-infrared (NIR) fluorescent 
probe
28
, Bremer et al were the first to demonstrate optical detection of MMP activity in 
vivo using a probe that allowed visualization of MMP2 inhibition in response to treatment 
with Prinomastat
26
. Also of interest are the optical MMP probes that were developed by 
Tsien et al to include a latent polycationic cell penetrating peptide to effect cellular 
internalization of attached payloads following activation by MMPs
25,36
. 
An important limitation of the first MMP imaging probes was the inability to 
quantitatively measure the specific enzymatic activity of MMPs. To address this issue, 
our laboratory developed dendrimer-based MMP-responsive fluorogenic macromolecules 
referred to as proteolytic beacons (PBs)
37
. A distinct advantage introduced in these 
probes was the inclusion of a “reference” fluorophore that quenches the sensor 
fluorophore by intramolecular Förster Resonance Energy Transfer (FRET), but also 
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fluoresces with an emission distinct from the sensor. This enabled semi-quantitative 
measurement of MMP activity by assessment of the sensor-to-reference fluorescence 
emission ratio (S/R), as proteolytic activation by MMPs disrupts FRET, resulting in 
dequenching and dramatic increase in emission of the sensor fluorophore while emission 
from the reference fluorophore remains relatively unchanged
37
. PBs employing this 
design were further developed by our laboratory and applied to in vivo and ex vivo 
measurement of MMP7 activity in mouse models of colon cancer by optical imaging of 
“PB-M7NIR” (structure shown in Figure I-1)24. 
 
Figure I-1: Structure of PB-M7NIR
24
 
A Cy5.5 optical sensor is linked via AHX to the N-terminus of the matrix 
metalloproteinase-selective cleavable peptide (RPLA*LWRS, cleavage site denoted by an 
asterisk) that is coupled via a second AHX and cysteine with the PAMAM. The internal 
reference, AF750, of PB-M7NIR is linked directly to the dendrimer (Starburst PAMAM 
dendrimer, Generation 4). The structure is not drawn to scale. Figure reproduced with 
permission
24
. 
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While PBs of this design have clearly demonstrated the ability to assess tumor-
associated MMP7 activity in vitro
24,37,38
 and in vivo
24
, they leave room for adaptation and 
further development. As alluded to above, a growing body of evidence suggests that the 
contributions of the various MMPs are tissue-, disease-, and stage-specific (reviewed 
elsewhere
15,19,20
), suggesting that proteolytically-activated diagnostics and therapeutics 
could be customized to best combat specific malignancies. In theory, PBs can be 
modified for selectivity of any protease of interest (e.g. another MMP) by substituting the 
appropriate amino acid sequence in the structure of the substrate peptide that tethers the 
sensor fluorophore to the dendrimer. An MMP family member that has attracted much 
attention particularly in the study of metastatic disease is MT1-MMP (also known as 
MMP14), so-named because it is the first identified member of a subfamily of MMPs that 
is membrane-bound, exerting its proteinase activity at the cell surface as opposed to being 
secreted into the surrounding ECM. MMP14 undergoes proteolytic processing in the 
trans-Golgi complex prior to trafficking to the cell surface in active form, providing 
spatial restrictions on substrate recognition and possibly affording protection from 
circulating proteinase inhibitors
11,39,40
. Nonetheless, MMP14 has demonstrated 
processing of diverse substrates including collagens types I-IV, fibronectin, vitronectin, 
laminin, fibrin, proteoglycan, some chemokines and downstream secreted proteinases 
such as proMMPs (2, 8, and 13)
11,20,40
. Importantly, MMP14 expression has been 
reported to correlate with the malignancy of various tumor types and is thought to be an 
essential mediator of cell migration, invasion, and expansion of solid tumors through 
ECM
41,42
. It has been shown to concentrate at the leading edges of various migrating 
cells
39,41
 and has been demonstrated to contribute to migration of MCF-7 breast cancer 
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cells on vitronectin
43
. Furthermore, invasive potential can be reconstituted in non-
invasive COS cells by expressing MT1-MMP, even in the absence of downstream MMPs 
(MMP2 and MMP13), resulting in degradation of type I collagen, invasion of three-
dimensional type I collagen gels, and traversing of a chick chorioallantoic membrane 
39,40
. Hotary et al found that MMP14 modulated invasive and morphogenic responses 
requiring remodeling of type I collagen matrices by stimulated Madin-Darby canine 
kidney epithelial (MDCK) cells, whereas secreted MMPs did not
42
. Taken together, a 
plethora of published data suggests that MMP14 plays a critical role in conferring cells 
with invasive and metastatic properties in-vivo via remodeling and penetrating of 
extracellular matrix (ECM) barriers and processing of multiple classes of extracellular 
molecules. MMP14 therefore presents an attractive target for enzyme-activated selective 
delivery of therapeutic and imaging agents to malignant tumor cells. 
A limitation of the aforementioned design of PBs is the lack of a tumor cell-specific 
uptake mechanism for intracellular delivery of imaging or therapeutic agents released by 
proteolytic activation. Various targeting ligands such as transferrin, riboflavin, Arg-Gly-
Asp (RGD) and other peptides, carbohydrates such as mannose, and folic acid have been 
employed for endocytic delivery of macromolecular compounds to tumor cells, as 
reviewed elsewhere
44–46
. Interestingly, Tsien et al very recently reported that dual 
targeting of MMP2 activity and integrin αvβ3 via an RGD motif to expose a latent 
nonspecific cell penetrating peptide (CPP) was successful at amplifying tumor targeting 
beyond levels attained by either mechanism alone
47
.We hypothesized that attachment of 
an appropriately chosen ligand to the terminus of a substrate peptide distal to the 
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nanobeacon core could enable selective internalization of PB cleavage products by tumor 
cells. 
I.2. FOLATE TARGETING IN CANCER CHEMOTHERAPY 
As a second strategy working in conjunction with proteolytic activation by MMPs, 
our research focused on the incorporation of folic acid (FA) as a tumor cell-selective 
targeting ligand in the design of modified PBs. The α- and β- isoforms of the folate 
receptor (FR) are glycosylphosphatidylinositol-anchored membrane proteins involved in 
the endocytosis of FA and its analogues. Because naturally occurring folates are vitamins 
required for de novo synthesis of nucleotides including thymidine and purines as well as 
the amino acid methionine, folate metabolism is a critical process during rapid cycles of 
cell division and growth such as those of proliferating tumor cells
48,49
. This pathway has 
been understood and exploited for chemotherapy since the introduction of aminopterin, 
an antifolate, in 1947 by Dr. Sidney Farber who is also known as the “Father of Modern 
Chemotherapy”. The research conducted by Farber and his colleagues demonstrated that 
aminopterin could induce remission in childhood leukemias
50,51
. Antifolates are 
analogues of folic acid that act as inhibitors, several of which bind the intracellular 
enzyme dihydrofolate reductase (DHFR) to prevent the processing of folic acid to a 
necessary intermediate form for nucleotide synthesis and effectively halt cell replication. 
Methotrexate and pemetrexed, a more recently developed antifolate, are currently 
prescribed as adjuvant therapies for malignancies including breast, lung, head and neck 
cancers, non-Hodgkin lymphoma, osteosarcoma, bladder cancer, and choriocarcinoma
52
. 
While many antifolates face limitations with respect to systemic delivery to tumors 
because they are endocytosed by the ubiquitously expressed reduced folate carrier (RFC) 
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protein, development of modified antifolates and folate conjugates with improved tumor 
selectivity is ongoing
52
. Folic acid is not internalized by the RFC, but rather by the 
isoforms of FR, which exhibit a much more favorable expression pattern for selective 
delivery to tumor cells. 
Increased significance of FR-α as a tumor marker was discovered in 1991 when a 
protein enriched on the surface of a human ovarian carcinoma cell line was shown by 
amino acid analysis to be FR
53,54
. In the time since, many studies have yielded a wealth of 
literature regarding FR and folate-targeting of directed therapeutic and imaging agents
55–
63
. FR-α is now recognized as an established tumor marker with elevated expression in 
many epithelial cancers but limited or negligible expression in normal tissues. One study 
of normal and malignant tissues showed that 86% of primary human breast carcinomas 
tested showed appreciable levels of FR
54
, while other studies reported that FR over-
expression was associated with poor patient outcomes as measured by recurrence and 
overall survival rates in cancers of the breast
64
 and colon
65
. 
Probably the most significant advantage to emerge from studies of FR-mediated 
delivery has been the surprisingly low level of toxicity to normal tissues. Studies by 
Leamon et al. indicate that folate-targeted drugs that fail to bind FR are rapidly (t
1/2
 < 10 
min) excreted via the kidneys, reducing nonspecific delivery and contributing to patient 
convenience during administration
66
. Nonetheless, the concern persists that FR is 
expressed in some normal tissues such as brain, lung and especially kidney
49,66,67
. In each 
case though, the FR expression is limited to the apical membrane of polarized epithelial 
cells
54
, unavailable to folates in systemic circulation. It is well known that FR is present 
on the proximal tubule cells of human and mouse kidney tissue, and in fact folate-
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targeted imaging agents are readily observed in the kidneys
49,68
. However, data suggests 
that captured folate-conjugates in the kidneys do not harm the proximal tubules because 
they are endocytosed at the apical cell surface and then transported in endocytic vesicles 
to the basolateral side of the epithelium
69
. Thus, the kidney FR appears to serve as a 
salvage receptor that captures folate (and its drug conjugates) in the urinary filtrate and 
transcytoses the vitamin back to the blood
54,67
. 
In addition to the favorable expression pattern of FR, several properties of the FA 
molecule itself make folate-targeting of solid tumors attractive. FA is small (441 Da) and 
innately non-immunogenic, facilitating its rapid and complete penetration of solid tumors 
without induction of an adverse immune or inflammatory reaction
67
. A quantitative 
analysis of folate biodistribution in vivo revealed that essentially every cell in a breast 
malignancy was bathed by FA-linked imaging agent within minutes of intravenous 
injection
66
, corroborating the ability of FA conjugates to diffuse throughout a solid tumor. 
FR has high affinity (Kd ~ 0.1-1.0 nM) for FA and therefore relatively low doses of 
folates are sufficient to saturate the folate binding capacity of FR-expressing cells
48,66
. 
Previous studies have shown that attachment of large macromolecules to FA has not 
significantly reduced this affinity (for a review of such conjugates, see Xia and Low, 
2010
70
).  
A variety of folate-conjugated imaging and therapeutic agents have already been 
developed
55–58,60,61,68,71–77
 and have been extensively reviewed elsewhere
49,66,70
. 
Importantly, several have shown efficacy in vitro and most have displayed improved 
potency with reduced toxicity when tested in vivo. In fact, at least four folate-targeted 
therapeutics have proceeded to human clinical trials (phase II) and several folate-targeted 
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imaging agents are in pre-clinical development. One folate-targeted imaging agent, 
99m
Tc-EC20, has been introduced into the clinic, where as of 2008 it had been used to 
image more than 200 cancer patients and showed excellent agreement with computerized 
tomography (CT) scans with no reports of adverse events
66
. The same company that 
produces 
99m
Tc-EC20 recently reported that its folate-vinca alkaloid drug conjugate 
(vintafolide)  in combination with docetaxel extended overall survival (OS) for patients 
with FR-positive recurrent non-small cell lung cancer (NSCLC) compared to patients 
receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial
78
. 
Together with the biochemically amenable properties of FA and significance of FR in 
many solid tumor malignancies, these results suggest that folic acid is an attractive 
molecule for extending the design of PBs to include a targeting ligand that may enable 
selective intracellular delivery of PB cleavage fragments to tumor cells. Interestingly, 
Vlahov and Leamon, among the foremost experts in the field of folate-targeted therapies, 
recently concluded that enzymatically cleavable folate conjugates represent an area of 
future potential for delivery to cancer cells
79
. 
I.3. RATIONAL DESIGN OF NANOPARTICLES FOR DELIVERY IN SOLID TUMORS 
While targeting of tumor-associated MMP activity and folate receptor expression is 
intended to provide selective imaging and delivery by PBs in the tumor 
microenvironment, one must also consider the ability of PBs to reach and accumulate in 
solid tumors or metastases via systemic delivery. The failure of even targeted 
chemotherapies to eradicate such malignancies, often due to dose-limiting off-target 
toxicities, emphasizes the importance of an engineered system for selective delivery that 
spares normal tissues. Over the past quarter-century, advances in the understanding of the 
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biological barriers to cancer drug delivery in vivo and the development of multifunctional 
nanoparticles to overcome such barriers has offered much promise to improve detection 
and chemotherapeutic treatment of solid tumors. 
The size, hydrophobicity, and surface charge of systemically delivered nanoparticles 
play important roles during vascular circulation. Upon introduction into circulation, 
adsorption of proteins and electrolytes by hydrophobic and electrostatic interactions 
contributes to the hydrodynamic diameter (HD) of a particle that is somewhat larger than 
the unhydrated diameter or may even be different than the diameter measured in non-
biological suspensions. Molecules with HD less than 5 nm are rapidly removed from 
circulation owing to glomerular filtration in the kidneys
80
. Molecules with HD between 6 
nm and 8 nm are typically filtered at a rate inversely correlated with size, whereas 
molecules with HD greater than 8 nm are typically not filtered
80
. For example, renal 
clearance studies in mice have shown that quantum dots (QDs) with HDs ranging 4.36-
5.52 nm were subject to renal excretion whereas QDs with HD greater than 8 nm were 
not, but rather exhibited uptake in the reticuloendothelial system (RES) and lungs
81
. 
An emergent “gold standard” for 21st century tumor targeting of compounds is the use 
of nanoparticulate (HD: 10-100 nm) formulations that may selectively accumulate in 
solid tumors upon intravenous injection
82,83
. The predominant mechanism of size-
selective accumulation of macromolecules in tumors was first described in 1986 and later 
termed the enhanced permeability and retention (EPR) effect by Maeda et al
84,85
. In 
normal vasculature, tight junctions between adjacent endothelial cells prohibit passive 
trafficking of all but the smallest molecules (HD less than about 5 nm)
81
 across the 
endothelium, as reviewed by Bazzoni (2006)
86
. In many tumors, though, a host of altered 
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chemical and physiological factors such as bradykinin, nitric oxide, prostaglandins, 
carbon monoxide, peroxynitride, MMPs, vascular endothelial growth factor (VEGF), 
tumor necrosis factor alpha (TNF-α), and heat, among others, contribute to the rapid 
formation of “leaky” neovasculature during tumor angiogenesis87,88. The resulting 
tortuous and fenestrated vessels in some tumors permit extravasation of macromolecules 
up to 500 kDa
82
 that does not occur in tissues with normal vasculature. A lack of 
functional lymphatic vessels in many solid tumors further contributes to selective 
accumulation of macromolecules as filtration by lymphatic drainage would otherwise 
clear many such molecules. In fact, it has been shown that this retention is the key 
mechanism enabling the EPR effect in solid tumors, as low-molecular weight molecules 
may return to circulation by diffusion
89
. Recently, Tang et al showed that despite better 
tumor penetration by 20 nm-diameter nonporous spherical silica nanoparticles as 
compared with either 50 nm or 200 nm particles
90
, 50 nm drug-conjugated particles were 
retained in tumors in the highest concentrations over time and were more effective at 
reducing tumor size in vivo
91
. Particles larger than 100-200 nm it seems may be too large 
to either extravasate in tumors or be effectively endocytosed by cells
91
. 
Even though the EPR effect has been observed and confirmed reproducibly in vivo in 
murine models of cancer
82,84,89,92
, the application of nanoparticulate formulations to 
significantly improve the overall proportion of injected drugs delivered to human tumors 
has not translated readily to the clinic
45
. Several researchers including Maeda have 
pointed out that the EPR effect is not solely sufficient for delivery or even universally 
applicable to solid tumors, owing to heterogeneity between individuals, between tumor 
types, and even within a tumor itself
93,94
. A thorough analysis of the strategies that have 
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been employed to overcome the heterogeneity of the EPR effect or augment it in tumor 
targeting is beyond the scope of this work, but has been reviewed elsewhere
88
. Many of 
these strategies focus on either increasing blood pressure within and around tumors or 
normalizing the distribution of neovasculature in tumors by regulating angiogenesis. 
With any of these strategies, though, careful control and optimization of nanoparticle size 
is nonetheless critical for efficacious delivery to solid tumors. 
In addition to size, the surface characteristics of systemically administered 
nanoparticles are critically important for circulation time, clearance route, and delivery. 
The body’s first line of defense against foreign bodies and substances introduced to the 
bloodstream is the innate immune system. To achieve a rapid response to unidentified 
potential pathogens without reliance on the slower specific recognition mechanisms 
involved in adaptive immunity, the innate immune system has evolved to recognize 
potential pathogens highly conserved molecules and non-specific threatening molecular 
patterns
95
. Hydrophobic moieties and overall hydrophobicity such as might be 
encountered in a bacterial cell membrane thusly trigger the innate immune system, 
resulting in much greater likelihood of adsorption of opsonins such as complement 
proteins, immunoglobulins, albumin, fibrinogen, and apolipoproteins
96
. Opsonized 
nanoparticles are efficiently removed from circulation by phagocytes
97
 such as circulating 
monocytes, splenic macrophages, alveolar macrophages, or Kupffer cells in the liver that 
are collectively known as the Monocyte Phagocytic System (MPS)
98
. Hence a common 
strategy to prevent nanoparticle clearance by the MPS is to encapsulate or decorate the 
nanoparticle surface with hydrophilic macromolecules such as poly(ethylene glycol) 
(PEG). These are commonly referred to as “stealth” nanoparticles, and the technique has 
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been applied to liposomes, inorganic metal nanoparticles, quantum dots, and polymer-
based nanoparticles alike
24,63,99–103
. Bioconjugation of PEG to nanoparticles can both 
improve water-solubility and sterically hinder adsorption of opsonins to prevent 
complement activation and undesired clearance by the MPS, thereby increasing the 
circulation half-life of PEGylated particles. Other MPS avoidance strategies have 
included mimicking the outward appearance of circulating red blood cells (RBCs), either 
by bioconjugation of immune-halting proteins such as CD47 to nanoparticles or by 
encapsulation of particles in natural RBC membrane bilayers
97
. 
The charge resulting from the surface composition of a nanoparticle also greatly 
influences its suitability for systemic delivery. The zeta potential (ζ) of a particle is 
defined as the electrical potential in the interfacial double layer where a stationary layer 
of fluid adhered to the particle meets the dispersion medium. In other words, it is the 
outwardly perceived difference in electrical potential between the dispersed or solvated 
particle and the solution in which it is dispersed. Several studies have indicated that 
particles with highly-positive ζ (cationic) or highly-negative ζ (anionic) are more rapidly 
cleared from circulation than electrostatically neutral particles
104–107
. While both types of 
charged surfaces may contribute to interactions with serum proteins and eventual uptake 
by the MPS, cationic particles have been found to interact nonspecifically with many cell 
types due to regions of negative charge (e.g. sialic acid) in the lipid bilayers of cell 
membranes. As such, polycationic particles may exhibit especially high levels of off-
target and systemic toxicity owing to this interaction with normal cells that often results 
in translocation across the plasma membrane. Like hydrophobic surfaces, the charged 
surfaces of nanoparticles may be shielded by encapsulation or bioconjugation with 
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macromolecules such as PEG or pairing of charged molecular regions with counter-ions. 
In fact, reversible shielding strategies have been employed to effect selective cellular 
internalization via multiply-charged cell penetrating peptides
25
 or “proximity-activated” 
nanoparticles
108
 that reveal a polycationic surface only upon enzymatic activation by 
tumor-associated enzymes (e.g. MMPs). 
Altogether, the above considerations contribute to a set of generalized axioms of 
biocompatibility and suitability for systemic delivery of tumor-targeted nanoparticles. As 
illustrated in Figure I-2, nanoparticles for this purpose should be approximately 8-100 nm 
in HD, as hydrophilic as possible, and should exhibit ζ of the smallest magnitude feasible 
during systemic vascular circulation. As indicated above, PEGylation of nanoparticles 
may aid in the optimization of each of these parameters. 
 
Figure I-2: Nanoparticle biocompatibility and tumor-targeting axioms 
To take advantage of the EPR effect for selective accumulation in solid tumors, 
systemically administered nanoparticles should be approximately 8-100 nm in HD, as 
hydrophilic as possible, and should exhibit ζ of the smallest magnitude feasible during 
systemic vascular circulation. Figure adapted from a conference presentation by Scott E. 
McNeil, Ph.D. of the Nanotechnology Characterization Laboratory within the National 
Cancer Institute. 
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I.4. HYPOTHESES AND GOALS OF THIS DISSERTATION 
The above considerations regarding the physiological properties of solid tumors and 
the strategies that have been developed to selectively deliver imaging and therapeutic 
agents to them lead us to believe that the design of PBs developed in our laboratory (see 
Figure I-1) can be extended to include folic acid as a targeting ligand to effect selective 
delivery of payloads to malignant cells within solid tumors. We hypothesize that 
nanoparticles conforming to the biocompatibility and tumor-selective delivery axioms 
described above and featuring folate-targeted conjugates tethered to their surfaces by 
MMP-cleavable linker peptides will prove more selective for delivery into tumor cells 
than macromolecular constructs employing any one of these elements. Optical imaging 
enabled by the fluorescent switch as designed in the previous iteration of PBs is a logical 
tool for measuring activation of and delivery by these particles that we have termed 
“folate-targeted proteolytic nanobeacons” (FTPNBs). The majority of this dissertation 
focuses on refining the design and reducing to practice the synthesis and characterization 
of FTPNBs, thereby enabling the study of the effects that the employed targeting 
mechanisms have on each other and on selective delivery when applied in concert. 
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CHAPTER II 
 SELECTION OF AN MMP SUBSTRATE FOR CLEAVABLE 
CONJUGATION TO CARRIER NANOPARTICLES 
II.1. INTRODUCTION 
Our laboratory has previously developed proteolytic nanobeacons with demonstrated 
applicability to the detection of tumor-associated MMP7 or MMP9 activity in vitro, ex 
vivo, and in vivo
24,37,38,109
. In the prototypical design of a proteolytic nanobeacon (Figure 
I-1), MMP substrate peptides, each with a “sensor” fluorophore attached to the 
N-terminus, were covalently linked to an organic PAMAM dendrimer core. The 
PAMAM core was also decorated with “reference” fluorophores designed to quench the 
sensor via intramolecular FRET and linear PEG molecules to improve water solubility 
and biocompatibility of the overall construct. The reference fluorophore provided 
constitutive fluorescence emission associated with the nanoparticle core, while emission 
from the sensor fluorophore was attenuated until proteolytic cleavage of the substrate 
peptide would eliminate intramolecular FRET and increase the sensor fluorescence. As 
such, semi-quantitative assessment of proteolysis was achieved by calculating the sensor-
to-reference emission ratio (S/R) in solutions, fluorescence microscopy images, or 
photographic images representative of proteolytic nanobeacons
37
. 
Building upon this design, the research presented hereafter was focused on 
developing two primary modifications for the synthesis of a newer generation of 
proteolytic nanobeacons: (1) incorporation of a linker substrate peptide selective for 
MMP14; and (2) covalent attachment of folic acid to the N-terminus of the substrate 
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peptide in addition to the sensor fluorophore. Selective activation of proteolytic 
nanobeacons by MMP14 would be advantageous for selective delivery and imaging of 
tumor-associated proteolysis in solid tumors owing to the pleiotropic roles of MMP14 in 
tumor progression. MMP14 has been reported to be relevant to all stages of tumor 
progression, as it can cleave a variety of substrates  including but not limited to the pro-
enzyme forms of other MMPs, ECM proteins, cell surface proteins such as cell adhesion 
molecules, and soluble molecules involved in cell signaling
11
. Importantly, expression of 
MMP14 has been shown to be required for invasion and migration of tumor cells through 
extracellular matrices where matrix remodeling is necessary to allow cellular 
mobility
42,110
, a critical component of tumor metastasis. A potential pitfall of designing 
proteolytic nanobeacons selective for MMP14 is the spatial confinement of MMP14 to 
the cell membrane that limits its availability for extracellular proteolysis of nanobeacons 
in the tumor microenvironment. On the other hand, there is evidence suggesting that the 
extracellular domains of MMP14 may be either shed from the cell membrane
111
 or 
secreted in microvesicular exosomes
112
. Theoretically, modification of the PB-M7 design 
(Figure I-1) to employ a peptide with a different amino acid sequence could impart 
selectivity for MMP14 instead of MMP7. However, as demonstrated by the data that 
follow in this chapter, development of substrates that are both efficiently cleaved and 
highly selective for MMP14 is non-trivial in practice. 
The second modification, attachment of folic acid to the N-termini of the linker 
substrate peptides distal to the nanoparticle cores, provides a new dimension to 
proteolytic nanobeacons in the form of a targeting ligand. Folic acid binds with and is 
internalized along with any conjugates by the folate receptor, the alpha isoform of which 
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has been reported to be overexpressed in many solid tumors but expressed at very low 
levels (if at all) in most normal tissues
49,54
. Therefore in addition to the selective 
activation of nanobeacons in the MMP-rich tumor microenvironment imparted by the 
substrate peptide, folate targeting may provide a mechanism for selective uptake of 
nanobeacons and released folate conjugates by malignant tumor cells. Covalent 
attachment of folic acid to substrate peptides in addition to the sensor fluorophore while 
preserving the capacity for bioconjugation with nanoparticles presented a technical 
challenge. Attachment of folic acid to conjugates in an orientation that permits 
subsequent binding with folate receptors requires linking through one or both of 
carboxylic acid functional groups at the same end of the molecule. Covalent bonding 
employing these carboxylic acid groups is most readily achieved with primary amine 
groups, but the PB-M7 design made use of the N-terminal primary amine of the substrate 
peptide for attachment of the sensor, leaving no suitable functional group for reaction 
with folic acid near the N-terminus. Substrate peptide designs were therefore modified to 
implement lysine residues possessing two primary amine groups, the α-amine as part of 
the peptide backbone and the ε-amine of the side chain. Assuming successful inclusion of 
folic acid, the hydrophobicity and extremely low solubility of folic acid in aqueous 
solutions at physiological pH was still of concern for the necessary function of the 
resulting peptides as MMP substrates. 
With the above considerations in mind, the primary objective of the research that 
follows was to develop methods for the synthesis and characterization of proteolytic 
nanobeacons that were dually-targeted to the folate receptor and proteolysis by MMP14 
and could generate an optical signal for detection of MMP activity. One of the 
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requirements, then, was to determine whether folic acid conjugation to substrate peptides 
would interfere with MMP cleavage. Shown below, the design of proteolytic 
nanobeacons was further modified to incorporate both the sensor and reference dyes by 
attachment to amino acid side chains of the substrate peptide. Troubleshooting of FRET-
equipped MMP substrate synthesis led to insights regarding steric hindrance, eschewing 
of an MMP14-selective substrate in favor of a broadly MMP-cleavable one, and 
ultimately to development of a robust method for preparing FRET substrates with visible-
spectrum fluorophores by solid phase peptide synthesis (SPPS). An optical switch was 
observed in folated substrates, though not upon treatment with MMPs. MMP cleavage of 
folated substrates not inclusive of fluorophores was confirmed by mass spectrometry. 
A number of peptide structures will be presented in the chapters that follow. For the 
ease of discernment by the reader, presented in Table II-1 are selected names, amino acid 
sequences, and design intentions of the central MMP-cleavable domains. Throughout this 
dissertation, to discriminate between L-amino acids and other chemical functional 
groups, amino acid residues are represented by capital letters corresponding to their 
conventional single-letter notations while other chemical functional groups are indicated 
using lowercase letters, e.g. amine groups as “-nh2” or carboxyl groups as “-cooh.”  
Table II-1: MMP substrate peptides nomenclature and intent 
Name/Identifier  MMP Cleavage Sequence  Design Intent  Origin  
Peptide #13      RIGF  *  LRTA  MMP14 selective  Kridel et al 113 
Peptide #14       PLA  *  XWAR  MMP14 selective  Mucha et al 114 
Weiss  ESSN  *  LFVL  MMP14 selective  Outyang et al 39 
Hybrid  WSLN  *  LFVL  MMP14 selective  Amalgam of Mucha/Weiss 39,114 
Broad2  RPLG  *  LWAR  Broadly MMP cleavable  Knight et al 115 
PEPDAB1001  GPLG  *  MRGC  ADAM/MMP cleavable  Rasmussen et al116  
M9  AVRW  *  LLTA  MMP9 selective  Chen et al 117 
  
* designates scissile bond 
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II.2. MATERIALS AND METHODS 
II.2.1. General Methods 
Materials. All chemicals and biochemicals were reagent-grade or HPLC-grade and 
solutions were prepared in filtered deionized water (dH2O) (Milli-Q, Billerica, MA, 
USA). Unless otherwise noted, all chemicals were purchased from either Sigma Aldrich 
(St. Louis, MO, USA) or Thermo Fisher Scientific (Waltham, MA, USA). 
5(6)-carboxytetramethylrhodamine succinimidyl ester (TAMRA-SE), 
5(6)-tetramethylrhodamine maleimide (TAMRA-mal), 5(6)-carboxyfluorescein 
succinimidyl ester (FAMSE), 5-fluorescein maleimide (FL-mal), and Fmoc-PEG1-CH2-
COOH  were purchased from Anaspec (Fremont, CA, USA). Succinimidyl iodoacetate 
(SIA) and phenylmethanesulfonylfluoride (PMSF) were purchased from Pierce Chemical 
(Rockford, IL, USA). Dye-quenched gelatin (DQG), Alexa Fluor 700™ (AF700), and 
Alexa Fluor 750™ (AF750) were obtained from Molecular Probes (Eugene, OR, USA). 
GM6001 broad-spectrum MMP inhibitor was purchased from Chemicon International 
(Temecula, CA, USA). Standard Fmoc-protected amino acids, Rink Amide AM LL resin 
(100-200 mesh), and 6-Chloro-benzotriazole-1-yloxy-tris-pyrrolidinophosphonium 
hexafluorophosphate (PyClock) were obtained from EMD Chemicals (Billerica, MA, 
USA).  Fmoc-Lys(5/6-FAM)-OH and Fmoc-Lys(5/6-TAMRA)-OH were purchased from 
AAT Bioquest (Sunnyvale, CA, USA). 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU) was obtained from ChemPep 
(Wellington, FL, USA). Broadly MMP-cleavable fluorogenic substrate peptide 
“PEPDAB1001” [dab-GPLGMRGC(fitc)-conh2, where dab is Dabcyl] was generously 
donated by Dr. Marcia Moss of BioZyme (Apex, NC, USA). 
24 
 
HPLC. High pressure liquid chromatography (HPLC) was generally performed using 
an Agilent Infinity 1260 HPLC system (Agilent, Santa Clara, CA, USA) with a 
photodiode array detector and analytical-scale fraction collector. HPLC columns for 
analytical scale (Polaris C18-A, 4.6 x 250.0 mm, 3 µm pore size) and semi-preparative 
scale (Polaris C18-A, 10 x 250.0 mm, 5 µm pore size) separations were obtained from 
Varian (Palo Alto, CA, USA). Mobile phases for chromatography gradients were water 
and acetonitrile (MeCN) with 0.1% trifluoroacetic acid (TFA) unless otherwise noted. 
LCMS. Liquid chromatography mass spectrometry (LCMS) separations were 
performed with an Acquity UPLC system in tandem with a Synapt Q-TOF high 
resolution mass spectrometer (Waters, Milford, MA, USA) in positive ion, V mode for 
determination of accurate masses. Mobile phases used for chromatography gradients 
were 95:5 H2O:MeCN (A) and 5:95 H2O:MeCN (B) with 0.2% formic acid and packed 
columns were C18, 4.6 x 100 mm with 1.7 µm pore size unless otherwise specified. The 
applied gradient was 0% to 90% (B) over 7 minutes unless otherwise noted. 
Spectrophotometry. UV-visible spectrophotometry was recorded using a Shimadzu 
UV-2501 PC spectrophotometer (Shimadzu, Kyoto, JP). Samples were diluted at least 1:1 
with 0.1M phosphate buffer (pH 7.0-7.5) and measured against identical solvent mixture 
as a baseline reference unless otherwise specified.  
II.2.2. Synthesis of PAMAM-based proteolytic nanobeacons from FITC-labeled 
peptides 
Peptide #13 [fitc{Ahx}RIGFLRTA{Ahx}C-cooh, where {Ahx} is aminohexanoic 
acid] and Peptide #14 [fitc{Ahx}PLAXWAR{Ahx}C-cooh] (see Appendix A) were 
obtained as custom syntheses from Genscript Corporation (Piscataw, NJ, USA). 
Generation 3 Starburst® polyamido amine dendrimer (PAMAM3) was purchased from 
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Sigma Aldrich (St. Louis, MO, USA). Methoxyl PEG succinimidyl ester, MW 1000 
(PEG1000-NHS) was purchased from Nanocs (Boston, MA, USA). BHQ-10 carboxylic 
acid, succinimidyl ester (BHQ-10SE) was purchased from Biosearch Technologies 
(Petaluma, CA, USA). To 50 µL PAMAM3 (1.14 µmol, 20 wt% in MeOH) was added 50 
µL (3.43 µmol) PEG1000-NHS to afford PAMAM3-PEG following 30 minutes 
incubation at room temperature (RT). 20 µL (228 nmol) of either PAMAM3 or 
PAMAM3-PEG in MeOH was then activated by addition of 62 µL (2.19 µmol) SIA in 
50/50% MeOH/DMF and reaction for 30 minutes at RT. To 36 µL (100 nmol) activated 
PAMAM3 or PAMAM3-PEG was then added 55 µL (330 nmol) of either Peptide #13 or 
Peptide #14 in 50/50% MeOH/DMF and reaction allowed to proceed overnight at RT 
with rocking. 7 µL (700 nmol) cysteine in MeOH was added to each of the four reactions 
to block any remaining iodoacetyl groups. Reaction mixes were diluted with 8 volumes 1 
mM EDTA solution (pretreated with 1 mM PMSF) and 1 volume EtOH and concentrated 
by ultrafiltration in Centriprep YM3 devices (EMD Millipore, Darmstadt, DE). 
Retentates were diluted again with 9 volumes 1 mM EDTA and reconcentrated. 20 nmol 
of PAMAM-equivalent from each of the resulting retentates were subsequently adjusted 
to pH 9.0 by addition of 1/9 volume 0.5 M Na2CO3 and reacted with either 14 µL (200 
nmol) or 11 µL (200 nmol) TAMRA-SE in DMF to give 8 final reaction mixes. 
Reactions proceeded overnight at RT under argon gas with gentle rocking. Concentration 
by ultrafiltration was applied as before to these reaction mixes to give 8 final product 
retentates, as listed in II.3.1 (final wash in deionized water pretreated with 1 mM PMSF). 
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II.2.3. FRET switch assay 
The ability of peptides and constructs to develop an increase in fluorescence as a 
result of disruption of FRET proximity by proteolytic enzymes was assessed according to  
previously published techniques 
24,116
. MMPs were purchased as recombinant human 
catalytic domains from either Calbiochem (La Jolla, CA, USA) or Enzo Life Sciences 
(Farmingdale, NY, USA). Analytes and enzymes were diluted into common assay buffer 
(50 mM Tris pH 7.5, 200 mM NaCl, 5 mM CaCl2, 2 µM ZnSO4, 0.01% Brij 35) treated 
with 1 mM PMSF approximately 10 minutes prior to assay to inhibit the activity of any 
contaminating serine proteases. Fluorescence was monitored in opaque white 96-well 
plates in a top-reading fluorescence plate reader. Final volumes of assay wells were 
generally either 100 µL or 80 µL with intraplate conformity. 
II.2.4. Synthesis and characterization of 2-color Peptides #13,14 via reactive dyes 
72 µL (1500 nmol) TAMRA-mal in DMF was added to 75 µL (305 nmol) of either 
Peptide #13 or Peptide #14 in 67/33% DMF/MeOH and reacted overnight at RT with 
gentle rocking to afford products “F13T” and “F14T.” 100 µL each of the resulting 
reaction mixes were diluted 1:1 with deionized water and dialyzed against 100 mL 
deionized water to remove unbound TAMRA-mal. Dialyzed F13T and F14T were 
subsequently diluted into tricine buffer (50 mM tricine pH 7.4, 200 mM NaCl, 10 mM 
CaCl2, 50 μM ZnSO4, 0.005% Brij 35) and treated overnight with trypsin (0.02 mg/mL), 
pronase (0.02 mg/mL), or EDTA for analysis by the FRET switch assay (see II.2.3, 
above) to determine maximum potential fluorescence fold change upon proteolysis 
(hereafter referred to as “FRET switch”). Dye quenched gelatin (DQG) was included as a 
control substrate. F14T was subsequently incubated with pronase (0.02 mg/mL), trypsin 
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(0.02 mg/mL), MMPs-2,7,9,14 (20 ng total enzyme per well, each separately), or EDTA 
and FRET switch monitored continuously over approximately 2 hours. 
II.2.5. Generalized synthesis of 2-color FRET peptides via dual fluorophore 
conjugation 
Peptides containing unmodified lysine and cysteine residues were dissolved to 10 
mg/mL in DMF and reacted with 2 molar equivalents of dithiolthreitol (DTT) in 
deionized water to reduce disulfide bonds that may have formed due to oxidation of 
cysteine. Reduced peptides were then precipitated 3 times in 10 volumes of ice cold 
acetone to remove DTT and finally dried under nitrogen gas flow. 2 molar equivalents 
(relative to starting peptide) of sulfhydryl-reactive dye (FL-mal or TAMRA-mal) in DMF 
was then added to dry reduced peptide and allowed to react 2 hours to overnight at RT 
with gentle rocking. Acetone precipitation and nitrogen drying was repeated to remove 
unreacted fluorescent dye. 2 molar equivalents of amine-reactive dye (FAMSE or 
TAMRA-SE) was then added to dry fluorescent peptide product and allowed to react 2 
hours to overnight at RT to afford a mixture of non-, singly-, and dually-fluorescent 
peptides. A final acetone precipitation and nitrogen drying procedure was used to remove 
unreacted fluorescent dye molecules and yield peptide product(s). 
II.2.6. Novel MMP14-selective FRET peptides 
Non-fluorescent peptides Ac-KWSLNLFVLC-cooh and 
Ac-K{Ahx}WSLNLFVL{Ahx}C-cooh (where Ac represents acetyl, COCH3) were 
obtained commercially as custom syntheses from American Peptide Company 
(Sunnyvale, CA, USA). Attachment of FL-mal and TAMRA-SE dyes was performed as 
outlined above (see II.2.5) to synthesize FRET peptides 
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[Ac-K(tamra)WSLNLFVLC(fam)-cooh and 
Ac-K(tamra){Ahx}WSLNLFVL{Ahx}C(fam)-cooh]. These peptides were then 
subjected to FRET switch assay with pronase or EDTA to determine suitability as a 2-
color FRET substrate.  
II.2.7. Synthesis and characterization broadly MMP-cleavable 2-color FRET 
substrates 
Broadly MMP-cleavable “Broad2” [h2n-RPLGLWARC-cooh] and “Ahx-Broad2” 
[h2n-{Ahx}RPLGLWAR{Ahx}C-cooh] peptides were obtained as custom syntheses 
from Biomer Technology (Pleasanton, CA, USA). Unless otherwise noted, “phosphate 
buffer” hereafter refers to 100 mM potassium phosphate buffer (pH 7.3) and all chemical 
reactions were performed at RT with gentle rocking, protected from light.  
A 2-color Broad2 FRET peptide [tamra-RPLGLWARC(fam)-cooh] was synthesized 
as described above with minor modifications. To 1.1 mg (1.03 µmol) Broad2 peptide was 
added 51 µL sterile-filtered PBS with 0.2 M DTT, 1 mM PMSF. Reduced Broad2 peptide 
was then precipitated by addition of 500 µL ice cold acetone and dried under nitrogen gas 
flow prior to resuspension in 51 µL phosphate buffer. 88 µL (2.05 µmol) FL-mal in DMF 
was then added and allowed to react for 3 hours to give the intermediate product, 
“Broad2-FL.” Broad2-FL was then precipitated and dried as before with 1 mL ice cold 
acetone and nitrogen gas to give a yellow solid that was reconstituted in 100 µL 
phosphate buffer. To 70 µL of Broad2-FL solution was added 76 µL (1.44 µmol) 
TAMRA-SE in DMF and left overnight. Acetone precipitation was then performed twice 
in 1 mL volume with final reconstitution of product, “TMR-Broad2-FL,” in 75 µL DMF. 
TMR-Broad2-FL was then diluted 1:100 in phosphate buffer for spectrophotometry and 
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1:100 in standard assay buffer for FRET switch assay with trypsin (0.02 mg/mL) or 
EDTA (25 mM). 
Another FRET peptide based on the Broad2 substrate sequence, “FL-Broad2-TMR” 
[fam-RPLGLWARC(tamra)-cooh], was synthesized with oppositely reactive fluorescent 
dyes to reverse the N-terminal and C-terminal attachment sites. 168 µL (3.55 µmol) 
FAMSE in DMF was added to 190 µL (1.77 µmol) Broad2 in phosphate buffer and 
allowed to react 3 hours. To 338 µL of this reaction mix was added 7 µL (3.5 µmol) DTT 
in deionized water. After 2 hours, the reaction mixture was precipitated in 1 mL ice cold 
acetone to afford a reduced yellow solid intermediate, “FL-Broad2.” 141 µL (3 µmol) 
TAMRA-mal in DMF and 282 µL phosphate buffer were added to the yellow solid. Due 
to incomplete dissolution, the mixture was again precipitated in acetone and dissolved in 
acetonitrile (MeCN) to give a completely dissolved solution. Another 141 µL (3 µmol) 
TAMRA-mal was then added and allowed to react 3 hours. Following a final acetone 
precipitation, the product (FL-Broad2-TMR) was reconstituted in 500 µL DMF and 
subsequently diluted 1:500 in standard assay buffer for FRET switch assay with trypsin 
(0.02 mg/mL) or MMPs-2,3,9,13,14 using 20 nM active MMP concentration per assay 
well as calculated from inhibitor titration assay (see Appendix B), and/or EDTA (25 
mM). 
A similar FRET substrate with flexible hydrophobic spacers designed to alleviate 
steric hindrance of the MMP cleavage site,“Ahx-Broad2-vis” 
[fam-{Ahx}RPLGLWAR{Ahx}C(tamra)-cooh, see Appendix A], was synthesized in a 
1-pot series of sequential dye-addition reactions. 73 µL (1.54 µmol) FAMSE in DMF 
was added to 50 µL (770 nmol) freshly reconstituted Ahx-Broad2 peptide. 12 µL 
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phosphate buffer was added and the reaction mix left shaking for 3 hours. To 100 µL of 
this reaction mix was added 64 µL (1.15 µmol) TAMRA-mal in DMF and 6 µL 
phosphate buffer. Following overnight (approximately 18 hours) reaction, peptide 
products were precipitated by addition of 1 mL ice cold acetone and reconstituted in 150 
µL DMF. Dissolved Ahx-Broad2-vis was then diluted in standard assay buffer and FRET 
switch assay repeated as with FL-Broad2-TMR above. 
II.2.8. Investigation of substrate steric hindrance via FRET switch assay 
“Peptide 13c” [tamra-RIGFLRTRK(fitc)R-cooh], “Peptide 13e” 
[tamra-SGRIGFLRTAK(fitc)R-conh2], “Peptide 13g” 
[tamra-{Ahx}SGRIGFLRTAK(fitc)R-conh2], and “Peptide 13i” 
[dab-SGRIGFLRTAK(fitc)R-conh2, where dab represents Dabcyl] were obtained as 
custom syntheses from Biomer Technology (Pleasanton, CA, USA). All substrate 
peptides were reconstituted from lyophilized powder to 5 mM concentration in dH2O or 
50% MeCN and diluted to final assay concentration of 8.75 µM in standard assay buffer 
for FRET switch assays with pronase (17 nM), MMPs-2,14 (5 nM) and/or EDTA (250 
µM). 
II.2.9. Synthesis and characterization of M9 and M9-Folate FRET peptides 
“M9” peptide [h2n{Ahx}AVRWLLTA{Ahx}C-cooh] was purchased as a custom 
product from Genscript (Piscataway, NJ, USA). “M9-Folate” peptide 
[fa-K{Ahx}AVRWLLTA{Ahx}C-cooh, where fa is folic acid] was obtained as a custom 
synthesis from Biomer Technologies (Pleasanton, CA, USA). “M9-vis” and 
“M9-Folate-vis” were synthesized using a procedure analogous to FL-Broad2-TMR (see 
II.2.7, above). Chemical reactions were performed at RT with gentle rocking, protected 
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from light.52 µL (1.1 µmol) and 72 µL (1.6 µmol) FAMSE in DMF were added to 50 µL 
each of M9-Folate (553 nmol) and M9 (795 nmol) in DMF, respectively. 10% volume 
0.1 M phosphate buffer (pH 7.3) was added to each reaction mix and the reactions were 
allowed to proceed overnight. 10 µL (1 µmol) and 15 µL (1.5 µmol) DTT in dH2O were 
added to M9F and M9 reaction mixes, respectively and reacted 60 minutes. Reduced 
peptide intermediates were precipitated in ice cold acetone, dried under nitrogen gas 
flow, and reconstituted in 100 µL DMF each with vortexing and sonication. 48 µL (997 
nmol) and 69 µL (1.43 µmol) TAMRA-mal in DMF and 10% volume phosphate buffer 
were added to M9F and M9 reaction mixes, respectively, and allowed to react overnight. 
Each peptide product was precipitated and dried as before, then reconstituted in 33/67% 1 
mM phosphate buffer (pH 7.5)/DMF to yield M9-Folate-vis and M9-vis FRET peptides. 
FRET switch assays were carried out as described earlier either with trypsin (0.02 
mg/mL) or MMPs-3,9,14 (20 nM active MMP). 
M9 and M9F peptides were incubated with and without MMP9 in assay buffer (see 
II.2.3) and then analyzed by LCMS to determine qualitatively whether or not proteolysis 
was occurring in the absence of attached fluorophores. Briefly, 4 µL (80 µg) of each 
peptide was dissolved in 200 µL total volume of assay buffer with or without MMP9 (20 
nM active MMP) and incubated overnight. The resulting mixtures were analyzed by 
LCMS (see general procedure, II.2.1). 
II.2.10. Commercially produced Broad2 FRET peptides 
“GG-B2-vis” [h2n-GGK(fam)GGRPLGLWARGGK(tamra)G-cooh] and 
“fa-GG-B2-vis” [fa-GGK(fam)GGRPLGLWARGGK(tamra)G-cooh] peptides were 
obtained as custom syntheses from Biomer Technologies (Pleasanton, CA, USA).  
32 
 
II.2.11. Synthesis and characterization of peg-Broad2-vis FRET peptide 
Conventional Fmoc-protected solid phase peptide synthesis (SPPS) was performed 
using a PS3 automated peptide synthesizer (Protein Technologies, Tucson, AZ, USA) 
according to manufacturer instructions to synthesize “peg-Broad2-vis” FRET peptide 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G-conh2]. Rink amide AM LL 
(100-200 mesh) low-substitution resin was used in amount equivalent to 50 µmol 
substitution. All Fmoc-protected monomer residues were portioned to 200 µmol per 
coupling, combined with 190 µmol HCTU, and double coupled with the exception of 
Fmoc-Lys(5/6-X)-OH (200 µmol per coupling), where X is FAM or TAMRA, where 
coupling was performed using 250 µmol PyClock instead of HCTU used in the standard 
single coupling reactions. The solvents employed for automated synthesis were 
N-methyl-2-pyrrolidone (NMP) as primary solvent, 20% piperidine in NMP for Fmoc 
deprotection cycles, and 0.4 M N-methylmorpholine (NMM) in NMP for residue 
activation solution. Final peptide products were simultaneously deprotected and cleaved 
from solid phase resin support by vigorous vortexing in cleavage cocktail B [88% TFA, 
5% H2O, 5% phenol, 2% triisoproylsilane (TIPS)] for 2 hours and recovered by filtration 
and precipitation in ice cold diethyl ether (Et2O). 
Molecular weights of the products of SPPS were determined by LCMS (general 
method, see II.2.1). Attempted purification of the intended peg-Broad2-vis (pB2v) 
peptide by semi-preparative HPLC was performed on a Waters Breeze 2 HPLC system 
(Waters, Milford, MA, USA) with monitoring of eluted chemical species at 550 nm that 
is characteristic of TAMRA dye. Collected fractions were diluted with dH2O, lyophilized, 
and reconstituted in dH2O prior to analysis by LCMS and further purification by HPLC. 
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After three rounds of iterative purification, peptide product “peg-Broad2-vis_2.2.1” 
(pB2v_2.2.1) was lyophilized and reconstituted in 100 µL dH2O. The concentration of 
the resulting aqueous solution was estimated to be 334 µM in pB2v by measuring 
absorbance at 550 nm on a Nanodrop 1000 instrument (Thermo Scientific, Wilmington, 
DE, USA) and applying the Beer-Lambert Law with a molar extinction coefficient for 
TAMRA dye of 80,000 M
-1
cm
-1
. This solution was diluted 80-fold in standard assay 
buffer for FRET switch assays with either trypsin (0.02 mg/mL) or MMPs-2,9,14 
(varying active concentrations, as determined by inhibitor titration assay, see Appendix 
B). 
II.3. RESULTS 
II.3.1. Attachment of FITC-labeled MMP14 substrate peptides to PAMAM 
dendrimers 
In order to develop proteolytic nanobeacons with selectivity for MMP14, custom 
peptides based on published substrates with demonstrated susceptibility to enzymatic 
cleavage selectively by MMP14
113,114
 were designed and obtained. As seen in Figure II-1, 
Peptide #13 and Peptide #14 each feature an N-terminal FITC moiety for quenchable 
fluorescence (“sensor”), a C-terminal cysteine residue for bioconjugation with PAMAM 
nanoparticles, and Ahx groups spatially separating these functional groups from the 
central MMP cleavage site. 
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Figure II-1: 1-color MMP14 substrate peptides 
Peptide substrates for MMP14 shown above were designed based upon literature reporting 
on the effects of primary amino acid sequence on substrate efficiency for MMP14 and 
other enzymes 
113,114
. “Peptide #13” and “Peptide #14” were designed to be selectively 
cleavable by MMP14 and to utilize the sulfhydryl-containing side chain of a C-terminal 
cysteine for attachment to a core nanoparticle decorated with a moiety to quench FITC 
fluorescence when in proximity. 
 A series of eight proteolytic nanobeacons was synthesized based on a previously 
established technique
24,37
 using Peptide #13 and Peptide #14 with generation-3 PAMAM 
dendrimers, with or without PEGylation, and with either TAMRA of BHQ-10 to quench 
FITC fluorescence, as schematically diagrammed in Figure II-2.  
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Figure II-2: Scheme, synthesis of PAMAM-based proteolytic nanobeacons from 1-color peptides 
MMP-14 substrate peptides (Peptide #13 and Peptide #14, see Figure II-1) were attached 
to PAMAM3 dendrimers via a multi-step synthesis to generate MMP14-selective 
proteolytic nanobeacons. Eight products were generated; number scheme as follows: 
PEGylated (C1xxx), non-PEGylated (C0xxx), bearing Peptide #13 (Cx13x) or Peptide #14 
(Cx14x), and bearing BHQ10 (CxxxQ) or TAMRA (CxxxR). 
The proteolysis sensing ability of the synthesized products was assessed by 
measurement of the sensor-to-reference fluorescence ratio (S/R) following overnight 
incubation with trypsin. None of the PNBs synthesized demonstrated a greater than 2-
fold change in S/R upon treatment (Figure II-3a), and only C113R and C114Q (Figure 
II-2, above) displayed a change greater than 1.5 fold. Incubation of C113 and C114Q 
with MMPs yielded similar changes in S/R relative to control (EDTA) and possessed no 
obvious selectivity for MMP14, though it was noted that MMP14 cleaved DQG less 
effectively than other MMPs in this assay (Figure II-3b). 
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Figure II-3: Fluorescent (FRET) switch of MMP14-cleavable proteolytic nanobeacon series 
A series of 8 PAMAM-based proteolytic nanobeacons with or without PEG, utilizing 
Peptide #13 or #14 and either TAMRA dye or BHQ10 as noted were incubated with 
trypsin or EDTA overnight at 37°C and the sensor-to-reference fluorescence emission 
ratio calculated before and after incubation (a). Emission bandwidths for sensor and 
reference fluorescence correspond to FITC and TAMRA dyes, respectively. C113R and 
C114Q were similarly incubated with MMPs (b). Dye-quenched gelatin (DQG) was 
included as a control. Values represent average of triplicates. Error bars: standard 
deviation. 
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II.3.2. MMP cleavability and FRET switch of 2-color (FRET) MMP14 substrates 
We hypothesized that intramolecular FRET of PNBs could be made more robust, 
both in terms of proportion of energy transferred (“quenching”) and batch-to-batch 
reproducibility, by incorporating paired fluorophores directly into the substrate peptide 
rather than attaching the quenching fluorophore to the PAMAM surface. We therefore 
synthesized dually labeled substrate peptides (“F13T” and “F14T”) by attaching 
sulfhydryl-reactive TAMRA dye to Peptide #13 and Peptide #14 (Figure II-4), leaving 
the C-terminal carboxyl functional groups available for attachment to nanoparticles. 
 
Figure II-4: Scheme, FRET peptides synthesized via maleimide-to-sulfhydryl reaction 
The sulfhydryl-reactive dye, TAMRA-(5,6)-maleimide, was used to label peptides on the 
side chain of their cysteine residues, generating peptides equipped with FITC (“sensor”) 
and TAMRA (“reference”) fluorophores which constitute a well-studied FRET pair. This 
strategy was extended to Peptide #14 to synthesize “F14T,” as well. 
FITC (sensor) fluorescence of both F13T and F14T increased dramatically following 
overnight incubation with trypsin and pronase (Figure II-5a), while TAMRA (reference) 
fluorescence remained mostly unchanged (Figure II-5b). Because treatment with pronase 
elicited a nearly 24-fold increase in the sensor fluorescence of F14T, the FRET switch of 
F14T upon treatment with MMPs was also assessed. While sensor fluorescence increased 
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with exposure to MMP14, other MMPs (MMP2, MMP7, MMP9) were also able to 
generate modest FRET switches in F14T (Figure II-5c). 
 
Figure II-5: FRET switch of 2-color MMP14 substrate peptides 
F13T and F14T 2-color peptides were incubated with trypsin, pronase, or EDTA overnight 
at 37°C and the sensor and reference fluorescence emission measured before and after 
incubation (a,b). F14T was incubated with proteolytic enzymes or EDTA and fluorescence 
measured over time (c). Values represent average of duplicates (a,b) or triplicates (c, 
except MMP2: duplicates). Error bars: standard deviation. 
II.3.3. Synthesis and characterization of novel MMP14 substrates 
In order to improve selectivity of PNBs for MMP14 over other MMPs, substrate 
peptides were designed based upon MMP14-selective substrate sequences reported in the 
literature. As depicted in Figure II-6, the amino acid sequence published by Ouyang et 
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al
39
 was modified, taking into consideration the insights outlined by Mucha et al
114
 to 
generate novel “hybrid” peptides. 
 
Figure II-6: Scheme, redesigned “hybrid” MMP14 substrates 
MMP14 substrate peptides were designed based upon reported MMP14-selective substrate 
sequences in the literature 
39,114
. Residues in red presented problems for fluorophore 
attachment due to their reactive side chains. Residues from the sequence presented by 
Mucha et al were substituted to generate new potential MMP14 substrates. Tryptophan 
(W) was chosen to replace the fluorescent dansyl (Dns) moiety due to structural similarity. 
Ac-KWSLNFLVC-cooh and Ac-K{Ahx}WSLNLFVL{Ahx}C-cooh were obtained 
as custom syntheses without any included fluorophores. To assess the suitability of these 
novel hybrid peptides as FRET substrates for MMP14, sequential attachment of 
sulfhydryl reactive FL-mal and amine reactive TAMRA-SE dyes was attempted, as 
schematically diagrammed in Figure II-7. 
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Figure II-7: Scheme, synthesis of 2-color FRET peptides using reactive dyes 
The general stepwise procedure (a) used to produce 2-color FRET peptides for visualizing 
MMP activity. Steps included reduction of disulfide dimers by reducing agent DTT, 
acetone precipitation to remove unreacted materials, and reaction with sulfhydryl-reactive 
fluorescein (b) as well as amine-reactive TAMRA (c) dyes. 
Unfortunately, handling of these peptides was generally difficult, often owing to 
insolubility in aqueous and organic solvents. When analysis was possible, products of 
synthesis generally reflected poor coupling of one dye or the other and afforded 
unsatisfactory FRET switch when treated with proteolytic enzymes (data not shown, 
outcomes summarized in Table II-2). 
Table II-2: Outcomes of MMP14-selective substrate trials 
Name Sequence  Outcomes/Properties  
#13 (Kridel)     FITC{Ahx}RIGF  *  LRTA{Ahx}C-cooh  Poor switch  
#14 (Mucha)      FITC{Ahx}PLA  *  XWAR{Ahx}C-cooh  Poor switch on dendrimer, non-selective  
Weiss        Ac-CSGESSN  *  LFVL{Ahx}-conh2  Solubility/dye conjugation issues 
Hybrid            Ac-KWSLN  *  LFVLC-cooh  Solubility/dye conjugation issues 
Hybrid-Ahx  Ac-K{Ahx}WSLN  *  LFVL{Ahx}C-cooh  Solubility/dye conjugation issues 
 
41 
 
II.3.4. Troubleshooting synthesis and MMP-cleavability of FRET peptides 
The challenges associated with synthesis of FRET substrates using unlabeled peptides 
and reactive dyes highlighted the need to characterize MMP cleavage efficiency 
following dye attachment. Therefore a broadly MMP-cleavable peptide 
(h2n-RPLGLWARC-cooh, hereafter referred to as “Broad2,” see Appendix A) with high 
sensitivity and previously characterized relative efficiencies with various MMPs
115
 was 
obtained. A 2-color FRET substrate, “TMR-Broad2-FL,” was synthesized by sequential 
addition of FL-mal and TAMRA-SE as depicted in Figure II-7, above. TMR-Broad2-FL 
possessed an absorbance spectrum characteristic of FAM and TAMRA dye inclusion 
(Figure II-8a), and upon incubation with trypsin demonstrated an increase in sensor 
(FAM) fluorescence over several minutes (Figure II-8b). The FRET switch potential of 
TMR-Broad2-FL was also assessed with MMP2 and MMP14, however only meager 
increases in sensor fluorescence were observed after 90 minutes (data not shown). 
Labeling of Broad2 peptide was repeated using the same synthetic strategy with several 
FRET-partnered dye pairs including TAMRA/FAM and AF700/AF750, however none of 
the substrates generated demonstrated a greater than 1.5-fold increase in sensor 
fluorescence upon proteolysis by trypsin (data not shown).  
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Figure II-8: Absorbance and FRET switch of 2-color Broad2 peptide 
2-color Broad2 FRET peptide was synthesized as diagrammed in Figure II-7 and analyzed 
by spectrophotometry (a) to confirm fluorophore attachment and fluorescence following 
treatment with trypsin or EDTA (b) to confirm proteolytic FRET switch. 
In an effort to troubleshoot the synthesis and consequent preteolysis sensing ability of 
FRET peptides, another 2-color substrate based on the Broad2 peptide was synthesized 
by sequential dye addition. “FL-Broad2-TMR” was synthesized by first attaching N-
terminal FAMSE and subsequently attaching C-terminal TAMRA-mal, as diagrammed in 
Figure II-9. This represented both a change in the positions of each dye and the order of 
reactions with succinimidyl ester- and maleimide-containing reactive dye species with 
respect to the previously synthesized TMR-Broad2-FL. Interestingly, the FRET switch of 
FL-Broad2-TMR reflected approximately a 17-fold increase in sensor fluorescence upon 
proteolysis by trypsin, however almost no difference from control with MMPs-
2,3,9,13,14 (Figure II-10).  
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Figure II-9: Scheme, synthesis of 2-color Broad2 FRET peptide using reactive dyes 
The stepwise procedure (a) used to produce 2-color “Broad2” FRET peptide for 
visualizing MMP activity. Steps included reduction of disulfide dimers by reducing agent 
DTT, acetone precipitation to remove unreacted materials, and reaction with amine-
reactive fluorescein (b) as well as sulfhydryl-reactive TAMRA (c) dyes. 
 
Figure II-10: FRET switch of 2-color Broad2 with proteolytic enzymes 
2-color Broad2 peptide with N-terminal fluorescein and C-terminal TAMRA, 
FL-Broad2-TMR, was synthesized as diagrammed in Figure II-9 and subjected to 
incubation with proteolytic enzymes with monitoring of sensor (FITC) fluorescence. Fold 
indicates multiple of initial fluorescence emission intensity (note: blank values were not 
subtracted prior to calculation of fold). Values represent average of duplicates. 
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To interrogate whether the lack of FRET switch with MMPs could be due to the 
carboxyl terminus or conformation of the peptide in solution, FL-Broad2-TMR was 
attached to PAMAM4 via EDAC-mediated coupling and the products recovered by 
ultrafiltration (technique analogous to II.2.2). FRET switch of the resulting PNBs 
demonstrated the same pattern as free peptide, with trypsin generating an increase in 
sensor fluorescence and MMPs generating no such increase (data not shown). 
We  hypothesized that the synthetic route of dye addition in solution phase as well as 
steric hindrance of the MMP cleavage site may have been interfering with the ability of 
substrate peptides to be cleaved by MMPs following synthesis. Therefore a series of 
peptides based on the previously described MMP14 substrate, Peptide #13, were obtained 
with FRET-partnered dyes attached during solid phase synthesis by the manufacturer 
(Peptide -13c, -13e, -13i, -13g, see Appendix A) and tested for FRET switch. The sensor 
fluorescence of Peptide 13c increased approximately 15-fold with exposure to pronase 
over 120 minutes, whereas MMP2 effected a modest 5-fold increase and other MMPs (3, 
7, 9 and 14) caused less than a 2-fold increase over the same time span (Figure II-11). 
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Figure II-11: FRET switch of Peptide 13c with proteolytic enzymes 
2-color Peptide 13c was incubated with proteolytic enzymes (50 nM active enzyme) with 
monitoring of sensor (FITC) fluorescence. Fold indicates multiple of initial fluorescence 
emission intensity after subtracting plate blank. Values represent average of triplicates. 
Error bars: SEM. 
To further investigate the role of steric hindrance of the cleavage site in preventing 
FRET switch, the series of Peptide 13-based 2-color substrates (Figure II-12a) were each 
incubated with pronase, MMP2, MMP14, or EDTA and sensor fluorescence monitored 
over time. All substrates exhibited rapid increases in sensor fluorescence when digested 
with pronase (Figure II-12b), however only Peptide 13i, which contained dabcyl instead 
of TAMRA, was apparently cleaved by both MMP2 and MMP14. Interestingly, only 
Peptide 13e, with two more amino acids between the dye-conjugated residues than 
Peptide 13c, demonstrated some selectivity for MMP14 over MMP2, an effect that was 
abrogated by the addition of an Ahx spacer in Peptide 13g (Figure II-12c,d). Baseline 
fluorescence from incubation of peptides with EDTA was subtracted from all other 
panels to calculate the increases in fluorescence with proteolytic enzymes (Figure II-12e). 
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Figure II-12: Investigation of Peptide #13 cleavage site steric hindrance 
A series of FRET peptides (a) based on the MMP14-selective cleavage sequence of 
Peptide #13 (Kridel et al) were purchased and subjected to incubation with pronase (b), 
MMP2 (c), MMP14 (d), or EDTA (e). The increase in FITC fluorescence generated due to 
incubation with enzymes (b-d) was calculated by subtracting the fluorescence of the 
EDTA control sample (e) at each timepoint. Values represent average of triplicates. 
To examine whether steric hindrance could explain the lack of MMP cleavage of FL-
Broad2-TMR despite demonstrated FRET switch potential, “Ahx-Broad2” 
[h2n-{Ahx}RPLGLWAR{Ahx}C-cooh, see Appendix A], a peptide design based on the 
Broad2 cleavage sequence with additional Ahx spacers to alleviate possible steric 
hindrance of the central MMP cleavage site, was obtained commercially. “Ahx-Broad2-
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vis” was synthesized in a 1-pot reaction analogous to the synthesis of FL-Broad2-TMR 
(Figure II-9), omitting the DTT reduction step and acetone precipitation between reactive 
dye attachment reactions. Measurable FRET switches resulted from proteolysis of Ahx-
Broad2-vis by MMP9, MMP2, and MMP14, in order of decreasing magnitude (Figure 
II-13). The increase in sensor fluorescence over time induced by MMPs was abrogated by 
the inclusion of EDTA in assay conditions. 
 
Figure II-13: FRET switch of Ahx-Broad2-vis with MMPs 
2-color Ahx-Broad2-vis peptide analogous to 2-color Broad 2 (Figure II-10) with 
additional Ahx spacers was subjected to incubation with MMPs (20 nM active 
concentration, each) with or without inclusion of EDTA and monitoring of sensor (FITC) 
fluorescence. Fluorescence of sample with buffer only was subtracted at each timepoint to 
calculate the enzyme-associated increase in fluorescence. Values represent single 
measurements. 
II.3.5. MMP-cleavability of folated substrate peptides 
Incorporation of folic acid as a targeting ligand tethered to nanoparticles by an MMP-
cleavable linker is integral to our dual-targeted nanoparticle design. It was therefore 
necessary to determine whether the covalent attachment of folic acid would prohibitively 
interfere with MMP proteolysis of dual-targeted constructs. Our laboratory has 
previously demonstrated FRET switch with 2-color variants of a substrate designed for 
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MMP9 cleavage, a peptide termed “M9” [h2n-{Ahx}AVRWLLTA{Ahx}C-cooh]109 
(unpublished data, Scherer and McIntyre). A folated version of this peptide, “M9-Folate” 
or “M9F” [fa-{Ahx}AVRWLLTA{Ahx}C-cooh] was obtained commercially for direct 
comparison of MMP cleavage and consequent FRET switch with M9. See Appendix A 
for detailed structures. 
2-color FRET peptides were synthesized from M9-Folate and M9 peptides (M9-
Folate-vis and M9-vis, respectively) via DTT reduction and sequential addition of 
FAMSE and TAMRA-mal, analogous to the synthesis of FL-Broad2-TMR, as 
diagrammed in Figure II-9. The resulting FRET peptides were analyzed for FRET switch 
potential and MMP cleavability by incubation with either trypsin or MMPs (3, 9, and 14). 
As seen in Figure II-14, the sensor fluorescence of both peptides increased rapidly over 
30 minutes of exposure to trypsin, however incubation with MMPs did not result in 
substantial increases in sensor fluorescence. The folation of M9F had no apparent effect 
on relative efficiencies of trypsin or MMP cleavage compared to M9. 
 
Figure II-14: FRET switch of M9-Folate-vis and M9-vis with proteolytic enzymes 
2-color FRET peptides were synthesized from M9-folate (a) and M9 (b) peptides via 
sequential dye addition with DTT reduction as diagrammed in Figure II-9 and subjected to 
incubation with proteolytic enzymes and monitoring of sensor (FITC) fluorescence. 
Fluorescence of sample with buffer only was subtracted at each timepoint to calculate the 
enzyme-associated increase in fluorescence. Values represent single measurements. 
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Because the FRET switch results with M9F and M9 mirrored those of FL-Broad2-
TMR and because there exists evidence of thiol-based inhibition of MMP activity
118–120
, 
the use of DTT in the synthesis of 2-color FRET substrates was questioned. Synthesis of 
M9-Folate-vis and M9-vis was therefore repeated employing a 1-pot reaction analogous 
to the synthesis of Ahx-Broad2-vis (see II.3.4) but with TAMRA-maleimide in the first 
reaction and FAMSE in the second. This had so significant impact either on the 
maximum potential FRET switch with trypsin or on the relative MMP cleavability for 
either peptide (data not shown). 
 To further investigate whether the presence of the folate moiety was affecting 
peptide cleavage by MMPs, unlabeled M9-Folate peptide was subjected to incubation in 
buffer with and without MMP9 for proteolysis and analyzed by LCMS. The most 
substantial ions detected in the non-cleaved control sample corresponded to the expected 
molecular weight of disulfide dimers of the intact M9-Folate peptide (Figure II-15a,d). 
The MMP9-treated sample, however, contained ions with M/z corresponding to doubly-
charged states of the N-terminal fragment and disulfide dimers of the C-terminal 
fragment expected from MMP cleavage of M9-Folate (Figure II-15b-d), thereby 
confirming proteolysis of the folated peptide by MMP9. 
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Figure II-15: LCMS analysis of M9-Folate peptide and MMP9 cleavage products 
M9-Folate (M9F) peptide was analyzed by LCMS before (a) and after (b,c) treatment with 
MMP9 to obtain mass spectra. M/z of ions detected in untreated M9F sample (a) 
corresponded to disulfide dimers of the intended structure. The MMP9-treated sample 
contained ions with M/z peaks corresponding to the N-terminal product (b) and disulfide 
dimers of the C-terminal product of MMP9 cleavage. Detected ions and corresponding 
chemical species are tabulated (d). 
To obviate the sequential dye addition synthesis as a potential confounding reason for 
lack of MMP cleavage of FRET substrates, two custom peptides with amino acid 
sequences based on the broadly MMP-cleavable Broad2 peptide and with fluorescein and 
TAMRA dyes incorporated as part of solid phase synthesis by the manufacturer were 
obtained. “GG-Broad2-vis” [h2n-GGK(fam)RPLGLWARGGK(tamra)G-cooh] and “FA-
GG-Broad2-vis” [fa-GGK(fam)RPLGLWARGGK(tamra)G-cooh] (see Appendix A) 
were analyzed by FRET switch assay with either trypsin or MMPs (2, 9, and 14). 
Unfortunately, neither peptide demonstrated greater than 3-fold increase in sensor (FAM) 
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fluorescence over 30 minutes of incubation with any enzyme, though surprisingly GG-
Broad2-vis developed a nearly 5-fold increase in reference (TAMRA) fluorescence 
during incubation with trypsin (data not shown). Subsequent UV-visible 
spectrophotometry comparing (FA-)GG-Broad2-vis with 2-color peptides previously 
acquired from the same supplier revealed low TAMRA absorbance relative to that of 
FAM (data not shown). The supplier confirmed difficulty in the coupling chemistry for 
attachment of the TAMRA fluorophore. 
II.3.6. Synthesis and characterization of a broadly MMP-cleavable FRET peptide 
by SPPS 
Due to the inconsistencies encountered with 2-color FRET peptides both from 
sequential fluorophore attachment to peptides in solution phase and from commercial 
sources, I explored the possibility of synthesizing a peptide using conventional Fmoc-
SPPS. In addition to traditional amino acids, several reagents were commercially 
available for synthesis of unusual and modified peptide structures, including fluorophore-
bearing lysine residues (Figure II-16a,b) and short polyethylene glycol (PEG) residues 
(Figure II-16c). As such, we designed and synthesized a broadly MMP-cleavable 
substrate bearing FAM and TAMRA dyes and flexible hydrophilic PEG spacers using an 
automated peptide synthesizer for conventional Fmoc-SPPS (Figure II-16d). Refer to 
Appendix A for chemical structure of “peg-Broad2-vis (pB2v).” 
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Figure II-16: Schema for solid phase peptide synthesis of peg-Broad2-vis 
Reagents for SPPS of fluorescent peptides, Fmoc-Lys(5/6-FAM)-OH (a) and Fmoc-
Lys(5/6-TAMRA)-OH (b), as well as hydrophilic spacer residue Fmoc-PEG1-CH2-COOH 
(c) were acquired commercially (shorthand representations in bold). “peg-Broad2-vis 
(pB2v)” peptide was synthesized on a rink amide resin using a PS3 automated peptide 
synthesizer to yield a C-terminally amidated peptide (d). 
LCMS performed on the crude peptide mixture recovered from final deprotection and 
cleavage of pB2v from the solid support resin indicated a heterogeneous mixture of 
chemical species partially resolved by chromatography (Figure II-17a). However, ions 
with M/z corresponding to the triply-charged state (Figure II-17b) as well as other charge 
states (Figure II-17c) of the expected structure of pB2v were identified within the LCMS 
analytes. 
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Figure II-17: LCMS of peg-Broad2-vis crude peptide mixture from SPPS 
The crude peptide mixture from SPPS of pB2v peptide (Figure II-16d) was characterized 
by LCMS to give total ion counts (a). A chromatogram representing the ions with M/z 
corresponding to the triply-charged state of the expected peptide was extracted (b) and the 
mass spectrum of the peak integrated (c). Ions with M/z corresponding to the multiple 
charge states of expected pB2v structure (472, 589, 786) were detected.  
As such, semi-preparative HPLC separation and recovery of the pB2v crude peptide 
mixture were performed and three separate fractions collected for further workup (Figure 
II-18a). LCMS analysis of each collection confirmed the presence of ions with M/z 
corresponding to pB2v in the second fraction collected, although “pB2v_2,” indicated a 
still heterogeneous mixture of chemical species (data not shown). pB2v_2 was therefore 
separated again by semi-preparative HPLC with a focused solvent gradient to afford three 
further subdivided collections: pB2v_2.1, _2.2, and _2.3 (Figure II-18b). LCMS analysis 
was repeated with each of the collected fractions to confirm the presence of pB2v in 
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pB2v_2.2 (data not shown), which was then purified again by semi-preparative HPLC to 
afford a single peak, collected as pB2v_2.2.1 (Figure II-18c). 
 
Figure II-18: Iterative HPLC purification of pB2v 
pB2v peptide mixture from SPPS was separated by semi-preparative RP-HPLC with 
monitoring of eluent absorbance at 550 nm (TAMRA) and fractions collected (a). This 
process was iterated to further purify Fractions #2 (b) and# 2.2 (c) as labeled to ultimately 
yield a product fraction labeled “pB2v_2.2.1.” Green and red dashed lines indicate 
approximate start and end of fraction collection, respectively. 
The purified peptide, pB2v_2.2.1, was then incubated with either trypsin or MMPs (2, 
9, or 14) to assess FRET switch potential and relative cleavage efficiency. Importantly, 
sensor fluorescence of pB2v_2.2.1 increased upon proteolytic cleavage by trypsin and 
each MMP (Figure II-19), though direct comparison of rates of fluorescence increase is 
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inappropriate because in this experiment the concentrations of active MMPs varied from 
enzyme to enzyme. 
 
Figure II-19: FRET switch of purified pB2v_2.2.1 peptide 
Following iterative purification by semi-preparative RP-HPLC, pB2v_2.2.1 peptide 
product was incubated with proteolytic enzymes and the fluorescence of the sensor moiety 
(FAM) monitored over time. Note: plot represents raw fluorescence measurements; plate 
blank was not subtracted from values. Values represent single measurements. 
The efficiency of enzymatic cleavage of pB2v_2.2.1 by MMPs was determined by 
calculating the specificity constants, kcat/Km, as follows: 
eem
cat
CF
M
K
k
 , 
where M is the initial rate of fluorescence increase, Fe is the maximum fluorescence 
increase for a particular enzyme-substrate pair and Ce is the concentration of active 
enzyme as determined by inhibitor titration assay (see Appendix B)
116
. From the results 
depicted in Figure II-19, peg-Broad2-vis_2.2.1 is roughly 1.5 times more efficient a 
substrate for MMP14 than for MMP2, and approximately twice as efficient for MMP9 as 
for MMP14 (Table II-3), which is in general agreement with published relative 
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efficiencies for substrates with a very similar amino acid sequence in the MMP cleavage 
site (P4-P4’)
115
.  
Table II-3: Enzyme specificity values for pB2v_2.2.1 with MMPs 
Enzyme kcat/Km (M
-1
 s
-1
) 
MMP2 6.51E+03 
MMP9 1.96E+04 
MMP14 9.57E+03 
 
II.4. DISCUSSION AND CONCLUSIONS 
The work presented above was initially focused on the development of proteolytic 
nanobeacons to provide optical sensing of MMP14 activity and targeting of the optical 
sensor to folate receptors for cellular internalization. To this end, proteolytic nanobeacons 
and FRET-equipped peptide substrates were synthesized and characterized for their 
optical properties and MMP-cleavability. 
Based upon the relatively small and inconsistent FRET switches observed from 
proteolytic nanobeacons synthesized with MMP14 substrate peptides derived from 
previously published studies (Figure II-3), we hypothesized that attachment of FRET-
paired fluorophores directly to the substrate peptide would provide a more robust optical 
switch than attachment of the quenching/reference fluorophore to the nanoparticle core, 
both in terms of proportional energy transfer and batch-to-batch reproducibility. To test 
this hypothesis we synthesized “2-color” peptides decorated with both FITC and 
TAMRA dyes, well-characterized visible-spectrum fluorophores that participate in 
FRET. “F14T” 2-color MMP14 substrate exhibited excellent optical switch potential 
when digested by the bacterial protease, pronase, and to a lesser degree with MMP14, 
however was not as selective for MMP14 as desired, as shown in Figure II-5. “F13T,” on 
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the other hand, demonstrated a smaller maximum optical switch, but was somewhat more 
selective for MMP14, corroborating previously published findings that a proline residue 
in the P3 substrate position is favorable for cleavage efficiency by the MMP family 
broadly, whereas an arginine residue in the P4 position seems to provide some degree of 
selectivity for MMP14 
113,114
. In general, cleavage efficiency and enzyme selectivity of 
substrates present a trade-off that must be managed to provide an effective sensor that is 
not promiscuous for other metalloproteinases or proteases. 
To provide an effective sensor for MMP14-selective proteolytic nanobeacons, several 
published amino acid sequences with either high selectivity
39
 or high efficiency
114
 of 
cleavage by MMP14 were amalgamated to generate novel MMP14 substrate peptides 
with side chains compatible with the chemistry of 2-color peptide synthesis. These 
peptides were obtained as unlabeled peptides, requiring the bioconjugation of FAM and 
TAMRA dyes to facilitate FRET and the consequent optical switch. Unfortunately, 
handling of these peptides was challenging due to insolubility in aqueous and organic 
solvents and multi-step processes to attach both fluorophores. As such, the products of 
our syntheses lacked sufficient optical switch for MMP activity sensing applications, as 
indicated in Table II-2. 
Revisiting the conceptual design of folate-targeted proteolytic nanobeacons and the 
current understanding of the tumor microenvironment, the use of a substrate peptide 
selective for MMP14 was questioned. Although MMP14 has been shown to possess 
pleiotropic roles as a proteinase capable of hydrolyzing several classes of proteins, 
including activation of MMP2 and MMP8
8,11
, and has been shown to play vital roles in 
tumor cell invasion and metastasis
42,110
, its confinement at the cell surface as a 
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membrane-type MMP could present a limitation to the extracellular processing of 
proteolytic nanobeacons prior to folic acid-mediated cellular internalization. On the other 
hand, the extracellular milieu of a solid tumor may often be rich in secreted MMPs
15,16
, 
especially near the leading edges of invasive malignant cells
121–123
. As such, the use of a 
broadly MMP-cleavable substrate as the scissile linker for proteolytic nanobeacons was 
investigated as a more promising approach to effect dual-targeted delivery. 
The chemistry of FAM and TAMRA labeling of substrate peptides was therefore 
troubleshot using a broadly MMP-cleavable substrate peptide termed Broad2. This 
peptide was derived from a published substrate with high cleavage efficiency with 
MMPs
115,124
 in order to provide the most robust means for evaluation of the optical 
switch resulting from fluorescent substrate hydrolysis. Interestingly, as demonstrated in 
Figure II-8 and Figure II-10, attachment of FAM and TAMRA was confirmed by UV-
visible absorbance and FRET switch upon proteolysis with trypsin, however no 
concordant increase in sensor (FAM) fluorescence emission was observed upon treatment 
with MMPs. These results suggest that this particular fluorophore-labeled peptide forms a 
conformation unfavorable for proteolytic cleavage by MMPs. 
In order to obviate peptide handling and the synthetic route of dye addition as 
confounding reasons for lack of an optical switch with MMPs in 2-color MMP substrates, 
peptides with FRET-paired fluorophores attached as part of synthesis in solid phase were 
acquired commercially. These substrates, all based on a core amino acid sequence with 
reported enzyme selectivity for MMP14 (“Peptide #13”)113, differed from one another 
either in the type or number of residues separating the fluorophores or in the fluorophore 
used to accept energy from FITC, as specified in Figure II-12. FRET was confirmed in all 
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peptides of the series, as each substrate exhibited a substantial increase in FITC 
fluorescence upon proteolysis by pronase. However only Peptide 13i, which featured a 
less bulky FITC quenching moiety in dabcyl instead of TAMRA, exhibited some 
fluorescence enhancement upon treatment with either MMP2 or MMP14 to indicate 
cleavage. This result suggests that steric hindrance of the MMP cleavage site may inhibit 
MMP cleavage of substrate peptides comparable in length and number of residues 
separating fluorophores. Furthermore, while Peptide 13c was not well-cleaved by MMPs, 
Peptide 13e possessing two additional amino acids between FITC and TAMRA was 
cleaved by MMP14 but not MMP2. Interestingly, Peptide 13g, longer still by the addition 
of a hydrophobic Ahx spacer, was not cleavable by MMPs, indicating that hydrophobic 
residues near the MMP cleavage site may also inhibit proteolysis by MMPs. These 
findings corroborate the documented crystal structures of MMPs and the proposed 
mechanism of proteolysis by metalloproteinases. MMP2 is reported to possess a 
shallower substrate binding pocket than MMP14
125
 and in each case the hydrolysis of the 
scissile peptide bond in the substrate requires water
10
. 
To isolate steric hindrance as the intervening problem in MMP cleavage of the 
aforementioned Broad2 peptide, an analogous peptide with an additional N-terminal Ahx 
group, Ahx-Broad2, was obtained commercially and labeled with FAM and TAMRA 
fluorophores as with Broad2, previously. The resulting Ahx-Broad2-vis peptide was 
cleaved by MMPs (2, 9, and 14) resulting in FRET switches with each MMP, as shown in 
Figure II-13. Proteolysis was confirmed to be attributable to metalloproteinase activity by 
the abrogation of FRET switch in samples including both MMPs and EDTA to chelate 
free metal ions. Taken together with the evident inability of MMPs to cleave dye-labeled 
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Broad2 and the Peptide 13-based series of substrates to varying degrees, this finding 
indicates that steric hindrance of the MMP cleavage site due to proximity of FITC and 
TAMRA is an important consideration in the design of fluorescent substrate peptides for 
proteolytic nanobeacon synthesis. Nonetheless, the results reported here demonstrate that 
synthesis of MMP substrate peptides with visible-spectrum fluorophores for optical 
imaging of MMP-associated proteolytic activity is feasible. 
Given the obstacles to proteolytic cleavage presented by the relatively bulky organic 
dye molecules, FITC/FAM and TAMRA, we hypothesized that N-terminal attachment of 
folic acid, another quite hydrophobic molecule, could also inhibit MMP-dependent 
proteolysis of substrate peptides. Because incorporation of folic acid as a targeting ligand 
tethered to nanoparticles by an MMP-cleavable linker is integral to our dual-targeting 
design, we assessed proteolysis of a folated analogue of an MMP9-selective substrate, 
M9, that was found previously to exhibit FRET switch from 2-color variants exposed to 
MMP9
109
 (unpublished data, Scherer and McIntyre). M9 and M9-Folate were obtained 
commercially as non-fluorescent peptides and initially labeled with FAMSE and 
TAMRA according to the same procedure used for 2-color Broad2 that incorporated DTT 
for reduction of intermolecular disulfide bonds that may have formed in solution (see 
Figure II-9). FRET switch was observed from both constructs (M9-vis and 
M9-Folate-vis) upon treatment with trypsin, but surprisingly neither construct was 
cleaved by MMPs, as shown in Figure II-14. As a result, no conclusion could be drawn 
from this experiment regarding the effect, if any, of N-terminal folation on MMP 
cleavage efficiency. 
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The FRET switch results with M9-vis and M9-Folate-vis mirrored those of 
FL-Broad2-TMR and other peptides synthesized using DTT as a reducing agent. Given 
that thiol-based inhibition of MMP activity has been sparsely reported
118–120
, synthesis of 
M9-Folate-vis and M9-vis was repeated employing a 1-pot reaction analogous to the 
synthesis of Ahx-Broad2-vis, a peptide that exhibited FRET switch upon MMP cleavage 
(see II.3.4). The revised synthetic route had no significant impact either on the maximum 
potential FRET switch with trypsin or on the relative MMP cleavability for either 
peptide, M9-vis or M9-Folate-vis (data not shown). Neither folate alone nor the use of 
DTT alone accounted for the inability of MMPs to cleave 2-color M9 peptides. 
To focus on the N-terminal attachment of folic acid as a possible interferent with 
MMP cleavage of substrate peptides, unlabeled M9-Folate peptide was incubated with 
MMP9 and the resulting reaction mix analyzed by LCMS. While ions with M/z 
corresponding to disulfide dimers of M9-Folate peptides were found in both the MMP9-
treated and control samples, the detection of ions corresponding to the expected MMP9 
cleavage products of M9-Folate in the MMP9-treated sample (Figure II-15) suggests that 
N-terminal folation alone does not block MMP-dependent proteolysis of substrate 
peptides. 
To obviate the sequential dye addition synthesis as a potential confounding reason for 
lack of MMP cleavage of FRET-equipped substrates, two peptides based on Broad2 with 
fluorescein and TAMRA dyes incorporated in solid phase synthesis by the manufacturer 
were obtained and analyzed by FRET switch assay with trypsin and MMPs (2, 9, and 14). 
Unfortunately, neither peptide demonstrated greater than 3-fold increase in sensor (FAM) 
fluorescence over 30 minutes of incubation with any enzyme. UV-visible 
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spectrophotometry comparing these peptides with 2-color peptides previously acquired 
from the same supplier revealed low absorbance by TAMRA relative to that of FAM 
(data not shown), suggesting that the lack of FRET switch from these peptides may have 
been attributable to insufficient quenching of fluorescein. A significant fraction of these 
particular peptide batches probably lacked the TAMRA quencher required for 
intramolecular FRET.  
Due to the challenges and inconsistencies encountered with 2-color FRET peptides 
both from sequential fluorophore attachment to peptides and from completely 
commercially prepared peptides, I designed and synthesized a 2-color peptide using 
conventional Fmoc-SPPS. Taking into consideration the potential inhibition of MMP 
cleavage by steric hindrance and/or hydrophobic spacers discussed above, we designed a 
FRET-equipped, broadly MMP-cleavable substrate peptide with hydrophilic spacers 
based on Broad2 and PEG, peg-Broad2-vis (pB2v), as diagrammed in Figure II-16. 
LCMS analysis of the crude peptide mixture produced by SPPS of pB2v (Figure II-17) 
indicated a heterogeneous mixture, although ions with M/z indicative of the intended 
macromolecular structure were detected, corroborating some degree of successful pB2v 
synthesis by SPPS. This synthetic route was further validated by assessing the FRET 
switch of pB2v_2.2.1, a peptide sample purified by iterative HPLC with collection of 
eluted analytes. Sensor (FAM) fluorescence of pB2v_2.2.1 increased at differing rates 
upon incubation of pB2v_2.2.1 with trypsin, MMP2, MMP9, or MMP14, as shown in 
Figure II-19. The calculated relative enzyme specificities of pB2v_2.2.1 with MMPs 
(Table II-3), show that synthesis of FRET-equipped substrate peptides by SPPS yielded 
an MMP-cleavable peptide with a FRET switch sufficient for optical sensing of MMP 
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activity. Furthermore, SPPS of FRET-equipped peptides provides the benefit of 
adaptability to any desired amino acid sequence that constitutes a substrate for an enzyme 
of interest and could therefore prove useful in many areas of biomedical research in 
which proteolytic degradation plays a key role. Indeed, over 570 individual proteases 
have been identified in the human proteome and linked to over 114 different hereditary 
diseases
126
. Subsequent studies were performed with beacon peptides produced by SPPS. 
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CHAPTER III 
 SYNTHESIS AND CHARACTERIZATION OF FOLATE-CONJUGATED, 
FRET-EQUIPPED, MMP-CLEAVABLE LINKER PEPTIDES 
III.1. INTRODUCTION 
The previous chapter focused on the design of proteolytic nanobeacons and synthesis 
and characterization of FRET-equipped MMP substrate peptides as precursors for 
proteolytic nanobeacon synthesis. Importantly, it was found that attachment of FAM and 
TAMRA directly to the substrate peptide can lead to robust FRET switch upon 
proteolysis. However, this strategy can also present significant challenges in the 
chemistry to attach fluorophores while preserving MMP cleavability as well as ability to 
attach folic acid and conjugate peptides to nanoparticles. Ultimately, SPPS presented a 
synthesis technique that could achieve all of these aims simultaneously by incorporating 
FAM and TAMRA attached to the side chains of lysine residues, leaving the N-terminus 
and C-terminus of peptides available for reaction.  
Neither attachment of dyes nor attachment of folic acid alone were found to block 
substrate cleavage by MMPs, yet FRET switch with a folated MMP substrate peptide 
cleaved by MMPs was not demonstrated above. A purified product of SPPS 
demonstrated sufficient FRET switch upon treatment with MMPs to optically sense 
MMP activity, however it represented a small fraction of the product of synthesis. As 
such, the scope of this chapter is two-fold. The research that follows focuses both on the 
optimization of SPPS techniques to produce FRET-equipped MMP substrate peptides in 
sufficient yields and the development of an appropriate chemical synthesis technique for 
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N-terminal folation of such peptides. The results below elucidate the development of a 
robust protocol for SPPS of folated MMP substrate peptides exhibiting FRET switch 
upon cleavage by MMPs and with the potential for conjugation to nanoparticles via 
appropriate chemical functional groups. We specifically demonstrate that a folation of a 
broadly MMP-cleavable peptide yields a substrate that is cleavable by MMPs, the sensor 
(FAM) fluorescence emission of which is amplified upon treatment with MMPs.  
III.2. MATERIALS AND METHODS 
III.2.1. General Methods 
All chemicals and biochemicals were reagent-grade or HPLC-grade and solutions 
were prepared in filtered deionized water (dH2O) (Milli-Q, Billerica, MA, USA). Unless 
otherwise noted, all chemicals were purchased from either Sigma Aldrich (St. Louis, MO, 
USA) or Thermo Fisher Scientific (Waltham, MA, USA). B16-F10 mouse melanoma 
cells and MDA-MB-468 human breast adenocarcinoma cells were obtained from ATCC 
(Manassas, VA, USA). CT26 mouse colon carcinoma cells were a gift from the Pozzi 
Laboratory (Vanderbilt University School of Medicine, Nashville, TN, USA). R221A 
mouse mammary tumor cells were isolated previously by our laboratory as described 
elsewhere
127
. 
III.2.2. Chromatography and mass spectrometry 
HPLC and LCMS were performed as described above (see II.2.1) unless otherwise 
specified. HPLC traces where chromatograms monitoring absorbance at 495 nm are 
shown were collected using mobile phases 50 mM phosphate buffer (pH 7.0) in HPLC-
grade water (A) and HPLC-grade MeOH (B) for chromatography. Matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry was performed 
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using a Voyager-DE™ STR Workstation (Applied Biosystems, Foster City, CA, USA). 
Samples were diluted 1:1 in a saturated solution of α-Cyano-4-hydroxycinnamic acid 
(CHCA) in 60% MeCN with 0.1% TFA and dried as 1.0-1.5 µL spots on gold-plated 
MALDI plates. 
III.2.3. Analysis of pB2v SPPS products by mass spectrometry 
HPLC-purified product of SPPS, pB2v_2.2.1, was analyzed by LCMS and MALDI-
TOF MS (1:100 dilution in dH2O prior to dilution into CHCA solution) to determine the 
molecular weight of constituent chemical species. pB2v_2.2.1 was subsequently diluted 
in assay buffer (see section II.2.3) and treated with trypsin, MMP2, or MMP14 overnight 
to allow for proteolysis. 10 µL from each protolysis sample was then desalted by repeated 
pipetting through u-C18 ZipTip (EMD Millipore, Darmstadt, DE) and analyzed by 
MALDI-TOF MS. 
III.2.4. Qualitative Ninhydrin assay (Kaiser test) 
Resin samples for analysis were transferred to glass test tubes, washed repeatedly 
with EtOH and air dried. To dried resin beads, equal parts of three solutions were added: 
1.4 M Ninhydrin reagent in EtOH, 21 M phenol in EtOH, and 100 µM potassium cyanide 
in pyridine. The resulting mixture was heated to 100 °C for 5 minutes in a stirring oil 
bath and visually inspected for development of blue-violet hue characteristic of formation 
of Ruhemann’s purple in the presence of amine functional groups. 
III.2.5. Troubleshooting of pB2v produced by SPPS 
Monitored synthesis. SPPS of pB2v peptide was repeated as before (see II.2.11), 
interrupting automated synthesis to assess completeness of residue coupling by 
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qualitative Ninhydrin assay (III.2.4, above) at suspect coupling steps. MALDI-TOF MS 
and FRET switch assay with trypsin and MMPs-2,9,14 were repeated as with previously 
synthesized pB2v.  
Mass spectrometry. Electrospray ionization quadrupole ion-mobility time-of-flight 
(ESI-Q-IM-TOF) mass spectrometry and MS-MS were performed on a Synapt G2 
HDMS (Waters, Milford, MA, USA) by Kelly Hines of the McLean Laboratory 
(Vanderbilt University, Nashville, TN, USA). The crude pB2v peptide mixture from 
SPPS was analyzed by ESI-Q-TOF MS and MS-MS. Following separation of pB2v by 
analytical-scale HPLC, ESI-Q-TOF MS was repeated on recovered HPLC fractions. 
NMR. Nuclear magnetic resonance (NMR) spectra were acquired by Don Stec (Small 
Molecule NMR Facility Core, Vanderbilt University, Nashville, TN, USA) using a 14.0 
T Bruker magnet equipped with a Bruker AV-III console operating at 600.13 MHz. All 
spectra were acquired in 3mm NMR tubes using a Bruker 5 mm TCI cryogenically 
cooled NMR probe. Chemical shifts were referenced internally to D2O (4.70 ppm) which 
also served as the 2H lock solvents. For 1D 1H NMR, typical experimental conditions 
included 32K data points, 13 ppm sweep width, a recycle delay of 1.5 seconds and 64 
scans. Total Correlation Spectroscopy (TOCSY) experiments were acquired using a 2048 
x 512 data matrix with a 120 ms DIPSI spinlock, 2 seconds recycle delay and 8 scans per 
increment. The data was processed using a π/2 shifted squared sine window function and 
displayed in absorption mode. J1(C-H) filtered heteronuclear multiple bond correlation 
(HMBC) experiments were acquired using a 2048 x 256 data matrix, a J(C-H) value of 9 
Hz for detection of long range couplings resulting in an evolution delay of 55ms, J1(C-H) 
filter delay of 145 Hz (34 ms) for the suppression of one-bond couplings, a recycle delay 
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of 1.5 seconds and 128 scans per increment. The HMBC data was processed using a π/2 
shifted squared sine window function and displayed in magnitude mode. 
MTT assay. B16 melanoma, CT26 colon cancer, and R221A breast cancer cells were 
seeded at 5,000 cells per well in wells of a clear 96-well plate and allowed to adhere in 
Dulbecco’s Modified Eagles Medium (DMEM, Life Technologies, Carlsbad, CA, USA). 
Unpurified pB2v peptide including the unidentified 56-Da adduct was dissolved in dH2O 
to an undetermined concentration and serially diluted in DMEM to give concentrations of 
100%, 33%, 10%, 3.3%, 1%, and no peptide (dH2O and medium). Cell culture medium 
was aspirated from wells containing cells and replaced with medium containing the serial 
dilutions of peptide. After overnight incubation, fresh medium was added to cells and a 
standard MTT Assay protocol performed. 20 µL Methylthiazolyldiphenyl-tetrazolium 
bromide (MTT reagent, 5 mg/mL in dH2O) was added to each well and incubated for 1 
hour at 37 °C. Media was then aspirated from wells and replaced with 100 µL isopropyl 
alcohol and the absorbance of each well at 570 nm measured. 
D-pB2v. Fmoc-D-amino acids were purchased from Anaspec (Fremont, CA, USA). A 
peptide homologous to pB2v with the exception of the inclusion of biologically inactive 
D-amino acids in place of L-amino acids in the cleavage sequence (RPLGWLAR) was 
synthesized by SPPS (method, see II.2.11). Preparation of analytical samples, MALDI-
TOF MS, FRET switch assay with either trypsin or MMPs-9,14, and UV-visible 
spectrophotometry were carried out in parallel with pB2v (L-amino acids) as described 
previously (see II.2.11, II.2.3, III.2.2). 
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III.2.6. Synthesis and characterization of N-terminally folated MMP substrate 
peptides 
The broadly MMP-cleavable substrate peptide, “Ahx-Moss” 
[{Ahx}GPLGMRGS{Ahx}C-conh2], was obtained as a custom synthesis from Biomer 
Technologies (Pleasanton, CA, USA). pB2v peptide was synthesized by SPPS as 
described previously (see II.2.11, III.2.5) and remained attached to solid support resin. 
DCC coupling in solution. Attachment of folic acid to the N-terminus of the peptide 
was first attempted by carbodiimide carboxyl-to-amine coupling. 1.2 mg (2.72 µmol ) 
folic acid (FA) was added to the manufacturer’s glass ampule containing 2 mg (1.81 
µmol ) Ahx-Moss peptide, followed by 70 µL dimethylsulfoxide (DMSO), 42 µL 
pyridine, 60 µL DMF, and a small magnetic stir bar. The ampule was then sealed and 
purged of atmospheric air by nitrogen gas bubbling for 15 minutes. 20 µL (3.63 µmol ) 
dicyclohexylcarbodiimide (DCC) was injected, preserving air-free conditions, and 
reacted with continuous stirring for 3 days. Aliquots were removed at 0, 1, 2, and 72 
hours and analyzed by HPLC. 
FA-NHS coupling in solution. Succinimidyl ester of folic acid (FA-NHS) was a gift 
from Dr. Wellington Pham (Institute of Imaging Science, Vanderbilt University, 
Nashville, TN, USA). To 2 mg (1.81 µmol ) Ahx-Moss peptide in the manufacturer’s 
glass ampule were added 300 µL of buffer [50% MeCN in dH2O adjusted to pH 7.5 using 
sodium carbonate (Na2CO3) and 1 N hydrochloric acid (HCl)] and a small magnetic stir 
bar. The ampule was then sealed and purged of atmospheric air by argon gas flow, 
maintaining positive pressure throughout addition of remaining reagents. 20 µL (495 
nmol) FA-NHS in DMSO was injected and the reaction stirred at RT. At 0, 1, and 2 hours 
following reaction start, aliquots of reaction mix and reactants at matched concentration 
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were spotted on disposable plates for thin-layer chromatography (TLC). Mobile phase 
used for all TLC was 35% MeOH in dichloromethane (DCM) with 1% 1 N HCl. TLC 
spots were visualized with iodine vapor staining. After overnight stirring at RT, 100 µL 
(2.25 µmol ) freshly-dissolved FA-NHS in DMSO was injected into the reaction mixture. 
Following 80 minutes further reaction, reaction mix and reactants were spotted for TLC. 
Due to formation of a turbid solution, 500 µL buffer was added and the entire reaction 
mix centrifuged to separate phases. Pelleted solute was resuspended in 100 µL DMSO 
and both phases analyzed by TLC and MALDI-TOF MS. Pelleted products of Ahx-Moss 
peptide and FA-NHS reaction were purified by semi-preparative HPLC (general method, 
see II.2.1) and lyophilized to yield an oily yellow solid. This recovered product was then 
analyzed by MALDI-TOF before and after overnight incubation with MMP9 in standard 
assay buffer (see II.2.3) at RT. 
FA-NHS coupling on solid phase. 31.9 mg (estimated 6 µmol  peptide equivalent) of 
pB2v peptide-resin was weighed into a 10 mL round-bottom Pyrex flask. 6.5 mg (14.7 
µmol ) FA-NHS, 1.0 mL DMSO, and 10 µL triethylamine (TEA) were then added to the 
flask and reacted overnight with stirring, protected from light. The reaction slurry was 
then filtered over a glass-fritted filter (Büchner funnel) and the solid peptide-resin washed 
thoroughly with DMF and EtOH prior to drying under vacuum. Final deprotection, 
cleavage from solid support, and precipitation of peptide was performed as before (see 
II.2.11), substituting cleavage cocktail K [82.5% TFA, 5% H2O, 5% phenol, 5% 
thioanisole, 2.5% ethanedithiol (EDT)] for cocktail B. After removing trace solvents by 
rotary evaporation, dried crude peptide mixture was reconstituted in HPLC-grade water 
and analyzed by MALDI-TOF MS (general method, see III.2.2). 
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HCTU coupling on solid phase. 360 µL (16.7 µmol ) HCTU in SPPS activator 
solution was combined with 360 µL (16.3 µmol ) FA in NMP and vortexed 10 minutes 
(Note: in general, this procedure was subsequently performed with 95:100 molar 
equivalents HCTU:FA). 405 µL (9.2 µmol  FA equivalent) of the resulting activated FA 
solution was added to 10 mg (1.83 µmol  estimated peptide equivalent) dry pB2v peptide-
resin and reacted at RT, vortexting, overnight. Folated peptide resin was washed over a 
glass Büchner funnel with DMF followed by EtOH, shell frozen in dH2O, and lyophilized 
prior to further workup. Final deprotection, cleavage from solid support, and precipitation 
of folated peptide was performed as before using cleavage cocktail R (95% TFA, 5% 
thioanisole, 3% EDT, 2% anisole). The resulting crude FApB2v peptide mixture was 
shell frozen in dH2O and lyophilized. Lyophilized peptide was reconstituted in 50% 
MeCN and analyzed by LCMS, purified by semi-preparative HPLC (general methods, 
see II.2.1), and characterized by FRET switch assay with either trypsin or MMPs-2,9,14. 
III.2.7. General procedures for folation and acetylation of peptides in solid phase 
Folation. Peptide-resins from SPPS were N-terminally deprotected as described 
previously (II.2.11), rinsed thoroughly with DMF and EtOH, and dried under vacuum. 
11.4 molar equivalents HCTU in SPPS activator solution and 12 molar equivalents FA in 
NMP (95:100 HCTU:FA) relative to the moles of peptide N-termini (calculated from the 
weight of dry peptide-resin) were combined and vortexed 10 minutes. The entirety of the 
resulting activated FA solution was added to dry peptide-resin and reacted at RT, 
vortexting, overnight. 
Acetylation. Peptide-resins from SPPS were N-terminally deprotected as described 
previously (II.2.11), rinsed thoroughly with DMF and EtOH, and dried under vacuum. 
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Dry peptide-resin was submerged in a solution of either [10% acetic anhydride, 10% 
diisopropylethylamine (DIPEA), 80% DMF] or (25% acetic anhydride, 25% pyridine, 
50% NMP) and reacted with vortexing at least 1 hour to effect acetylation of peptide N-
termini. 
III.2.8. Synthesis and characterization of FRET peptides for oxime ligation 
Fmoc-Dpr(Boc-Aoa)-OH and Fmoc-Lys(ivDDE)-OH were purchased from EMD 
Chemicals (Billerica, MA, USA). Synthesis of “pB2vAoa” FRET peptide 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2] bearing a 
C-terminal aminooxy moiety for chemoselective attachment to carbonyl functional 
groups by oxime ligation was performed by SPPS as described previously (see II.2.11) 
with modifications for optimization of yield.  
SPPS using K(fam). pB2vAoa was initially synthesized using a procedure analogous 
to pB2v (see II.2.11) with single-coupling of Fmoc-Lys(5/6-X)-OH (where X is FAM or 
TAMRA) mediated by HCTU (instead of PyClock) to impart K(tamra) and K(fam) in the 
peptide structure. Analytical samples were prepared using cleavage cocktail R (see 
III.2.6) to yield crude peptide mixture and were assessed by LCMS, purified by HPLC, 
and reassessed by LCMS. 
SPPS using K(ivDDE). pB2vAoa was synthesized by an alternative route employing 
SPPS with a protected lysine residue followed by selective deprotection and reaction with 
amine-reactive FAMSE. Precursor peptide, 
[Fmoc-{peg1}K(ivDDE){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2], was 
synthesized by SPPS as described above with double coupling of Fmoc-Lys(ivDDE)-OH 
mediated by HCTU. Analytical samples of this precursor were prepared as described 
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previously (see II.2.11) by cleavage and deprotection in cleavage cocktail B and assessed 
by HPLC and LCMS. Because the Fmoc protecting group is labile in the conditions 
required to remove the ivDDE protecting group (but not vice versa), the precursor peptide 
on resin (approximately 25 µmol  peptide equivalent) was also N-terminally folated or 
acetylated (general procedure, see III.2.7, above) and examined by LCMS prior to 
proceeding to FAM attachment. Folated precursor peptide on resin was subsequently 
deprotected by three repetitions of submersion in 2% hydrazine solution in DMF, 
standing for 3 minutes, and removal of supernatant to effect removal of ivDDE from the 
side chain of lysine (confirmed by qualitative Ninhydrin assay, see III.2.4). 2.87 mL (60 
µmol ) FAMSE in DMF was added to the resin and allowed to react overnight at RT with 
shaking, protected from light. After removing the supernatant, the resin sample was 
rinsed repeatedly with DMF followed by EtOH and dried under vacuum. Cleavage 
cocktail B (II.2.11) was applied to generate analytical samples of crude “FApB2vAoa” 
peptide [fa{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2] mixture 
for subsequent analysis by LCMS and spectrophotometry. 
SPPS using triple-coupling. pB2vAoa was synthesized using a procedure analogous 
to pB2v (see II.2.11) with triple-coupling of the second introduced arginine (N-terminal 
to MMP cleavage site) and triple-coupling of Fmoc-Lys(5/6-FAM)-OH with 2 molar 
equivalents relative to peptide N-termini per coupling, with all couplings mediated by 
HCTU. Final deprotection and cleavage from solid support resin was performed 
according to general procedures (II.2.11) using cleavage cocktail R (III.2.6). Crude 
peptide mixture was purified by analytical scale HPLC and subsequently characterized by 
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LCMS and FRET switch assay with trypsin and MMPs-9,14 (see general methods, II.2.3 
and III.2.2).  
FApB2vAoa. pB2vAoa on resin (from triple-coupling technique) was N-terminally 
deprotected, folated (see III.2.7), and cleaved from resin with cleavage cocktail R to yield 
FApB2vAoa which was then characterized by LCMS and FRET switch assay with 
trypsin and MMP14 with and without inclusion of EDTA. FApB2vAoa was also purified 
by analytical-scale HPLC and recovered fractions again analyzed by LCMS. 
AcpB2vAoa. pB2vAoa on resin (from triple-coupling technique) was N-terminally 
deprotected, acetylated (see III.2.7), and cleaved from resin with cleavage cocktail R to 
yield AcpB2vAoa peptide 
[Ac{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2]. AcpB2vAoa 
was similarly purified by analytical-scale HPLC and purified fractions analyzed by 
LCMS and FRET switch assay with MMPs-2,9,14 with and without inclusion of EDTA.  
III.2.9. Validation of FRET peptide function with endogenous MMPs in vitro 
Unpurified AcpB2vAoa FRET peptide was incubated with a human metastatic breast 
cancer cell line, MDA-MB-468, in the presence or absence of GM6001 broad-spectrum 
MMP inhibitor. Briefly, MDA-MB-468 cells were seeded at approximately 250,000 cells 
per well of 6-well plastic tissue culture plates in RPMI1640 medium and allowed to 
expand for 18 hours. Lyophilized AcpB2vAoa crude peptide mixture (from SPPS triple-
coupling method) was reconstituted in DMF to a concentration of 10 mg/mL (3.92 mM, 
validated by spectrophotometry using empirically determined extinction of TAMRA dye, 
data not shown). Media containing approximately 5 µM AcpB2vAoa or DMF (sham) and 
approximately 10 µM GM6001 or DMSO (sham) were added to assigned wells of the 
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tissue culture dish. At several intervals following medium additions, aliquots of 
conditioned media were removed and diluted with equal volumes fresh medium 
containing EDTA to prevent further metalloproteinase activity. The sensor (FAM) 
fluorescence of all samples was measured simultaneously at the endpoint (24 hours) by 
plate reader assay. 
III.3. RESULTS 
III.3.1. Analysis of peg-Broad2-vis (SPPS products) by mass spectrometry 
To confirm successful synthesis and characterize yields, the products of SPPS of 
pB2v peptide were purified by semi-preparative HPLC (Figure II-18) and analyzed by 
LCMS. While LCMS confirmed the presence of ions with M/z corresponding to the 
intended structure of pB2v, it also revealed that multiple chemical species were present in 
recovered products (Figure III-1a). The most abundant peak contained ions with M/z 
corresponding to multiple charge states of a parent ion with a mass of 1940 Da (Figure 
III-1b) that was smaller than the expected mass of pB2v (2354 Da). MALDI-TOF MS 
was performed to corroborate LCMS results with pB2v_2.2.1 wherein the most 
abundantly detected ions had M/z values of approximately 1941 and 2438 (Figure III-1c), 
indicating that the sample included a second unidentified product larger than the intended 
peptide. 
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Figure III-1: Mass spectrometry analysis of purified pB2v_2.2 
Chromatogram (a) represents total ion counts in ESI+ mode following reversed-phase 
liquid chromatography of pB2v sample collected from iterative HPLC separation. Mass 
spectrum (b) represents the integration of the most abundant peak, indicated by a black 
arrow in (a). Detected peaks (486, 647, 970 M/z) correspond to multiply charged states of 
a parent ion with mass ~1940 Da, as depicted in MALDI-TOF mass spectrum (c). 
To aid in identification of the majority products in pB2v_2.2.1 with unexpected MW, 
pB2v_2.2.1 was incubated with trypsin, MMP9, or MMP14 to proteolytically cleave 
peptides and the resulting mixtures were analyzed by MALDI-TOF MS. Analysis of a 
buffer-only sample confirmed the presence of one of the previously detected ions with 
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M/z of 2438. In all samples containing proteolytic enzymes, ions with M/z corresponding 
to intact forms of the previously detected species were not detected (Figure III-2b-d). 
MMP-treated samples had in common an ion with M/z of 1144.9, corresponding to an 
unpredicted, unidentified cleavage fragment. In all, proteolysis of the peptide products 
contained in pB2v_2.2.1 was confirmed, however a predicted chemical structure was not 
corroborated.   
 
Figure III-2: MALDI-TOF MS of cleaved pB2v_2.2.1 peptide 
Enzymatic cleavage fragments of purified pB2v peptide (pB2v_2.2.1) were analyzed by 
MALDI-TOF MS following incubation with buffer (a), trypsin (b), MMP9 (c), or MMP14 
(d) and desalting. 
III.3.2. Investigation of unidentified products of SPPS 
Because SPPS of pB2v yielded MMP-cleavable substrates with measurable FRET 
switch but initial synthesis yielded mostly unidentified products, pB2v was synthesized 
again by SPPS with the inclusion of checkpoints at residues suspected to couple 
inefficiently. Qualitative Ninhydrin testing of peptides on solid support resin at these 
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checkpoints indicated the presence of available amines following attempted couplings of 
the C-terminal Fmoc-PEG1-CH2COOH residue and Fmoc-Lys(5/6-FAM)-OH (Figure 
III-3). 
 
Figure III-3: Resynthesis of pB2v with Ninhydrin analysis of suspect couplings 
Growing peptides on resin were sampled after 6 selected couplings (a) during the synthesis 
of pB2v. Highlighted couplings gave positive qualitative results by Ninhydrin test as 
depicted in (b). 
Following final deprotection and cleavage from the solid support, crude pB2v peptide 
mixture was analyzed by MALDI-TOF MS. The majority products detected possessed 
M/z of 1925 and 2412, corresponding to parent ions with masses of 1924 Da and 2411 
Da, respectively (Figure III-4). These findings corroborated the qualitative results of 
Ninhydrin testing during SPPS (above), as the masses observed correspond to either the 
intact pB2v structure with a 56 Da adduct (2411 Da) or a structure omitting the FAM-
bearing lysine residue, also with a 56 Da adduct (1924 Da). The peptide mixture was 
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desalted and analyzed by LCMS that confirmed the presence of products with the same 
MW (data not shown). 
 
Figure III-4: MALDI-TOF MS of resynthesized pB2v peptide 
To confirm MMP-cleavability and FRET switch potential, crude pB2v peptide 
mixture was incubated with either trypsin or MMPs (2, 9, or 14) with monitoring of 
sensor fluorescence, as before (see II.3.6). Similar to the previously synthesized batch of 
pB2v, sensor fluorescence intensity of the crude mixture rapidly increased within a 10-20 
minutes of exposure to each proteolytic enzyme and continued to increase up to 110 
minutes (Figure III-5), confirming the inclusion of the FAM-bearing lysine residue in 
some proportion. 
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Figure III-5: FRET switch of resynthesized pB2v peptide with MMPs 
Sensor (FAM) fluorescence emission of pB2v peptide from SPPS increased upon 
treatment with proteolytic enzymes. Fold indicates increase over initial fluorescence 
intensity of control sample. Values represent single measurements. 
To confirm the biological relevance of pB2v cleavability by MMPs and to provide a 
non-cleavable control for biological experiments, a peptide with amino acid sequence 
identical to pB2v but substituting D-amino acids for all conventional L-amino acids (“D-
pB2v”) was synthesized by SPPS. MALDI-TOF MS analysis of crude D-pB2v peptide 
mixture following final deprotection and detachment from solid support in cleavage 
cocktail confirmed the same majority product masses (1924 Da, 2411 Da) detected from 
SPPS of (L-)pB2v (data not shown). A FRET switch assay was performed comparing 
(L-)pB2v and D-pB2v in the presence of trypsin or MMPs (9 or 14). Similar to previous 
observations, sensor fluorescence of (L-)pB2v increased rapidly over several minutes 
with either trypsin or MMP14, whereas there was no concordant increase in sensor 
fluorescence of D-pB2v with any enzyme (Figure III-6).  
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Figure III-6: FRET switch assay of D-pB2v versus L-pB2v peptides 
Sensor (FAM) fluorescence of pB2v peptides synthesized by SPPS with either L-amino 
acids or D-amino acids upon incubation with proteolytic enzymes. Values represent 
average of duplicates. 
To ensure that D-pB2v lacked a FRET switch not because of a lack of fluorophore 
inclusion but because of inability of biological enzymes to proteolytically cleave it, the 
UV-visible absorbances of D-pB2v and (L-)pB2v were compared by spectrophotometry. 
Both peptides exhibited absorbance spectra characteristic of FAM and TAMRA dye 
inclusion, as shown in Figure III-7. The lower FAM absorption relative to TAMRA 
absorption in (L)-pB2v was indicative of inefficient coupling of the K(fam) residue 
during SPPS. On the other hand, the relatively equal peak heights in the spectrum of 
D-pB2v confirms the inclusion of both dyes and suggests that D-pB2v was not cleaved in 
the FRET switch assay (Figure III-6) by proteinases specific for L-amino acids. 
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Figure III-7: Absorbance of pB2v peptides from SPPS 
UV-vis absorbance spectra of pB2v vis peptides synthesized with either l-amino acids 
(blue) or d-amino acids (red) in SPPS. Peaks at 495 nm and 560 nm correspond to 
characteristic absorbance maxima of FAM and TAMRA dyes, respectively. 
In order to further characterize the constituent chemical species produced by the 
repeated SPPS of pB2v and to troubleshoot the apparent chemical adduct, crude pB2v 
peptide mixture was desalted and analyzed by ESI-Q-IM-TOF MS by Kelly Hines of the 
McLean Laboratory (Dept. of Chemistry, Vanderbilt University). As seen in Figure III-8, 
the mass spectrometer detected ions with M/z representative of multiple charge states of 
pB2v peptide structures inclusive and exclusive of K(fam), each with and without a 56 
Da addition, corroborating the previous findings from MALDI-TOF MS (Figure III-4) 
and LCMS but also confirming the presence of the intended pB2v structure without the 
adduct. 
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Figure III-8: ESI-Q-IM-TOF MS of pB2v 
Masses of detected ions in ESI-Q-IM-TOF MS of pB2v (a) are encircled and color coded 
to correspond with the table of expected M/z for each chemical species and charge state 
(b). Data and figure courtesy of Kelly Hines of the McLean Laboratory in the Department 
of Chemistry at Vanderbilt University. 
Because mass spectrometry indicated the presence of the intact structure of pB2v in 
an unknown proportion in the crude peptide mixture from SPPS, analytical-scale HPLC 
with collection of detection peak fractions was performed to determine whether the 
products of SPPS could be separated and identified. Eluents were monitored for 
absorbance at 280 nm and 550 nm (representative of tryptophan and TAMRA peak 
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absorbance, respectively) to automate collection of four eluted chemical species (Figure 
III-9). 
 
Figure III-9: HPLC separation of pB2v 
Crude pB2v peptide from SPPS was separated by analytical-scale HPLC. Material peaks 
collected during analyte elution indicated by red numerals. 
The separated products collected from HPLC of pB2v crude peptide were analyzed 
separately by ESI-Q-IM-TOF MS to determine the identities of chemical species 
contained therein. The four products previously identified by mass spectrometry were 
partially resolved by HPLC separation, as indicated in Table III-1, below. The most 
intense MS signal in the sample collected from the most abundant HPLC peak (Peak 1 in 
Figure III-9, above) corresponded to the peptide product omitting K(fam), with some 
signal also representative of the same chemical structure with the additional 56 Da adduct 
(data not shown). Each of the other three samples similarly contained ions corresponding 
to two of the previously identified products of SPPS, with one signal being greater than 
the other. These results confirmed attachment of the adduct to some portion of the 
products and /or absence of K(fam) and partial separation of these products by 
chromatography. 
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Table III-1: Detected chemical species in ESI-Q-IM-TOF MS of pB2v HPLC Fractions 
HPLC Fraction -K(fam) -K(Fam)+56 Expected Expected+56 
1 ++ +   
2 + ++   
3   ++ + 
4   + ++ 
 
The specific site of attachment of the 56 Da adduct was interrogated by reassessing 
the desalted crude pB2v peptide mixture with fragmenting ESI-Q-IM-TOF MS-MS. 
Interestingly, Figure III-10 shows that the detectable ions with a 56 Da addition included 
expected fragments of pB2v as short as a peptide composed of only the four C-terminal 
residues of pB2v [h2n-{peg1}K(tamra)G-conh2 (+56 Da)]. 
 
Figure III-10: Fragmenting ESI-Q-TOF MS-MS of pB2v peptide 
Detected C-terminal (red) and N-terminal fragments of pB2v peptide from SPPS are 
overlaid on mass spectrum of detected ions. Inset: schematic indicating nomenclature of 
detected fragments. Data and figure courtesy of Kelly Hines of the McLean Laboratory in 
the Department of Chemistry at Vanderbilt University. 
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To investigate the chemical structure of the 56 Da adduct repeatedly detected in 
products of SPPS by mass spectrometry, 2D NMR experiments correlating protons with 
other protons separated by as many as three bonds (TOCSY) and correlating protons with 
carbon atoms (HMBC) were performed by Don Stec of the Small Molecule NMR 
Facility Core at Vanderbilt University. TOCSY detected four groups of unique methyl 
peaks correlating with branched alkyl structures, two of which are represented in the 
expected structure of pB2v and two of which are not (Figure III-11a). HMBC also 
indicated a proton-carbon correlation not accounted for in the expected structure of pB2v 
(Figure III-11b). While the molecular weight of the adduct detected by MS and the NMR 
spectra jointly corroborated the structure of a t-butyl attachment to pB2v, neither MS nor 
the NMR correlation spectra definitively identified its structure or intramolecular site of 
attachment. 
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Figure III-11: 2D-NMR Spectra of pB2v peptide 
TOCSY (a) and HMBC (b) 2D-NMR spectra of pB2v peptide. Correlating peaks either 
corresponding (boxed, blue) or not corresponding (boxed, green) to the expected 
molecular structure are indicated in (a). Red box and dashed lines in (b) indicate HMBC 
correlation not accounted for in expected peptide structure. 
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Because the above analyses corroborated the postulate that the adduct could be 
caused by the release of t-butyl cations from Boc and other protecting groups during final 
peptide deprotection, a common occurrence in SPPS
128
, several strategies designed to 
mitigate t-butyl release and/or attachment were attempted. Protection of pB2v amino acid 
residues with trityl chloride or selective removal of Boc protecting groups by treatment of 
peptide-resin with bismuth (III) trichloride (confirmed successful by qualitative 
Ninhydrin test) prior to TFA-based deprotection and cleavage from resin were performed. 
Final deprotection and detachment of pB2v peptide from solid phase resin was performed 
in cleavage cocktail K and cleavage cocktail R (see III.2.5). Crude pB2v peptide mixture 
was treated with formic acid to remove t-butyl groups and reprecipitated in Et2O. 
Unfortunately, none of the above processes eliminated the presence of the adduct in 
analytical samples. Analysis by ESI-Q-IM-TOF, LCMS, and/or MALDI-TOF MS 
reproduced earlier results, indicating similar relative abundance of the unidentified 56 Da 
adduct (data not shown). 
With the aid of Jenn Duan, an undergraduate student in the Dept. of Biomedical 
Engineering at Vanderbilt University, a short peptide representative of the C-terminus of 
pB2v [h2n-WAR{peg1}KG-conh2] was synthesized and confirmed to possess a 56 Da 
adduct by LCMS (data not shown). 2D NMR analysis of this simpler structure was 
attempted as with full-length pB2v above, but provided no further insights as to the 
identity and attachment site of the adduct (data not shown). 
To determine whether pB2v peptide including the unidentified 56 Da would be toxic 
to cells, as might be the case for TFA-derived salts, an MTT viability assay with three 
mouse cancer cell lines was performed following overnight incubation with pB2v (+56 
89 
 
Da) crude peptide mixture at concentrations covering a range of two orders of magnitude. 
While the different cell lines metabolized MTT reagent at slightly different rates, there 
were no significant changes in cell viability with changes in peptide concentration 
(Figure III-12). 
 
Figure III-12: MTT assay of mouse cell lines incubated with pB2v(+56) peptide 
Percentages reflect serial dilution to establish concentration range from medium 
containing peptide at undetermined absolute concentration. NPC sample represents 
medium alone with no peptide. Values represent average of duplicates. Error bars: 
standard deviation. 
III.3.3. Development of a protocol for N-terminal folation of peptides 
In the analyses above, the feasibility of producing MMP-cleavable peptides endowed 
with measurable FRET switch potential by SPPS was confirmed despite the unintended 
inclusion of an unidentified, non-toxic 56 Da chemical adduct. To move forward the 
synthesis of dual-targeted constructs, several strategies were tested to facilitate and 
optimize N-terminal attachment of folic acid to peptides. 
Because the chemical structure of folic acid presents two carboxylic acid function 
groups in an orientation favorable for preserving ligand function following conjugation, 
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the commonly used technique of carbodiimide-mediated amide bond formation with 
primary amines was attempted using DCC as a reactant to form amine-reactive 
intermediates with folic acid. A commercially-sourced, broadly MMP-cleavable substrate 
peptide [h2n-{Ahx}GPLGMRGS{Ahx}C-conh2] was reacted with folic acid and DCC 
overnight with monitoring by HPLC (data not shown), as schematically diagrammed in 
Figure III-13. After overnight reaction, the reaction mix was compared with unreacted 
peptide by gel permeation chromatography (GPC). Unfortunately, distinctive shifts in 
GPC peaks detected by the in-line refractive index detector were not observed, therefore 
successful attachment of folic acid to peptides was not confirmed. 
 
Figure III-13: Scheme, synthesis of folated peptide by DCC coupling 
A known-cleavable MMP peptide substrate was reacted with folic acid and DCC to effect 
carboxyl-to-amine amide bonding.  
A second strategy for N-terminal folation of peptides relied on the well-known 
reactivity of succinimidyl esters with primary amines
129
. Succinimidyl ester of folic acid 
(FA-NHS) was provided by Dr. Wellington Pham in the Vanderbilt Institute of Imaging 
Science. Dr. Pham oversaw the reaction of FA-NHS with aforementioned peptide (above) 
in buffered solution (diagrammed in Figure III-14) as well as development of a method to 
monitor the reaction by TLC. 
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Figure III-14: Scheme, synthesis of folated peptide by NHS-ester of folic acid 
 
TLC monitoring of the amide-forming reaction was begun with FA-NHS as the 
limiting reactant and analyzed immediately following reaction start. Iodine staining of the 
chromatographically separated reaction mix indicated a reduction in the intensity of the 
spot representing FA-NHS reactant (Figure III-15a). After 1 hour of reaction, reaction 
mix appeared to contain a diminished though still observable amount of FA-NHS, 
although the two spots representative of peptide remained indistinguishable from peptide 
reactant alone (Figure III-15b). The same pattern was observed following 2 hours of 
reaction with a slight reduction observed in the intensity of peptide-associated spots in 
the reaction mix sample (Figure III-15c). As such, the reaction was allowed to proceed 
overnight, then excess FA-NHS was added to the reaction mix and analyzed by TLC after 
80 minutes further reaction. As seen in Figure III-15d, the spot associated with FA-NHS 
was apparent in this reaction mix sample while one of the two peptide-associated spots 
was not observable. Because precipitates formed as reaction of peptide with excess FA-
NHS proceeded, the precipitate and supernatant phases were separated by centrifugation 
and reassessed separately by TLC. One immobile and one FA-NHS-associated spot 
appeared in the supernatant sample, whereas the pellet sample appeared to contain only 
one spot that was immobile in the TLC conditions used (Figure III-15e). 
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Figure III-15: Thin layer chromatography tracking folation of peptide by FA-NHS 
Peptide with sequence {Ahx}GPLGMRGS{Ahx}C-conh2 was reacted with limiting FA-
NHS and analyzed at 0 (a), 1 (b), and 2 (c) hours following reaction start. Excess FA-NHS 
was subsequently added to the reaction mix (d). Precipitates formed during reaction were 
separated by centrifugation and each phase reanalyzed (e). 
The pelleted components of the reaction mix were analyzed by MALDI-TOF MS to 
characterize the chemical species contained therein. As seen in Figure III-16a, the 
prevalent ions detected corresponded to four predicted chemical structures: unreacted 
peptide, a disulfide dimer of the starting peptide, folated peptide, or (singly) folated 
disulfide dimer (molecular weights tabulated in Figure III-16b). 
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Figure III-16: MALDI-TOF MS of pelleted FA-peptide reaction mix 
Mass spectrum (a) from MALDI-TOF MS analysis of pelleted precipitates of reaction 
between FA-NHS and {Ahx}GPLGMRGS{Ahx}C-conh2 peptide. Labeled peaks 
correspond to masses of folated and non-reacted peptides as well as disulfide-dimerized 
analogues of each (b). 
The pelleted products of peptide and FA-NHS reaction were subsequently purified by 
semi-preparative HPLC. TLC analysis of purified material indicated a chemical structure 
with composition distinct from reactants (either FA-NHS or peptide, data not shown). 
Purified material was then incubated with MMP9 to determine whether or not attachment 
of folic acid using succinimidyl ester chemistry would interfere with proteolytic cleavage. 
As Figure III-17 shows, MALDI-TOF analysis of the incubation mixture detected ions 
representative of both folated and non-folated N-terminal products of MMP9 peptide 
cleavage as well as singular and disulfide dimerized C-terminal products of MMP9 
pepitde cleavage (predicted molecular weights in inset), but very little if any signal 
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corresponding to intact peptides. These results confirmed near-complete proteolysis of 
folated peptide by MMP and corroborated previous findings that non-folated peptides 
remained after reaction with excess FA-NHS. 
 
Figure III-17: MALDI-TOF MS of folated, MMP9-cleaved peptide 
HPLC-purified product of peptide folation by FA-NHS was incubated with MMP9 and the 
proteolytic cleavage fragments thereof analyzed by MALDI-TOF MS. Labeled mass peaks 
correspond to molecular weights (inset) of expected MMP cleavage fragments. 
To provide flexibility in the design and modification of peptides produced by Fmoc-
protected SPPS, it was desirable to folate peptides on resin as part of solid phase 
synthesis. Given the above evidence of at least partial yield of folated peptides from 
succinimidyl ester reaction with peptide N-termini in solution, folation of pB2v on solid 
support resin was attempted using FA-NHS. Subsequent analysis by MALDI-TOF MS 
and analytical HPLC provided no evidence of successful folic acid attachment to pB2v 
under these conditions (data not shown). 
Due to the demonstration of incomplete folation in the presence of excess reactant 
and lack of evidence for folation in solid phase using FA-NHS, a strategy adapting the 
coupling reagent used in each coupling of automated SPPS to couple folic acid in solid 
phase was tried. As schematically diagrammed in Figure III-18, folic acid was reacted 
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with HCTU to form amine-reactive intermediates and applied to N-terminally 
deprotected pB2v peptide on resin to generate “FApB2v” peptide 
[fa-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G-conh2] on resin.  
 
Figure III-18: Scheme, synthesis of folated peptide in solid phase using HCTU activator 
 
FApB2v peptide was simultaneously deprotected and detached from solid support in 
cleavage cocktail R using conditions similar to those used for pB2v (see III.2.5), and the 
resulting crude peptide mixture analyzed by LCMS. The majority of detectable ions were 
represented by two partially-resolved majority peaks, as depicted in Figure III-19a. The 
integrated mass spectrum of the first peak (Figure III-19b) shows the M/z of multiple 
charge states of a chemical species resembling the expected structure of FApB2v but 
omitting K(fam) and including a 56 Da adduct. The mass spectrum of the second peak 
(Figure III-19c) represents multiple charge states of intact FApB2v, again with a 56 Da 
adduct. Importantly, ions with M/z corresponding to predicted pB2v structures lacking 
folic acid were not detected. 
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Figure III-19: LCMS of FApB2v peptide from HCTU-activation synthetic route 
Total ion counts (a) following LC of FApB2v crude peptide mixture from solid phase 
synthesis route employing HCTU activation to conjugate FA. Arrows are color-
coordinated with mass spectra (b,c) corresponding to the integrated ion peaks. Detected 
ion masses correspond to multiple charge states of peptide including FA and a 56 Da 
adduct but lacking K(fam) (b: 685, 783, 1174) or complete peptide including FA and 56 
Da adduct (c: 709, 945, 1417). 
FApB2v peptide was purified by semi-preparative HPLC and the collected fractions 
analyzed by LCMS. As seen in Figure III-20, a substantial though non-majority peak 
contained ions with M/z representing multiple charge states of the designed FApB2v 
peptide prepared by SPPS. 
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Figure III-20: Purification of FApB2v 
Semi-preparative HPLC (a) was used to purify FApB2v peptide from SPPS employing 
HCTU activation of FA for folate conjugation. Arrow indicates the peak containing the 
intended product, as identified by the detected ions in LCMS (b, mass spectrum). M/z of 
709, 945, 1417 represent charge states of a chemical species with molecular weight 
matching expected FApB2v structure. 
To confirm that FApB2v was cleavable by MMPs and had a FRET switch suitable for 
sensing proteolytic activity, purified FApB2v was incubated with trypsin or MMPs (2, 9, 
or 14) and monitored for sensor (FAM) fluorescence. The fluorescence of sample wells 
containing trypsin or MMP14 increased 8-fold over 120 minutes and displayed a trend 
towards continued increase (Figure III-21). Notably, this represents a conservative 
estimate of FRET switch because the background fluorescence intensity due to the 
microplate and assay milieu was not subtracted. Sensor fluorescence increased modestly 
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with MMP2 and MMP9, as well, although assay wells with different MMPs were not 
standardized for active MMP concentration. 
 
Figure III-21: FRET switch of purified FApB2v 
FApB2v peptide purified by semi-preparative HPLC was incubated with proteolytic 
enzymes. Sensor fluorescence increase due to dequenching of FAM dye upon proteolytic 
cleavage was monitored. Note that fold-change in sensor fluorescence does not account for 
background fluorescence subtraction in this case. 
Given the lack of evidence for FA coupling with peptides via carbodiimide chemistry, 
the evident lack of FA-NHS coupling to peptides in solid phase, and the apparent success 
of HCTU-mediated FA coupling in synthesizing folated peptides capable of generating 
FRET switch upon cleavage by MMPs, the synthetic route of SPPS followed by HCTU-
mediated coupling of FA in solid phase was established as the standard protocol for 
producing folated MMP-FRET substrates presented hereafter. 
III.3.4. Synthesis and characterization of peptides suitable for oxime ligation 
To enable our design of dual-targeted nanoparticles based upon bioconjugation of 
MMP-cleavable, FRET-equipped substrate peptides to nanoparticle surfaces, we required 
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a chemistry that provided efficient coupling and chemoselectivity in mild conditions. 
Dirksen et al reported the ability to site-specifically ligate peptide fragments in the 
presence of unprotected amino acid side chains via oxime ligation with nucleophilic 
catalysis
130
  (see Figure III-22). This technique was also previously demonstrated 
effective for attaching MMP9 substrate peptides to aldehyde-presenting polyester 
dendrons (Scherer and McIntrye, unpublished). 
 
Figure III-22: Scheme, chemoselective oxime ligation (adapted from Diksen et al
130
) 
Oxime ligation between R1-glyoxylyl (an aldehyde) and aminooxyacetyl-R2 performed in 
either the absence or the presence of aniline as a catalyst. Reactive groups (aldehyde, 
aminooxy) and oxime bond are indicated in bold. 
As such, the design of broadly MMP-cleavable pB2v peptide was modified to include 
an C-terminal aminooxy functional group for use in oxime ligation chemistry by utilizing 
the protected residue, Fmoc-Dpr(Boc-Aoa)-OH, as the first residue in SPPS of 
“pB2vAoa” [h2n-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2] 
(chemical structure in Appendix A). Following SPPS of pB2vAoa, crude peptide mixture 
from peptide-resin cleavage was analyzed by LCMS to assess relative yield and identity 
of products. The trace of total ions detected subsequent to LC (Figure III-23a) indicated 
the presence of multiple chemical species. As in previous syntheses using the same SPPS 
strategy, the majority of ions detected corroborated a predicted chemical structure 
corresponding to the intended peptide construct but without the K(fam) residue (Figure 
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III-23b,c), although ions with M/z representative of intact pB2vAoa were also detected 
(Figure III-23d,e). Ions with and without an unidentified 67 Da adduct were also 
detected, constituting a pair of structures for each case. Most importantly, DprAoa was 
present in the corresponding predicted molecular structures and masses (tabulated in 
Figure III-23f). 
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Figure III-23: LCMS of unpurified pB2vAoa from SPPS 
Total ion counts in ESI+ MS (a) following LC of pB2vAoa crude peptide mixture from 
SPPS. Chemical species eluting at distinct times (b-e) corresponded to intended structure 
omitting (b,c) or including (d,e) K(fam) residue as well as including an unidentified 67-
Dalton adduct (c,e), as tabulated (f). 
To validate the LCMS indications of the relative abundance of peptide products in 
pB2vAoa crude mixture, semi-preparative HPLC was performed with monitoring of 
tryptophan (280 nm) and TAMRA (550 nm) peak absorbance to automate eluent 
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collection and LCMS was repeated on separately collected fractions. As depicted in 
Figure III-24, the HPLC eluent peak containing the intended pB2vAoa structure 
represented a minority product of the synthesis. The majority peaks in HPLC 
corroborated the LCMS findings that a predicted structure lacking K(fam), with or 
without additional chemical adducts, contributed to the majority of SPPS products (data 
not shown).  
 
Figure III-24: Purification of pB2vAoa 
Semi-preparative HPLC (a) was used to purify pB2vAoa peptide from SPPS. Arrow 
indicates the peak containing the intended product, as identified by the detected ions in 
LCMS (b, mass spectrum). M/z of 503, 629, 838 represent charge states of a chemical 
species with molecular weight matching expected pB2vAoa structure. Note that the most 
abundant peak (a, 14.2 mins) contained ions with mass corresponding to a product 
omitting the K(fam) residue (data not shown). 
III.3.5. Attempt to improve yield from SPPS by substitution of K(ivDDE) for K(fam)  
Because incomplete coupling of K(fam) appeared to be a persistent cause of 
unintended product yield from SPPS of FRET peptides, a strategy employing a lysine 
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residue with a protecting group less bulky than fluorescein in SPPS was explored with the 
purpose of providing more efficient coupling for higher yields and preserving the ability 
to later attach fluorescein via a reaction with a relatively inexpensive amine-reactive dye. 
This strategy also presented the potential to extend applications of SPPS of MMP 
substrate peptides to include moieties not commercially available as lysine conjugates or 
that are intolerant of the acid-base conditions required for SPPS, such as NIR dyes or 
drug molecules. Fisher et al demonstrated that the (4,4-dimethyl-2,6-dioxocyclohex-1-
ylidine)ethyl (DDE) group could be removed from peptides in SPPS on rink amide resin 
by application of 2% hydrazine solution in DMF (a basic solution) without affecting acid-
labile protecting groups
131
. As such, the design for SPPS of pB2vAoa was modified to 
substitute Fmoc-Lys(ivDDE)-OH, a more recently developed analogue of DDE-protected 
lysine that generates less side-reactive byproducts during deprotection, in place of Fmoc-
Lys(5/6-FAM)-OH, as schematically diagrammed in Figure III-25. 
 
Figure III-25: Scheme, synthesis of (FA/Ac)pB2vAoa peptides via K(ivDDE) route 
The peptide containing protected lysine K(ivDDE) in place of K(fam) was produced in 
SPPS, then the N-terminus terminated by removal of Fmoc (a) and acylation with either 
FA or acetyl group (b). The ivDDE protecting group was then removed (c) and the side 
chain of lysine reacted with FAMSE (d) to introduce FAM as the sensor dye. 
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Following synthesis of ivDDE-protected pB2vAoa by SPPS, the crude peptide 
mixture was analyzed by HPLC and LCMS to elucidate relative product purity and 
identity. Monitoring the peak absorbance of tryptophan at 280 nm, three substantial 
eluent peaks from HPLC were detected, as can be seen in Figure III-26a. Interestingly, 
only one of these peaks was accompanied by a substantial peak in 550 nm absorbance, 
representative of TAMRA dye. Concordantly, LCMS also indicated the presence of a 
predicted ion corresponding to the intended peptide lacking K(tamra), however also 
indicated an abundance of ions representing the intact intended peptide structure with or 
without a 67 Da adduct (Figure III-26b,c). All structures corroborated by MS contained 
K(ivDDE), indicating robust coupling of Fmoc-Lys(ivDDE)-OH during SPPS. 
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Figure III-26: HPLC and LCMS of ivDDE-protected pB2vAoa peptide 
A peptide with sequence analogous to pB2vAoa substituting K(ivDDE) for K(fam) was 
synthesized by SPPS as diagrammed in Figure III-25 and analyzed by analytical scale 
HPLC (a). LCMS was subsequently performed, wherein total ion counts (b) were 
correlated with predicted products of SPPS (c). Peak numbers in (b) correspond to 
chemical species (c) with masses detected in each peak.  
To validate the applicability of the protected lysine strategy to the synthesis of folated 
FRET peptides, the folate-conjugated, ivDDE-protected peptide depicted in Figure 
III-25b was synthesized via SPPS terminating with the previously demonstrated HCTU-
mediated method of FA attachment. As seen in Table III-2, LCMS of the resulting crude 
peptide mixture detected ions with M/z corresponding to the multiple charge states of the 
intended product of SPPS as well as adducts similar to those observed previously (40, 67, 
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107 Da). Importantly, molecules smaller than the folated peptide (i.e. not folated) were 
not detected, suggesting that the coupling of folic acid to peptides was robust. 
Table III-2: Detected ions via LCMS of folated, ivDDE protected pB2vAoa peptide 
 
 
To complete the synthesis of a folated and FRET-equipped peptide, the ivDDE 
protecting group was removed with 2% hydrazine solution and the resin-bound peptide 
subsequently reacted with FAMSE to generate “FApB2vAoa” 
[fa-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra)G{DprAoa}-conh2], as 
diagrammed in Figure III-25, above. Notably, peptide-resin was observed by visual 
inspection to change color from intense pink-magenta to yellow-brown during treatment 
with hydrazine and finally to orange upon removal of hydrazine and washing in organic 
solvents (DMF, EtOH, NMP). LCMS analysis of the resulting crude peptide mixture 
detected ions corresponding to the expected FApB2vAoa structure with adducts of 67 and 
107 Da (Figure III-27). Ions representing structures smaller than the expected construct 
were not detected, indicating successful coupling of the fluorescein moiety. 
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Figure III-27: LCMS of FApB2vAoa via ivDDE-route 
FApB2vAoa peptide was synthesized by SPPS employing K(ivDDE) residue, hydrazine 
deprotection, and subsequent reaction with FAMSE as diagrammed in Figure III-25. Total 
ion counts (a) following HPLC were collected and ions corresponding to FApB2vAoa 
peptide with additional adducts of +67 Da (b) and +107 Da (c) were detected, as tabulated 
(d). 
The observation that FApB2vAoa synthesized in SPPS by the aforementioned 
K(ivDDE) route appeared to have anomalous optical properties (yellow in pH7 buffer by 
visual inspection instead of the expected pink hue characteristic of TAMRA dye) was 
conspicuous. To investigate, crude peptide mixture was diluted in buffered solutions 
ranging in pH from 3.5 to 7.0 and assessed for UV-visible absorbance by 
spectrophotometry. While FAM and TAMRA dyes are known to exhibit reversibly pH-
sensitive optical properties, each should absorb visible light with comparable peak molar 
extinction coefficients at neutral pH. However, as seen in Figure III-28, FApB2vAoa 
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synthesized according to the scheme in Figure III-25 had absorbance characteristic of 
FAM (495 nm maximum) but not TAMRA (560 nm maximum) at pH 7.0. The presence 
of TAMRA dye was indicated by its characteristic absorbance in acidic buffers, but this 
absorbance was attenuated with increasing pH and practically absent at pH 7.0. On the 
other hand, FAM absorbance was reversibly quenched in acid, as expected. 
 
Figure III-28: pH-dependent absorbance of FApB2vAoa via ivDDE-route 
Aliquots of FApB2vAoa peptide synthesized via SPPS including K(ivDDE), hydrazine 
deprotection, and FAMSE coupling as diagrammed in Figure III-25 were diluted to 
equivalent concentrations in pH buffers and analyzed by spectrophotometry. 
Because the ability of proteolytic nanobeacons hinges on the optical properties of the 
constituent fluorophores at physiologic pH, an alternative synthesis strategy was 
necessary. Based upon the unusual observations of color change during treatment of 
peptide-resin with hydrazine solution, deprotection of K(ivDDE) was attempted using 
hydroxylamine hydrochloride and imidazole according to a published technique
132
. 
Subsequent spectrophotometric analysis reproduced pH sensitivity of FApB2vAoa 
treated with 2% hydrazine solution but did not demonstrate this property with 
hydroxylamine/imidazole-treated peptide. However, deprotection of K(ivDDE) with 
hydroxylamine/imidazole was found to be very inefficient at best as determined by 
109 
 
qualitative Ninhydrin assay (data not shown). Further troubleshooting to optimize 
synthesis of FRET peptides in SPPS using protected lysine residues was not explored.  
III.3.6. Capping and triple coupling in SPPS to improve yield of FRET peptides 
While the coupling efficiency of K(ivDDE) in SPPS was apparently superior to that 
of K(fam), the complications of the additionally required deprotection and dye 
conjugation steps limited the feasibility of this approach to synthesis of FRET peptides. 
As such, the coupling of K(fam) was revisited. pB2vAoa peptide was synthesized 
following the originally devised scheme for SPPS of pB2v (see II.2.11), using HCTU as 
the carboxyl activating reagent for all couplings rather than using PyClock for Fmoc-
Lys(5/6-X)-OH (where X is FAM or TAMRA). Importantly, Fmoc-Lys(5/6-FAM)-OH 
was reacted with triple-coupling of 2 molar equivalents of residue relative to resin 
substitution in each coupling and an acetic anhydride capping step was added 
immediately after this step to terminate any peptide products not successfully conjugated 
with K(fam) prior to proceeding with the remaining N-terminal residue couplings. 
Crude pB2vAoa peptide mixture from SPPS was analyzed by analytical-scale HPLC 
with a mobile phase gradient composed of 50 mM potassium phosphate buffer (pH 7.0) 
and MeOH to allow monitoring of eluent absorbance at 495 nm attributable to FAM in 
addition to 280 nm (tryptophan) and 560 nm (TAMRA). As seen in Figure III-29a, the 
resulting chromatograms reflect a less heterogeneous mixture of products, with most of 
the integrated signal belonging to a closely grouped set of eluted product peaks. 
Importantly, each of these peaks was coincident in each of the three chromatogram 
channels (280 nm, 495 nm, 560 nm) with magnitudes suggestive of incorporation of both 
fluorescent dyes. Eluents represented by these peaks were collected jointly and analyzed 
110 
 
by LCMS, in which ions with M/z representative of multiple charge states of two 
predicted chemical structures were detected: the intended Fmoc-pB2vAoa product with a 
40 Da addition (as was seen with previously analyzed pB2v analogues from SPPS) and a 
peptide product missing the DprAoa residue with no adduct (Figure III-29b). The 
identification of only two different molecular weights from the multiple co-collected 
peaks in HPLC was not wholly unexpected. Both of the fluorophores, FAM and TAMRA 
were present as a mixture of two isomers each. The slightly different attachments of these 
isomers may contribute to different retention times in HPLC, leading to the possibility of 
four analyte peaks representative of molecules with identical molecular weights. 
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Figure III-29: HPLC and LCMS of pB2vAoa via triple-coupling SPPS 
pB2vAoa peptide was synthesized via SPPS with triple coupling of 2 molar equivalents 
each K(fam) residue and left Fmoc-protected at the N-terminus. Material was recovered 
from analytical scale HPLC (a) of crude peptide product as indicated by dashed lines and 
subsequently analyzed by LCMS to yield a mass spectrum (b). M/z of ions detected 
correspond to multiple charge states of Fmoc-pB2vAoa with a +40 Da adduct (694, 926, 
1388) or an analogous structure lacking the C-terminal DprAoa residue (645, 859, 1289). 
To confirm successful coupling of all residues and consequent optical properties of 
Fmoc-pB2vAoa from triple-coupling SPPS, the partially purified peptide solution 
recovered from analytical-scale HPLC was analyzed by FRET switch assay, incubating 
peptides with either trypsin or MMPs (9 or 14). Sensor (FAM) fluorescence of Fmoc-
pB2vAoa increased rapidly upon cleavage by MMP14 or  trypsin, reaching the end of the 
linear stage of fluorescence amplification within 5 minutes, as plotted in Figure III-30. A 
15-fold increase in sensor fluorescence attributable to MMP14 activity was observed in 
less than 25 minutes. 
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Figure III-30: FRET switch of purified Fmoc-pB2vAoa from triple-coupling SPPS 
Sensor (FAM) fluorescence emission from HPLC-purified Fmoc-pB2vAoa peptide from 
SPPS with triple-coupling of K(fam) residue increased upon treatment with proteolytic 
enzymes.  Values represent single measurements. 
Given the provision of peptides with demonstrated MMP-inducible FRET switch 
from triple-coupling SPPS, the peptide-resin material from synthesis of Fmoc-pB2vAoa 
(above) was deprotected and reacted in solid phase as diagrammed in Figure III-25 to 
acylate the N-terminus with either FA or the acetyl group (COCH3, “Ac”), yielding 
FApB2vAoa or “AcpB2vAoa”, respectively. 
Crude peptide mixture from synthesis of FApB2vAoa was incubated with trypsin or 
MMP14, with and without EDTA to inhibit metalloproteinase activity. As with the 
parental peptide, a FRET switch developed rapidly from FApB2vAoa with both trypsin 
and MMP14 in the absence of EDTA, reaching a 6-fold increase in sensor emission 
intensity within 20 minutes (Figure III-31). Notably, this FRET switch is representative 
of an unpurified peptide mixture, whereas the FRET switch of Fmoc-pB2vAoa (above) 
was measured with partially purified peptide. EDTA abrogated the amplification of 
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sensor fluorescence with MMP14 but had no effect on the increase caused by trypsin 
cleavage. 
 
Figure III-31: FRET switch of unpurified FApB2vAoa from triple-coupling SPPS 
Sensor (FAM) fluorescence emission from unpurified FApB2vAoa peptide from SPPS 
with triple-coupling of K(fam) residue increased upon treatment with proteolytic enzymes. 
EDTA was included in control samples to inhibit metalloproteinase activity. Values 
represent single measurements. 
As with previously synthesized peptides, FApB2vAoa was analyzed by HPLC with 
automated fraction collection and LCMS of the collected eluents. Chromatograms of the 
absorbance channels employed for fraction collection (Figure III-32a) reflect slightly 
poorer resolution of the folated peptide than the parental Fmoc-protected pB2vAoa 
(Figure III-29a). Nonetheless, the majority of integrated absorbance was recorded within 
a group of clustered peaks corresponding to separately collected eluent volumes, two of 
which were found by LCMS to contain ions with M/z representative of the multiple 
charge states of FApB2vAoa with a 40 Da adduct (Figure III-32b,c). Corroborating the 
results of previous peptide folation reactions (see III.3.3, III.3.5), ions representative of 
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non-folated products were not detected, indicating successful attachment of folate to 
peptides. 
 
Figure III-32: HPLC and LCMS of FApB2vAoa from triple-coupling SPPS 
Crude peptide mixture from SPPS of FApB2vAoa with triple-coupling of K(fam) residue 
was analyzed by analytical scale HPLC, recording absorbance of eluted analytes at 280 
nm, 495 nm, and 560 nm (a). Color-coordinated arrows in (a) indicate material peaks 
collected from HPLC that were subsequently characterized by LCMS to give mass spectra 
(b,c). M/z of detected ions (745, 993) correspond to multiple charge states of the expected 
structure of FApB2vAoa with a +40 Da adduct. 
AcpB2vAoa, the MMP-cleavable but non-folate-targeted counterpart to FApB2vAoa 
(for detailed structure see Appendix A), was similarly characterized by HPLC and 
LCMS. As seen in Figure III-33a, the crude product of SPPS appeared relatively 
homogeneous compared to either Fmoc-pB2vAoa or FApB2vAoa, with the majority of 
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integrated absorbance signals assigned to only two peaks. As shown in Figure III-33, 
LCMS of the HPLC eluents collected based upon these peaks detected ions representing 
the expected structure of AcpB2vAoa with a chemical adduct of similar weight (42 Da) 
to that found on FApB2vAoa (40 Da). 
 
Figure III-33: HPLC and LCMS of AcpB2vAoa from triple-coupling SPPS 
Crude peptide mixture from SPPS of AcpB2vAoa with triple-coupling of K(fam) residue 
was analyzed by analytical scale HPLC, recording absorbance of eluted analytes at 280 
nm, 495 nm, and 560 nm (a). Color-coordinated arrows in (a) indicate material peaks 
collected from HPLC that were subsequently characterized by LCMS to give mass spectra 
(b,c). M/z of detected ions (650, 866) correspond to multiple charge states of a structure 
42 Da larger than the intended AcpB2vAoa peptide. 
To validate its FRET switch potential and MMP-cleavability, purified AcpB2vAoa 
collected from analytical-scale HPLC (Figure III-33a, eluent peak indicated by red arrow) 
was mixed with MMPs (2, 9, or 14) in the presence and absence of EDTA to inhibit 
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metalloproteinase activity. Sensor (FAM) fluorescence increased with each MMP in the 
absence of EDTA, reaching greater than 25-fold the starting intensity upon treatment 
with MMP14 in less than 10 minutes (Figure III-34). FRET switch continued to increase 
with MMPs past 100 minutes of reaction. These effects were nearly completely abrogated 
by the inclusion of EDTA in the assay buffer. 
 
Figure III-34: FRET switch of purified AcpB2vAoa from triple-coupling SPPS 
Sensor (FAM) fluorescence emission from HPLC-purified AcpB2vAoa peptide from 
SPPS with triple-coupling of K(fam) residue increased upon treatment with proteolytic 
enzymes. EDTA was included in control samples to inhibit metalloproteinase activity. 
Values represent single measurements. 
Further validation of AcpB2vAoa peptide as a biosensor for MMP-associated 
proteolytic activity was performed in vitro by incubating MDA-MB-468 human breast 
cancer cells with cell culture media containing AcpB2vAoa either with or without broad 
spectrum MMP inhibitor GM6001. Because HPLC and LCMS results (above) indicated 
that most of the product of SPPS represented the intended structure of AcpB2vAoa, crude 
peptide was employed in this experiment. Conditioned media were sampled at several 
intervals over a 24-hour period and diluted into medium containing EDTA to halt 
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metalloproteinase activity prior to analysis by plate reader fluorescence spectroscopy. 
Sensor (FAM) fluorescence increased through 24 hours in conditioned media from 
culture conditions containing cells and AcpB2vAoa in the absence of inhibitor, exhibiting 
a greater than 10-fold increase in media sampled after 24 hours of incubation, whereas 
fluorescence of AcpB2vAoa in the absence of cells remained constant (Figure III-35). 
Interestingly, the inclusion of GM6001 partially abrogated the increase in sensor 
fluorescence, as only a 4-fold increase in sensor emission intensity was observed at the 
endpoint in this condition. 
 
Figure III-35: FRET switch of AcpB2vAoa in cell culture 
Unpurified AcpB2vAoa peptide was incubated with MDA-MB-468 human breast cancer 
cells. Medium samples were collected at timepoints and sensor (FAM) fluorescence 
assessed. GM6001 was added to control samples to inhibit MMP activity. Fold change 
expressed as multiple of no cell control sample initial fluorescence intensity. Values 
represent average of duplicates (except no cell control, single measurements). Error bars: 
standard deviation. 
Altogether, the findings above with FApB2vAoa and AcpB2vAoa indicated that 
peptides possessing all the requisite components for folate targeting, optical sensing of 
proteolytic activity, and oxime ligation with nanoparticles were produced by SPPS. 
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III.4. DISCUSSION AND CONCLUSIONS 
The results presented in this chapter have detailed the development of a robust 
protocol for solid phase synthesis of folate-targeted, MMP-sensing substrate peptides 
with C-terminal aminooxy functional groups for attachment to nanoparticles via oxime 
ligation. Troubleshooting of SPPS and chemical analyses of SPPS products yielded 
insights into the efficiencies of residue coupling in automated SPPS and incompatibility 
of organic dyes with the reaction conditions required for deprotection of protected amino 
acid side chains in SPPS. Together, these insights led to the development of a revised 
triple-coupling strategy to improve yields of expected products from SPPS. 
Mass spectrometric analysis of pB2v, the broadly MMP-cleavable substrate peptide 
bearing FAM and TAMRA dyes for FRET and including monomeric PEG residues as 
hydrophilic spacers produced by SPPS (see II.3.6), indicated the presence of multiple 
chemical species with unexpected molecular weights, even in the sample iteratively 
purified by HPLC (Figure III-1). The masses of detected ions corroborated multiple 
possible products of SPPS, such as a peptide omitting both arginine residues and one 
PEG1 residue from the intended structure. However, because mass spectrometry provides 
no structural information and NMR data would have been confounded by the presence of 
multiple structures, no definitive structures of the products of SPPS could be identified 
from these data and samples. 
To provide additional insight into the chemical identities of peptides produced, SPPS 
of pB2v was repeated with qualitative interrogation of suspect coupling reactions during 
automated SPPS by Ninhydrin assay as indicated in Figure III-3, revealing uncoupled 
primary amines following attempted coupling of the K(fam) residue. Combined with the 
finding that the molecular weights of two of the most abundantly detected ions by mass 
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spectrometry differed by 56 Da each from either the expected MW of pB2v or of pB2v 
without K(fam), these data suggested that coupling of K(fam) was incomplete during 
synthesis. The majority of the final products of SPPS contained this unidentified 56 Da 
adduct. However, as seen in Figure III-5, incubation of the crude peptide mixture from 
the repeated SPPS of pB2v with MMPs confirmed the MMP-induced FRET switch seen 
previously with purified pB2v_2.2.1 from the first synthesis (Figure II-19). Furthermore, 
the dependence of the observed FRET switch on biologically relevant MMPs and 
incorporation of FAM dye was confirmed by assessing the FRET switch (Figure III-6) of 
D-pB2v, a peptide analogous to pB2v but synthesized with D-amino acids. D-pB2v did 
not exhibit a FRET switch upon treatment with MMPs, however like (L-)pB2v did 
possess an absorbance spectrum representative of FAM and TAMRA dye inclusion 
(Figure III-7). Therefore the K(fam) residue was necessarily coupled in some proportion 
during SPPS of pB2v peptides and the unidentified 56 Da adduct did not block MMP 
cleavage or the consequent sensor (FAM) fluorescence amplification upon peptide 
hydrolysis. 
Further characterization of the 56 Da adduct seen in repeated SPPS of pB2v peptides 
was attempted by advanced mass spectrometry and NMR techniques in collaboration 
with other laboratories at Vanderbilt University. Detection of ions corresponding to the 
intended pB2v structure with and without incorporation of K(fam) and/or the 56 Da 
adduct by ESI-Q-IM-TOF MS in a desalted crude peptide sample, as seen in Figure III-8, 
both confirmed the previous findings and suggested that the adduct could not be removed 
by desalting, such as might be the case with an ionic adduct such as iron (
56
Fe). Rather, 
the adduct was likely covalently bonded, as could be the case if a t-butyl cation was 
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liberated from a protecting group and reattached at another molecular site, a common 
occurrence during TFA-mediated deprotection of protected amino acid side chains 
following Fmoc-SPPS
128
. Covalent attachment of the 56 Da adduct was further 
corroborated by the finding that the four products of SPPS identified above [pB2v +/-
K(fam), +/-56 Da] were partially separable by HPLC (Figure III-9), but all detected by 
ESI-Q-IM-TOF MS (Table III-1) following separation. To determine possible site of 
adduct attachment on the peptide, fragmenting ESI-Q-IM-TOF MS-MS was performed 
focusing on an ion representative of the intact pB2v structure including the adduct. 
Shown in Figure III-10, the predicted fragments represented in the mass spectrum 
suggested that the 56 Da adduct was likely attached within the three or four residues 
nearest the C-terminus. Additional efforts to identify the structure and location of the 
adduct by 2D NMR experiments with HPLC-purified pB2v(+56) (Figure III-11) 
corroborated the covalent attachment of a branched alkyl group with two methyl groups 
that are not present in the predicted structure of pB2v. Ultimately, the NMR spectra could 
not resolve the exact location of adduct attachment. The TAMRA fluorophore, while a 
probable candidate for modification owing to an unprotected carboxylic acid functional 
group, was probably not the site of covalent attachment, as a short peptide representative 
of a C-terminal portion of pB2v [h2n-WAR{peg1}KG-conh2] was also found to have the 
56 Da adduct (data not shown). 
Given the evidence in agreement with covalent attachment of a branched alkyl cation 
that could be the result of inadequate scavenging during TFA-mediated deprotection and 
cleavage of pB2v from the solid support resin, several strategies involving protection, 
deprotection, or scavenging of liberated protecting groups by organic molecules were 
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attempted to either mitigate or remove the adduct following SPPS. Unfortunately, none of 
these strategies generated peptide products free of the 56 Da adduct as determined by 
mass spectrometry (data not shown, see III.2.5), suggesting that transfer of t-butyl cations 
from protected amino acid side chains to other moieties might not have been the source 
of the adduct. 
As documented above, SPPS of pB2v peptide and variants thereof repeatedly 
produced peptide mixtures that possessed the same 56 Da adduct that was not readily 
prevented nor removed, and peptide mixtures containing the adduct nonetheless exhibited 
FRET switches upon treatment with MMPs. Therefore to determine whether the adduct 
could be considered an inert artifact of synthesis, the toxicity of crude pB2v(+56) peptide 
mixture to cells was assessed in vitro. A colorimetric MTT assay, the results of which are 
shown in Figure III-12, indicated no toxicity to three different mouse cancer cell lines 
upon 24 hours of exposure to a range of peptide concentrations spanning two orders of 
magnitude. Taken together, the experiments characterizing pB2v validate the requisite 
optical and biological functions of peptides produced by SPPS for use in proteolytic 
nanobeacons, even with the inclusion of an unidentified adduct. As such, further studies 
to identify the origin and structure of the common 56 Da adduct were not pursued. 
Having confirmed the feasibility of using SPPS to produce MMP-cleavable peptides 
endowed with measurable FRET switch potential, the production of dual-targeted peptide 
constructs further required development and testing of an efficient synthesis technique for 
the attachment of folic acid to the N-termini of peptides. Despite the presence of two 
carboxylic acid functional groups in the structure of folic acid and the published use of 
carbodiimide chemistry to attach folic acid to amine-terminated nanoparticles
57,63,133
, 
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DCC-mediated coupling of folic acid to the N-terminal primary amines of peptides in 
solution could not be demonstrated effective in our hands (see III.3.3). Reaction of the 
NHS ester of folic acid (FA-NHS) with peptides in solution was shown by TLC (Figure 
III-15) and MALDI-TOF MS (Figure III-16) to provide partial but incomplete coupling 
of folic acid despite the use of excess FA-NHS reactant. Importantly, MALDI-TOF MS 
of the products of reaction of FA-NHS and broadly MMP-cleavable peptides following 
treatment with MMP9 (Figure III-17) detected predicted cleavage products but not intact 
peptides, validating the findings in the previous chapter that folation of substrate peptides 
does not block MMP cleavage. However, attempts to incorporate N-terminal folation of 
peptides in SPPS by reacting peptides on solid support resin with FA-NHS were not 
shown by HPLC or MALDI-TOF MS to induce the expected changes in HPLC retention 
time or molecular weight (data not shown). 
Labeling of peptides with folic acid during as part of solid phase synthesis, while 
peptides are attached to solid support resin and the side chains of constituent residues are 
protected from undesired side reactions by acid-labile protecting groups, provides 
flexibility and extensibility in the design of multifunctional peptides produced by SPPS. 
The application of HCTU, the aminium-based carboxyl-to-amine coupling mediator used 
in most couplings during automated SPPS of pB2v, was shown by LCMS (Figure III-19 
and Figure III-20) to successfully mediate attachment of folic acid to resin-bound 
protected pB2v peptide. Importantly, while the resulting peptide mixture contained 
products including or omitting the K(fam) residue and/or a 56 Da adduct, characteristic of 
the previous SPPS of pB2v, ions corresponding to peptides absent folic acid were not 
detected. Furthermore, as seen in Figure III-21, a purified product of HCTU-mediated 
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folation of pB2v (FApB2v) exhibited up to an 8-fold increase in sensor (FAM) 
fluorescence upon treatment with MMPs, confirming again that neither attachment of 
folic acid nor the synthetic steps preceding prohibitively interfered with the fluorescence 
or MMP-cleavability of substrate peptides produced by SPPS. It should also be noted that 
the sensor fold-changes up to 8-fold shown in Figure III-21 reflect a conservative 
calculation of the effect on sensor fluorescence attributable to cleavage of FApB2v, as 
they do not account for the background emission intensity inherent to the assay 
conditions. Altogether, the above analyses confirm that folated, FRET-equipped, MMP-
cleavable peptides can be produced in total solid phase synthesis and have FRET 
switches appropriate for optical imaging of MMP activity. 
  To enable our design of dual-targeted nanoparticles based upon bioconjugation of 
FRET-equipped MMP substrate peptides to nanoparticle surfaces, we required a 
synthesis technique that provided efficient coupling and chemoselectivity in mild 
conditions for compatibility with organic dyes and amino acid side chains. Adapting a 
published technique for nucleophile-catalyzed oxime ligation of unprotected peptide 
fragments
130
, it was shown by LCMS following synthesis (Figure III-23 and Figure 
III-24) that incorporation of an aminooxy functional group at the C-terminus of pB2v to 
yield pB2vAoa peptide could be achieved by SPPS. These peptides were then endowed 
with a functional group with great selectivity for reaction with carbonyls (ketones and 
aldehydes)
130,134,135
. However, like previously discussed variations of pB2v peptides 
synthesized by SPPS, the pB2vAoa crude peptide mixture was found to contain a 
majority of peptide products lacking the intended K(fam) residue, as shown in Figure 
III-24. A minority of HPLC-separated synthesis products represented structures with the 
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predicted molecular weight of pB2vAoa, corroborating the results of previous syntheses 
suggesting inefficient coupling of Fmoc-Lys(fam)-OH during automated SPPS. 
 
Because incomplete coupling of the K(fam) residue was determined to be a persistent 
cause of unintended yield from SPPS of FRET peptides and resulted in peptides with no 
sensor fluorescence to potentiate optical sensing of proteolytic activity, further 
optimization of pB2vAoa synthesis was necessary. Considering steric hindrance by the 
multiple aromatic rings of FAM a likely impediment to the coupling reaction, SPPS of 
pB2vAoa was repeated with substitution of Fmoc-K(ivDDE)-OH for the K(fam) residue. 
HPLC and LCMS of the resulting peptide, shown in Figure III-26, confirmed more 
efficient coupling of K(ivDDE) during automated SPPS. Despite the requirement of 
additional synthesis steps to remove the ivDDE protecting group and to attach FAM via 
amine-reactive FAMSE, the improved coupling efficiency and lower relative costs of 
reagents should have made this strategy more economical than the initial design 
employing the more expensive Fmoc-Lys(5/6-FAM)-OH precursor. LCMS following 
additional reactions after automated SPPS confirmed successful conjugation of folic acid 
and FAM, as seen in Table III-2 and Figure III-27, to provide complete synthesis of 
FApB2vAoa peptide. Additionally, owing to the stability of ivDDE to the conditions 
required for repeated deprotection of Fmoc during SPPS and its compatibility with 
deprotection without affecting acid labile protecting groups
131
,  this strategy also 
presented the potential to extend applications of SPPS to substrate peptides including 
moieties not commercially available as lysine conjugates or that are intolerant of the acid-
base conditions required for SPPS, such as NIR dyes or drug molecules. However, the 
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2% hydrazine in NMP solution employed for removal of ivDDE in preparation for FAM 
attachment was found to alter the quenching fluorophore, TAMRA, as indicated by the 
anomalous pH-sensitive UV-visible absorbance properties of FApB2vAoa obtained by 
this synthetic route (Figure III-28). While TAMRA is normally reversibly pH-sensitive, 
absorbing maximally at 550-560 nm in acidic to neutral pH, the indicated lack of such 
absorbance by FApB2vAoa at pH 6.5-7.5 consequently hindered its potential FRET 
switch under physiologic conditions, as quenching of FAM emission was compromised. 
As such, an alternative ivDDE deprotection scheme employing hydroxylamine 
hydrochloride and imidazole
132
 was attempted and was shown compatible with desired 
optical properties of TAMRA. However, this strategy was minimally effective at 
removing ivDDE from the protected lysine residue (data not shown, see III.3.5). As such, 
further attempts to produce pB2vAoa peptides using K(ivDDE) residue were not pursued. 
 Instead, I sought to improve yields of pB2vAoa by altering the coupling scheme for 
Fmoc-Lys(5/6-FAM)-OH during automated SPPS. pB2vAoa peptide was synthesized 
following the originally devised scheme for SPPS of pB2v (see II.2.11), with the 
important modifications that: i) Fmoc-Lys(5/6-FAM)-OH was reacted with triple-
coupling of 2 molar equivalents of residue relative to resin substitution in each coupling; 
and ii) an acetic anhydride capping step was added immediately after the third coupling 
to terminate any peptide products not successfully conjugated with K(fam) prior to 
coupling the remaining residues. This synthesis strategy was found by HPLC and LCMS 
analysis of crude peptide mixture (shown in Figure III-29) to produce a much less 
heterogeneous mixture of peptide products, the majority of which had molecular weights 
corroborating the inclusion of K(fam). The products of this synthesis also contained an 
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unidentified 40 Da adduct. Furthermore, the important optical and biological functions of 
pB2vAoa from triple-coupling SPPS were validated by the demonstration of greater than 
15-fold increase in FAM fluorescence after 20 minutes incubation with MMP14 (Figure 
III-30). Paradoxically, triple-coupling using 2 molar equivalents (relative to resin 
substitution sites) per coupling required less of the relatively expensive 
Fmoc-Lys(5/6-FAM)-OH reactant than the previously employed double-coupling using 4 
molar equivalents per coupling. Interestingly, as seen in Figure III-29, a minority product 
corresponding to the structure of pB2vAoa omitting the C-terminal DprAoa residue but 
not inclusive of any adduct was also detected. 
HPLC and LCMS were again used to confirm successful acylation of pB2vAoa from 
triple-coupling SPPS with either folic acid or acetic anhydride (as described in III.2.7) to 
yield FApB2vAoa (Figure III-32) or AcpB2vAoa (Figure III-33), respectively. FRET 
switch was confirmed in an unpurified sample of FApB2vAoa crude peptide (Figure 
III-31) as well as in HPLC-purified AcpB2vAoa (Figure III-34). The MMP-associated 
FRET switches in each case were abrogated by the inclusion of EDTA in the assay 
media, confirming the dependence of the observed fluorescence enhancement on 
metalloproteinase activity. Additionally, the sensor (FAM) fluorescence emission of cell 
culture medium containing crude AcpB2vAoa peptide mixture was also shown to 
increase during 24 hours incubation with human breast cancer cells, as seen in Figure 
III-35. This effect was partially inhibited by the addition of GM6001, a broad-spectrum 
MMP inhibitor, suggesting that AcpB2vAoa was cleaved by MMPs in the cell culture 
medium to generate the increase in FAM emission.  
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Altogether, the above results validate the triple-coupling SPPS and subsequent N-
terminal modification protocol as a robust set of techniques for total solid phase synthesis 
of folate-targeted, FRET-equipped, MMP-cleavable peptides suitable for oxime ligation 
reactions for the synthesis of proteolytic nanobeacons. This SPPS protocol is adaptable to 
any amino acid sequence of interest to generate substrates for other proteolytic enzymes 
as well as to the inclusion of many other targeting ligands and chemical functional groups 
for subsequent bioconjugation reactions, and may therefore be of interest to many 
researchers studying the plethora of human diseases in which protein or peptide 
degrading enzymes play key roles
126
. 
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CHAPTER IV 
 SYNTHESIS AND CHARACTERIZATION OF FOLATE-TARGETED 
PROTEOLYTIC NANOBEACONS 
IV.1. INTRODUCTION 
The preceding chapters have detailed the design, synthesis, and characterization of 
beacon peptides exhibiting a detectable increase in visible-spectrum fluorescence upon 
cleavage by MMPs. The peptides feature N-terminal attachment to either folic acid as a 
targeting ligand or an acetyl group for inertness, and a C-terminal aminooxy functional 
group for bioconjugation to nanoparticles or surfaces. The intent of this design is that the 
portion of a peptide on the N-terminal side of a scissile bond, presenting either folic acid 
or an acetyl group in addition to the sensor fluorophore (e.g. FAM), should be liberated 
from the nanoparticle surface upon cleavage by an MMP or MMPs for which the peptide 
is a selective substrate. In the case of a folate-targeted proteolytic nanobeacon, the 
liberated peptide fragment represents a folate conjugate that should be readily 
internalized by cells displaying membrane-anchored folate receptors
136,137
. 
With a robust protocol for the synthesis of these multifunctional peptide linkers 
established, selection of a suitable nanoparticle core for proteolytic nanobeacons was also 
required. As discussed earlier (see I.3), nanoparticles for tumor-targeted proteolytic 
nanobeacons should have at least one dimension greater than about 10 nm and no 
dimensions much larger than 100 nm to avoid rapid secretion in the kidneys, avoid 
undesired diffusion throughout body tissues, and to take advantage of the EPR effect in 
solid tumors. Additionally, the nanoparticle cores of nanobeacons must present a suitable 
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functional group for bioconjugation with peptides and other molecules important for 
biocompatibility (e.g. PEG). Finally, the nanoparticles themselves must ultimately be 
relatively non-toxic in the form injected for systemic administration. 
Several candidate classes of nanoparticles meeting these criteria were considered. Our 
laboratory previously reported detection of MMP7 activity using proteolytic nanobeacons 
based on PAMAM dendrimers
24
. PAMAMs are well-studied, commercially available in 
several nominal sizes with different numbers of surface functional groups, and amenable 
to several types of bioconjugation reactions. However, prepared PAMAM solutions are 
typically relatively polydisperse due to the divergent generational synthesis employed in 
the production of PAMAMs. Furthermore, the primary amines at branch termini 
effectively present a polycationic surface with a high-positive Zeta potential that may 
lead to nonspecific cell uptake and potentially undesirable elimination from circulation in 
vivo
138
. A substantial fraction of the amine termini must be functionalized or terminated 
with neutral or anionic groups to abrogate this effect and improve biocompatibility. 
Fréchet-style polyester dendron nanoparticles have also been employed previously by 
our laboratory for the synthesis of MMP9-responsive carriers of near-infrared 
fluorophores and/or paclitaxel (PXL)
109
. Dendrons of this type can be synthesized rapidly 
and efficiently
139
 with defined sizes and near monodispersity by convergent synthesis 
schema
140
. The diversity of available terminal cores for organic dendrons also provides 
the ability to mix-and-match differently equipped dendrons for multiplexed conjugates of 
imaging agents and drug molecules (Scherer et al, unpublished). However, in vivo 
imaging studies with nanodendron-based proteolytic nanobeacons indicated substantial 
accumulation of dendrons in mouse livers following parenteral administration 
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(Sameulson et al, unpublished). The cause(s) of this accumulation have not be elucidated, 
but there is very likely a size-dependent influence on biodistribution of dendrons
104,106,138
. 
We also considered partially inorganic nanoparticles for use as multifunctional cores 
in proteolytic nanobeacon design. Iron oxide (FeOx) nanoparticles have been 
increasingly used for biomedical imaging applications and are commercially available or 
easily synthesized with biocompatible surface coatings amenable to several types of 
bioconjugation reactions. For example, dextran-coated FeOx nanoparticles may be 
synthesized with either amine or carboxylic acid functional groups on their surfaces and 
typically have hydrodynamic diameters ranging 20-45 nm
141
, a size range that has been 
reported to be optimal for the EPR effect and cellular internalization with other spherical 
inorganic nanoparticles
142
. Unlike the organic nanoparticles discussed above, FeOx 
nanoparticles innately enable additional imaging modalities such as magnetic resonance 
contrast, transmission electron microscopy (TEM) without additional staining, and 
histology of tissue sections by Prussian blue staining. Separation and recovery of FeOx-
based nanoparticles may also be simplified owing to the superparamagnetic property of 
Fe3O4 (magnetite) and its oxidized analogue, γ-Fe2O3 (maghemite). However, strong 
absorbance in the UV-visible region of the electromagnetic spectrum by iron is a concern 
for spectrophotometric analyses of such nanoparticles, though fluorescein-labeled FeOx 
imaging agents have been reported in the literature 
66,143–146
. Conceivably, this absorbance 
could serve as a quencher of sensor (FAM) in addition to TAMRA in intact nanobeacons, 
leading to the potential for even greater relative FRET switch and S/R ratio increase upon 
MMP cleavage. 
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The research that follows documents the development and troubleshooting of 
strategies to covalently attach peptides and other molecules to nanoparticles for the 
purpose of synthesizing folate-targeted proteolytic nanobeacons. Weighing the 
advantages and potential pitfalls of each class of nanoparticle described above, FeOx 
nanoparticles were chosen as the principal candidates for bioconjugation with FRET-
equipped MMP substrate peptides. Despite several attempts at nanobeacon synthesis 
using FeOx-based nanoparticles and data suggesting attachment of peptides to FeOx 
nanoparticles, FRET switches indicative of proteolytic cleavage were not observed from 
nanobeacons of this type. The results of i) troubleshooting of the reaction conditions and 
each of the reactants for oxime ligation; ii) revisited analysis of the peptide-nanoparticle 
linking chemistry; and iii) synthesis of nanobeacons using a peptide with a lengthier 
hydrophilic spacer at its C-terminus collectively indicated steric hindrance and impurities 
in peptide mixtures from SPPS as the probable causes for ineffective bioconjugation 
reactions. To address these issues, a peptide with a flexible, hydrophilic spacer group 
near the C-terminus was synthesized and used for nanobeacon synthesis. Ultimately, the 
successful synthesis of folate-targeted proteolytic nanobeacons on organic PAMAM 
dendrimers as well as preliminary evidence of folate-dependent nanobeacon uptake in 
vitro is presented below. 
IV.2. MATERIALS AND METHODS 
IV.2.1. General Methods 
Materials. All chemicals and biochemicals were reagent-grade or HPLC-grade and 
solutions were prepared in filtered deionized water (dH2O) (Milli-Q, Billerica, MA, 
USA). Unless otherwise noted, all chemicals were purchased from either Sigma Aldrich 
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(St. Louis, MO, USA) or Thermo Fisher Scientific (Waltham, MA, USA). Chemical 
reactions were performed protected from light and at RT with rocking unless otherwise 
specified. Dextran-coated iron oxide nanoparticles (“IDX”), with 5 nm iron-oxide cores 
and 30 nm hydrodynamic diameter according to the manufacturer’s quality assessments 
were purchased from Ocean Nanotech (Springdale, AR, USA). mPEG-SH(1k) was 
obtained from Creative PEGWorks (Winston Salem, NC, USA). Generation 4 Starburst® 
polyamido amine dendrimer (PAMAM4) was purchased from Sigma Aldrich (St. Louis, 
MO, USA). MDA-MB-468 human breast adenocarcinoma cells were obtained from 
ATCC (Manassas, VA, USA). 
Mass spectrometry. LCMS was performed as described above (see II.2.1). 
Electrospray ionization mass spectrometry in positive ion mode (ESI+ MS) was 
performed using the same instrumentation as LCMS. Samples were injected using the 
autosampler of the UPLC system by mixture with 5:95 H2O:MeCN with 0.2% formic 
acid for injector flow.  
IV.2.2. Introduction of aldehydes on dextran-coated iron oxide nanoparticles 
Measurement of iron content. Iron (Fe) concentration of iron oxide nanoparticle 
suspensions was determined according to manufacturer’s recommended protocol. UV-
visible spectra of suspensions were recorded and the absorbance at 500 nm used to 
calculate Fe mass concentration using the provided extinction coefficient of 3.25 
mg(Fe)
-1
*mL*cm
-1
. 
General oxidation procedure. 900 µL of sodium meta-periodate (NaIO4) oxidant 
diluted to various concentrations in dH2O was added to 100 µL (1 mg Fe equivalent) of 
IDX nanoparticles (nominally 10 mg/mL Fe as purchased) in Eppendorf microcentrifuge 
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tubes and vortexed on low speed, protected from light, for 1 hour, to afford oxidized IDX 
nanoparticles termed oIDX[n], where [n] indicates the concentration of NaIO4 oxidant 
applied during oxidation. Nanoparticle suspensions were then dialyzed (1,000 MWCO) 
against 1-4 L dH2O for 48 hours with several replacements of dialysate with fresh dH2O. 
Aldehyde quantitation. Amplite™ Fluorimetric Aldehyde Quantitation kit was 
obtained from AAT Bioquest (Sunnyvale, CA, USA). The assay was performed 
according to supplier instructions with minor modifications. Due to optical interference 
from the broad UV-visible absorption of Fe, the provided aldehyde standards solutions 
were spiked with IDX nanoparticle stock solution to give a final assay concentration of 1 
mg/mL Fe in each well. All sample solutions were also adjusted to 1 mg/mL Fe following 
determination of iron content by spectrophotometry (see above). The estimated number 
of aldehydes per nanoparticle in each sample was calculated by dividing the interpolated 
aldehyde concentration by the nanoparticle number concentration that was calculated 
from the spectrophotometrically measured Fe concentration and expected mass of iron in 
each nanoparticle core based on the density of iron oxide (5.49 g/cm
3
, 70% Fe)
147
 and the 
supplier’s size measurements (e.g. 1 mg/mL Fe corresponds to 6.9 nMoles/mL of IDX 
nanoparticles with 5 nm-diameter cores). 
IV.2.3. Nanoparticle synthesis by oxime ligation  
To each of two Eppendorf microcentrifuge tubes were added 246 µL (2 nmol) oIDx-
500uM nanoparticles in dH2O and 3 µL (33 µmol ) aniline. Then, 18 µL (6 nmol) or 36 
µL (12 nmol) FApB2vAoa in 10% DMF was added slowly to give “NP3
++” and “NP6
++” 
reaction mixes, respectively. Reactions were allowed to proceed for approximately 5 days 
before attempted recovery of nanoparticles. Approximately 10% of each reaction mix 
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was aliquotted for later analysis and the remainder of each mix was diluted to 500 µL 
total volume in dH2O.  
Diluted reaction mixes were transferred to Amicon Ultra 10k (NMWL 10,000) 
centrifugal filter devices (EMD Millipore, Darmstadt, DE) and centrifuged according to 
supplier instructions. To aid in recovery of aggregated samples, 450 µL dH2O was added 
to filter devices and thorough sonication and repeated dispersion by pipetting performed. 
Mock reactions containing 18 µL (6 nmol) FApB2vAoa and 3 µL (33 µmol ) aniline with 
or without inclusion of 246 µL (2 nmol) IDX non-oxidized nanoparticles in dH2O (“+++ 
Ctl” and “++ Ctl,” respectively) were assembled as controls. All containers for collection 
of reaction mix and recovered product components were weighed before and after 
collection in order to determine relative amounts of material recovered. 
Recovered NPn
++
 reaction mixes
 
and concentrates were characterized by UV-visible 
spectrophotometry (general method, see II.2.1) and fluorescence spectroscopy using 
opaque 96-well plates in a fluorescence plate reader using excitation wavelengths of 495 
nm and 555 nm. To assess the relative amount of peptide-associated FAM and TAMRA 
dyes in each sample, absorption spectra were corrected by scaling the spectrum of the 
parental (oIDX-500uM, non-reacted) nanoparticle to the sample absorbance at 400 nm (a 
relative minimum for the dye species) and subtracting the scaled spectrum from the 
sample spectrum, the difference representing added absorbance presumed attributable to 
the peptide-associated dyes. 
Recovered NP6
++
 concentrate from ultrafiltration (above) was subsequently pelleted 
by centrifugation at 14,000 relative centrifugal force (rcf), washed twice with 200 µL 
MeOH and centrifugation at 2,000 rcf, and resuspended in 400 µL dH2O with sonication. 
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The resulting suspension was serially diluted in dH2O to 1:3 and 1:10 dilutions and the 
dilution series analyzed by plate reader fluorescence spectroscopy using excitation 
wavelengths of 495 nm and 555 nm and emission bandwidths of 5 nm and 10 nm. 
IV.2.4. Oxime ligation comparing nucleophilic catalysts 
To three microcentrifuge tubes containing 182 µL (2 nmol) oIDX-1000uM 
nanoparticles in dH2O, each, were added 3.3 µL (3.3 µmol ) p-phenylenediamine (pPDA) 
and 36 µL (12 nmol), 71 µL (24 nmol), or 107 µL (36 nmol) FApB2vAoa in 10% DMF 
to generate “NP6
++ 
pPDA,” “NP12
++
 pPDA,” and “NP18
++
 pPDA” reaction mixes 
respectively. Similarly, 3 µL (33 µmol ) aniline and 36 µL (12 nmol) FApB2vAoa in 
10% DMF were added to a microcentrifuge tube containing 182 µL (2 nmol) oIDX-
1000uM nanoparticles in dH2O to generate “NP6
++
 An” reaction mix. Two control 
reaction mixes were set up, either with no nanoparticles or with 22 µL (2 nmol) IDX 
(non-oxidized) nanoparticles in dH2O. To each was added 36 µL (12 nmol) FApB2vAoa 
in 10% DMF to prepare “No-IDX Ctl” and “No-Rxn Ctl” reaction mixes, respectively. 
To all reaction mixes including controls were added 33 µL 1 M sodium phosphate buffer 
(pH 6.0) and dH2O sufficient to bring total volume to 330 µL. Reactions were then 
allowed to proceed 24 hours before further workup. 
Reaction mixes were separated and components recovered by centrifugation, 
precipitation, and magnetic separation. All reaction mixes were handled identically, first 
by centrifugation at 10,000 rcf for 10 minutes to pellet suspended inorganic 
nanoparticles. Supernatants were aspirated while pellets were held stationary using a 1 
Tesla magnet. Pellets were then twice washed with 330 µL MeOH with vortexing and 
sonication and pelleted as before. Final pelleted solids were resuspended in 330 µL dH2O 
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each and subsequently analyzed by UV-visible spectrophotometry and plate reader 
fluorescence spectroscopy, as with NPn
++
 nanoparticles (see IV.2.3, above). 
IV.2.5. Oxime ligation with fresh aniline catalyst in organic solvent 
484 µL (5 nmol) oIDX-1000uM and 55 µL (5 nmol) IDX nanoparticles were each 
precipitated separately by increasing volume to 1.9 mL in microcentrifuge tubes with 
EtOH. Each nanoparticle slurry was then centrifuged at 12,000 rcf for 5 minutes and 
pellets held with a 1 Tesla magnet while supernatants were decanted. Pellets were air 
dried and resuspended in 145 µL DMSO each. 19.4 µL 1 M sodium acetate (pH 4.5) 
buffer was added to nanoparticle suspensions and each sonicated gently. 59.5 µL (200 
nmol) FApB2vAoa in DMSO was combined with 4 µL (44 µmol ) aniline from a freshly 
opened supplier’s bottle. 31.75 µL (100 nmol FApB2vAoa equivalent) of this mixture 
was added to each nanoparticle suspension and reacted for 5 days. 
Nanoparticle products of reactions were precipitated by pipetting reaction mixes into 
1.6 mL ice cold MeOH and pelleted by centrifugation at 12,000 rcf for 10 minutes at 0 
°C. Supernatants (“Supernatant 1”) were collected by aspiration, holding pellets with a 1 
Tesla magnet, prior to adding 200 µL ice cold MeOH to pellets. The above processes 
were repeated, culminating in the collection of “Supernatant 2” from each tube and air 
drying of each nanoparticle pellet using 1 Tesla magnet to retain drying solids. Pellets 
were resuspended in 145 µL DMSO each with sonication and 10 µL aliquots diluted into 
1 mM phosphate buffer (pH 7.0) for UV-visible spectrophotometry. 
Resuspended nanoparticles in DMSO were subsequently precipitated again by 
pipetting slowly into 1 mL ice cold MeOH. The resulting turbid mixtures were gently 
sonicated and centrifuged as above to provide “Supernatant 3” from each tube. 
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“Supernatant 4” was similarly obtained by washing nanoparticle pellets with 1 mL 
MeOH. Following air drying, pellets were once again resuspended in 135 µL DMSO 
each and 6 µL aliquots diluted in 1 mM phosphate buffer (pH 7.0) for UV-visible 
spectrophotometry. 
Nanoparticles suspended in DMSO were once more precipitated by slowly pipetting 
into 500 µL ice cold MeOH in microcentrifuge tubes on a DynaMag™-spin magnetic 
separator (Life Technologies, Carlsbad, CA, USA). Supernatants were collected and 
transferred to empty microcentrifuge tubes on the magnetic separator. Nanoparticle 
pellets were resuspended in 129 µL each DMSO and 6 µL aliquots measured by UV-
visible spectrophotometry as before. Because magnetically-separable solids were still 
discovered in the transferred solutions, the newly-formed supernatants were again 
collected and labeled “Supernatant 5.1”. 300 µL 1 mM phosphate buffer (pH 7.0) was 
added to magnetically retained solutes and the resulting solutions labeled “Supernatant 
5.” In summary, from each of the two reactions were derived the following fractions: 
reaction mix, supernatants 1-5, and supernatant 5.1, and final product. 
Spectrophotometric measurement of the UV-visible absorbance of each fraction and a 
diluted sample of recovered nanoparticle products was performed after each centrifugal 
or magnetic separation. 
IV.2.6. Peptide-focused troubleshooting of oxime ligation 
Trypsin cleavage. 5 µL (1.7 nmol) FApB2vAoa in 10% DMF was combined with 40 
µL dH2O and 5 µL trypsin (0.2 mg/mL) in dH2O and incubated several hours at RT. 
Molecular weights of products resulting from the cleavage reaction were determined by 
LCMS (general method, see II.2.1). 
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Diagnostic reaction. 14.9 µL (50 nmol) FApB2vAoa, 7.5 µL 4-formylbenzoic acid, 
and 3 µL fresh aniline (300 nmol) all in DMSO were combined and reacted for 6 hours at 
RT. 1 µL (3.4 nmol) FApB2vAoa and 1 µL reaction mix were each diluted with 99 µL 
95:5 H2O:MeCN with 0.2% formic acid and analyzed by ESI+ MS (see IV.2.1) to assess 
the extent of reaction, if any. 
IV.2.7. Nanoparticle synthesis via Steglich esterification 
Synthesis of carboxyl-terminated FRET peptide. Fmoc-Gly-Wang LL Resin (100-200 
mesh) was purchased from EMD Chemicals (Billerica, MA, USA). A broadly MMP-
cleavable FRET peptide based on the structure of pB2v, “pB2vp-cooh” 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg1}G-cooh], was 
synthesized by SPPS on Fmoc-Gly-Wang resin with an intended maximum yield of 25 
µmol in a procedure analogous to previously synthesized peptides (see II.2.11). 
pB2vp-cooh on resin was acetylated as described previously (see III.2.7) and final 
deprotection and cleavage from solid support performed using cleavage cocktail R to 
generate “AcpB2vp-cooh” 
[Ac{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg1}G-cooh]. 
Nanoparticle synthesis (attempted). Attachment of AcpB2vp-cooh to IDX 
nanoparticles displaying secondary alcohols of dextran polymers on their surfaces was 
attempted according to a published scheme for Steglich esterification of amino acids to 
starch derivatives 
148
. 110 µL (10 nmol) IDX nanoparticles in dH2O were precipitated in 
MeOH and resuspended in 145 µL DMSO with thorough sonication, as described in 
detail previously (see IV.2.5). To this were added (in order) 12.7 µL (50 nmol) AcpB2vp-
cooh, 2.4 µL (15 nmol) N,N’-diisopropylcarbodiimide (DIC), and 4.0 µL (4 nmol) 4-
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dimethylaminopyridine (DMAP), all in DMSO. The mixture was reacted for 20 hours in 
air-free conditions with continuous nitrogen bubbling before the reaction was quenched 
by addition of 4 µL dH2O. Nanoparticle products were precipitated by pipetting the 
reaction mix into ice cold methanol on a magnetic separator device as described 
previously (see IV.2.5). Magnetically recovered nanoparticles were reconstituted in 150 
µL DMSO and peptide attachment was characterized as described previously (see IV.2.3) 
by UV-visible spectrophotometry with dilution of nanoparticle solution in 100 mM 
phosphate buffer (pH 7.3). 
IV.2.8. Nanoparticle synthesis via carbodiimide coupling to quantum dots 
Qdot® 605 ITK™ Amino (PEG) Quantum Dots (“Qdot(605)NH2,” Life 
Technologies, Carlsbad, CA, USA) were a generous gift from the Rosenthal Laboratory 
(Dept. of Chemistry, Vanderbilt University, Nashville, TN, USA). 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC) was obtained from 
Calbiochem (La Jolla, CA, USA). “Borate buffer” hereafter refers to 100 mM sodium 
borate buffer (pH 8.5) unless otherwise specified.  
Using reaction conditions recommended by Ian Tomlinson, Ph.D. (personal 
communication), to 10 µL (80 pmol) Qdot(605)NH2 in 50 mM borate (pH 8.3) were 
added (in order) 90 µL borate buffer, 10 µL (8 nmol) Peptide 13c (see II.2.8)  in DMF, 10 
µL (8 nmol EDAC) in borate buffer, and100 µL additional borate buffer to give 
“100:100:1” (where ratios represent molar equivalents of peptide:EDAC:Qdot) reaction 
mix. “No EDAC Control” (100:0:1) reaction mix was generated by reproducing the 
above mixture but substituting 10 µL borate buffer instead of EDAC. A “No Peptide 
Control” sample (0:100:1) was similarly produced by substituting 10 µL DMF instead of 
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Peptide 13c. “1000:500:1” reaction mix was composed of 10 µL (80 pmol) 
Qdot(605)NH2 in 50 mM borate (pH 8.3), 100 µL (80 nmol) Peptide 13c in DMF, 14 µL 
(40 nmol EDAC) in borate buffer, and 100 µL borate buffer and was reacted with stirring 
for approximately 65 minutes. “2000:1500:1” reaction mix consisted of 10 µL (80 pmol) 
Qdot(605)NH2 in 50 mM borate (pH 8.3), 200 µL (160 nmol) Peptide 13c in DMF, and 
15 µL (120 nmol EDAC) in borate buffer. 
The above reaction mixes and samples were reacted with magnetic stirring in glass 
scintillation vials. Following 90 minutes and overnight reaction, 5 µL per well of the 
reaction mixes and samples were analyzed by electrophoresis in freshly cast 1% agarose 
gels in TAE buffer on ice, with samples migrating towards the cathode. Qdot(605)NH2 
was diluted in borate buffer to the same concentration as in reaction mixes and to serve as 
the reference point for electrophoretic mobility. Gels were visualized following 
electrophoresis by ultraviolet excitation in a BioDoc-It® Gel Imaging System (UVP, 
Upland, CA, USA). 
IV.2.9. Nanoparticle synthesis via carbodiimide coupling to organic dendrimers 
Coupling of peptides to PAMAM dendrimers was tested by combining 10 µL (56 
nmol) PAMAM4 in MeOH, 147 (112 nmol) Peptide 13c in DMF, and 10 µL (223 nmol) 
EDAC in MeOH and allowing reaction overnight at RT with constant stirring. A non-
reactive mixture (“No Rxn”) was generated in parallel by reproducing above reaction mix 
but substituting 10 µL MeOH for EDAC. 
Following overnight reaction, 3.2 mL 2 mM EDTA in dH2O was added to each 
mixture and 300 µL conserved for later analysis. Diluted reaction mixes were then 
concentrated by ultrafiltration in Centriprep YM3 devices (EMD Millipore, Darmstadt, 
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DE) according to supplier instructions. Due to adsorption of colored solutes onto YM3 
filter membranes in both mixtures, 4 mL of 1 mM EDTA in 50% EtOH solution was 
added to devices to dissolve and recover solutes. Diluted YM3 retentates were again 
concentrated by ultrafiltration in Centriprep YM10 devices (MWCO 10,000 Da). Dilution 
and concentration of each sample was repeated in the same YM10 devices with 4 mL 1 
mM EDTA in 50% ethanol solution. Retentates and effluents containing 50% EtOH from 
YM10 devices were recombined and concentrated using YM3 devices. All recovered 
solutions were subsequently diluted at least 1:2 in PBS (pH 7.1) for analysis by UV-
visible spectroscopy using a Varian Cary 50 Bio spectrophotometer (Agilent, Santa 
Clara, CA, USA). 
IV.2.10. Synthesis of a broadly MMP-cleavable FRET peptide with a flexible C-
terminal linker and cysteine for bioconjugation 
Fmoc-Cys(Trt)-Wang Resin was purchased from Anaspec (Fremont, CA, USA). 
Fmoc-NH-PEG5-CH2COOH  was purchased from ChemPep (Wellington, FL, USA). A 
broadly MMP-cleavable FRET peptide based upon the design of pB2v peptide with a C-
terminal hydrophilic spacer and cysteine, “pB2vp5C-cooh” 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg5}C-cooh], was 
synthesized by SPPS on Fmoc-Cys(Trt)-Wang resin using the triple-coupling scheme 
developed for pB2vAoa (see III.2.8). 126  mg Fmoc-Cys(Trt)-Wang resin with 0.55 
mmol/g substitution was down-loaded by coupling of 107 mg (206 µmol ) 
Fmoc-NH-PEG5-CH2COOH with 81 mg (196 µmol ) HCTU activator on the PS3 
automated peptide synthesizer. Substitution (available N-termini for coupling) following 
down-loading was determined to be 0.33 mmol/g by comparing absorbance of Fmoc-
deprotection solutions from untreated and down-loaded resin at 301 nm corresponding to 
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released Fmoc protecting groups. Resin substitution sites not coupled with PEG5 were 
subsequently blocked by acetylation with 25% acetic anhydride, 25% pyridine, 50% 
NMP solution using the standard capping program on the PS3 instrument. Automated 
SPPS then proceeded as described previously with a corresponding intended scale of 40 
µmol peptide based on down-loading of the resin. 
pB2vp5C-cooh peptide on resin was folated as described previously (see III.2.7) to 
generate FApB2vp5C-cooh FRET peptide 
[fa-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg5}C-cooh]. An analytical 
sample of FApB2vp5C-cooh was generated by submerging fa-peptide-resin in cleavage 
cocktail containing 90% TFA, 5% thioanisole, 2.5% TIPS, and 2.5% dH2O, blanketing 
with nitrogen gas, and vortexing protected from light for 2 hours prior to precipitation in 
ice cold Et2O as described previously (II.2.11). The analytical sample of uncharacterized 
mass/amount was dissolved in 500 µL MeOH and further diluted 1:10 in 95:5 
H2O:MeCN with 0.2% formic acid [LCMS mobile phase (A)] and characterized by ESI+ 
MS and LCMS (see IV.2.1). 
A stock of FApB2vp5C-cooh was generated by final deprotection and detachment 
from solid phase resin in cleavage cocktail as before (see above), precipitated in Et2O, 
and lyophilized to yield 12.1 mg of dry crude peptide mixture. 3.8 mg of unpurified 
FApB2vp5C-cooh was dissolved in 380 µL anhydrous DMSO and further diluted 1:100 
in PBS (pH 7.1) for analysis by UV-visible spectrophotometry. The concentration of 
TAMRA dye, a surrogate measure of peptide concentration, was determined by 
absorption of the solution at 562 nm and application of the Beer-Lambert Law using an 
empirically determined extinction coefficient of TAMRA dye (72,110 M
-1
cm
-1
). 
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To assess the FRET switch of FApB2vp5C-cooh peptide, 1 µL (57 pmol) 
FApB2vp5C-cooh in 5:95 DMSO:PBS (pH 7.1) containing equimolar β-mercaptoethanol 
(“reduced FApB2vp5C-cooh”) was diluted to 100 µL total volume in FRET switch assay 
buffer and analyzed by plate reader fluorescence spectroscopy with excitation at 494 nm 
and 555 nm. FApB2vp5C-cooh was also assessed by FRET switch assay with MMPs-
2,9,14 by dilution of reduced FApB2vp5C-cooh solution to approximately 700 nM final 
assay concentration in standard assay buffer (see general method, II.2.3). 
IV.2.11. Nanoparticle synthesis via heterobifunctional linker-mediated conjugation 
to amine-bearing iron oxide nanoparticles 
SIA, sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate (Sulfo-SMPB), and 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Pierce 
Chemical (Rockford, IL, USA). Recombinant human MMP14 catalytic domain (MMP14) 
was purchased from Enzo Life Sciences (Farmingdale, NY, USA). γ-Fe2O3 nanoparticles 
(FeOx) with core diameters of approximately 17 nm were synthesized and aminated with 
(3-aminopropyl)triethoxysilane (APTES) by Charleson Bell of the Giorgio Laboratory 
(Dept. of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA) as 
described
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 to afford FeOx-NH2 nanoparticles. Amine functionalization of FeOx-NH2 
was confirmed by qualitative Ninhydrin assay (see III.2.4). Iron (Fe) and number 
concentrations of FeOx-NH2 nanoparticles were characterized by measuring absorbance 
of suspensions at 500 nm and applying the Beer-Lambert Law with an extinction 
coefficient of 5 mg
-1
mLcm
-1
 and converting Fe concentration to nanoparticle number 
concentration using the same formula that was applied to IDX nanoparticles (see IV.2.2). 
Prior to the coupling reaction, 75 µL (523 nmol) TCEP in DMSO was added to 25 µL 
(32 nmol) FApB2vp5C-cooh in DMSO and reacted 50 minutes to reduce any disulfide 
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bonds that may have formed between peptides in solution. In parallel, 100 µL (30 pmol) 
FeOx-NH2 nanoparticles in DMSO were separately combined with 10 µL (37.5 nmol) of 
either SIA or Sulfo-SMPB in DMSO and reacted 50 minutes to generate activated 
“FeOx-IA” and “FeOx-mal” solutions. 47 µL (15 nmol peptide equivalent) reduced 
FApB2vp5C-cooh was added to FeOx-IA and FeOx-mal solutions to produce “NP++SIA” 
and “NP++SMPB” reaction mixes, respectively, and reaction vessels flushed with nitrogen 
gas prior to overnight reaction with vortexing, protected from light. 2.4 mg (2.4 µmol ) 
mPEG-SH(1k) was dissolved in 1.07 mL (7.4 µmol ) TCEP in DMSO solution to reduce 
and prevent oxidation of sulfhydryl functional groups. 10 µL (22.5 nmol mPEG-SH(1k) 
equivalent) of this solution was added to each NP
++
SIA and NP
++
SMPB reaction mixes and 
vortexing continued 90 minutes. 
Nanoparticle products of reactions were pelleted by magnetic attraction using a 1 
Tesla magnet and supernatants collected for subsequent analysis. 250 µL DMSO was 
added to each pellet and magnetic separation repeated. Final nanoparticle pellets were 
resuspended with 100 µL anhydrous DMSO. Peptide recovery and attachment to FeOx-
NH2 nanoparticles was assessed by UV-visible spectrophotometry of recovered 
supernatant solutions diluted in PBS (pH 7.1). Magnetic separation was used to exchange 
DMSO for EtOH in NP
++
SIA and NP
++
SMPB solutions prior to further 1:10 dilution in 
EtOH and analysis by fluorescence plate reader spectroscopy. Transmission electron 
microscopy (TEM) with energy-dispersive X-ray spectroscopy (EDX) of NP
++
SIA 
nanoparticles in EtOH was performed by Charleson Bell. FRET switch assay of FeOx-
based NP
++
SIA and NP
++
SMPB was performed with MMP14 (740 ng/mL final assay 
concentration) by diluting nanoparticles in standard assay buffer (see II.2.3). Because 
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nanoparticles flocculated in assay wells, supernatants were transferred to new assay wells 
and the fluorescence of the iron-depleted solutions was reassessed. 
IV.2.12. Nanoparticle synthesis via bioconjugation to organic dendrimers 
Methoxyl PEG succinimidyl ester, MW 5000 (PEG5000-NHS) was purchased from 
Nanocs (Boston, MA, USA).  
PAMAM4 was PEGylated by combining 145 µL (870 nmol) PAMAM4 in MeOH 
with 104 µL (1.74 µmol ) PEG5000-NHS in MeOH and reacting 30 minutes to generate 
“PAMAM4(PEG5k)2.” Two PAMAM activation reactions were composed by reacting 10 
µL (35 nmol) PAMAM4(PEG5k)2 with 35 µL (438 nmol) of either SIA or Sulfo-SMPB 
for 40 minutes. FApB2vp5C-cooh was reduced to eliminate disulfide dimers that may 
have formed in solution by combining 129 µL (165.5 nmol) FApB2vp5C-cooh in DMSO 
with 16.5 µL (165 nmol) β-mercaptoethanol in EtOH and reacting 40 minutes. Three 
parallel bioconjugation reactions were performed in glass 1.0 mL Reacti-Vials (Thermo 
Fisher Scientific, Waltham, MA, USA) to synthesize multifunctional nanoparticles from 
the intermediate materials above. 44 µL (50 nmol peptide equivalent) reduced 
FApB2vp5C-cooh solution, 5 µL (250 nmol) EDAC, and 14.5 µL (10 nmol) 
PAMAM4(PEG5k)2 solution were combined to form “NP
++
EDAC” reaction mix. 
44 µL (50 nmol peptide equivalent) reduced FApB2vp5C-cooh solution and 11.5 µL (10 
nmol) of either SIA- or Sulfo-SMPB-activated PAMAM4(PEG5k)2 solutions were 
combined to form “NP++SIA” and “NP
++
SMPB” reaction mixes, respectively. Reaction vials 
were blanketed with Argon gas and all reactions proceeded overnight at RT with gentle 
rocking, protected from light. Following overnight reaction, 10 µL (75 nmol) of mPEG-
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SH(1k) was added to NP
++
SIA and NP
++
SMPB reactions, each, to terminate any unreacted 
maleimides on nanoparticle surfaces. 
The products of nanoparticle synthesis reactions above were concentrated by 
ultrafiltration, as described previously (see II.2.2, IV.2.9). “EDTA buffer” hereafter refers 
to 1 mM EDTA in dH2O treated with 1 mM PMSF. Reaction mixes were diluted with 10 
volumes EtOH and 39 volumes EDTA buffer to give final volumes of 3.2 mL each for 
concentration by ultrafiltration in Centriprep YM10 devices. After one round of 
concentration to less than 1 mL retained volume, concentrates were diluted with 600 µL 
EtOH and 2.4 mL EDTA buffer and again concentrated in the same YM10 devices. 
Concentrated retentates were collected by aspiration and combined with two washes of 
retentate compartments with 150 µL each of 20:80 EtOH:EDTA buffer. FApB2vp5C-
cooh peptide recovery and conjugation to PAMAM nanoparticles in each reaction was 
assessed by UV-visible spectrophotometry of the effluents and concentrate collected from 
ultrafiltration diluted in PBS (pH 7.1). As with previous solution, concentrations of 
recovered nanoparticle solutions was determined by absorption at 562 nm and application 
of the Beer-Lambert Law using an empirically determined extinction coefficient of 
TAMRA dye (72,110 M
-1
cm
-1
) that is similar to reported values for 
tetramethylrhodamine-based dyes
150
. 
The FRET switches of NP
++
EDAC, NP
++
SIA, and NP
++
SMPB with MMP9 (nominally 5 
µg/mL final assay concentration, provided by Gilead Sciences, Foster City, CA, USA) 
were assessed by standard assay procedures (II.2.3) with alteration of the assay buffer to 
account for EDTA content of nanoparticle solutions. To 1.0 mL of a 10X concentrated 
stock of standard assay buffer were added 10 µL (200 nmol) ZnSO4 and 5 µL (1 µmol ) 
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PMSF. Stocks of 200 mM EDTA and dH2O were also treated with PMSF (1 mM final 
concentrations) prior to use in sample preparation for FRET switch assays. Final 
concentrations of NP
++
EDAC, NP
++
SIA, and NP
++
SMPB were estimated to be 360 nM, 370 
nM, and 320 nM, respectively, based on absorbance measurements (see above). 
Fluorescence was recorded by plate reader every minute for 2 hours, then every 30 
minutes for 12 additional hours. 
IV.2.13. In vitro assessment of folate- and MMP-dependent NP++EDAC uptake 
Phenol red-free RPMI 1640 and folate-free RPMI 1640 media were purchased from 
Life Technologies (Carlsbad, CA, USA). MDA-MB-231 human breast adenocarcinoma 
cells were purchased from ATCC (Manassas, VA, USA). Microscopy was performed 
using a Nikon Eclipse Ti inverted fluorescence microscope (Nikon Instruments, Melville, 
NY) and images analyzed using ImageJ software (NIH, Bethesda, MD, USA). 
Fluorescence of plated samples was measured using a TECAN Infinite F500 multimode 
microplate reader (Tecan Group, Männedorf, CH). 
Fluorescence Microscopy. 8-chamber slides (Thermo Scientific, Waltham, MA, 
USA) were coated with fibronectin and seeded with 12,000 MDA-MB-231 cells per 
chamber in phenol red-free RPMI-1640 medium containing 1% fetal bovine serum 
(FBS). Cell treatment conditions were made in folate-free RPMI 1640 medium with 1% 
FBS, 20 µM ZnSO4 and 100 nM NP
++
EDAC (except control, no beacon). Treatment media 
were prepared the day before cell exposure with or without approximately 700 ng/mL 
MMP14 and with or without 1.1 mg/mL free folic acid and baseline fluorescence 
determined using a microplate reader. After overnight expansion of cells, cell growth 
medium was removed and cells were incubated with treatment media for 4 hours. 
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Following treatment, media were removed to microplates for separate analysis and cells 
were washed and covered with PBS before imaging by fluorescence microscopy. 
Fluorescence of conditioned treatment media was assessed again by microplate reader. 
Flow Cytometry. MDA-MB-231 cells from fluorescence microscopy were harvested 
using standard cell culture techniques employing 0.25% trypsin-EDTA (Life 
Technologies, Carlsbad, CA, USA) and suspended in sterile PBS. Flow cytometry was 
performed on recovered cells using a BD FACSCalibur™ flow cytometer with a single 
488 nm excitation source (BD Biosciences, San Jose, CA, USA). Flow cytometry data 
was analyzed using FlowJo software (Tree Star, Ashland, OR, USA). 
IV.3. RESULTS 
IV.3.1. Introduction and quantification of aldehydes on dextran-coated iron oxide 
nanoparticles 
In order to prepare nanoparticles for oxime ligation with multifunctional peptides 
from SPPS (e.g. FApB2vAoa, see III.3.4 and III.3.6), dextran-coated iron oxide 
nanoparticles (IDX) were oxidized with sodium meta-periodate (NaIO4), a well-
established technique to introduce aldehyde functional groups in dextran polymers
129
, as 
schematically represented in Figure IV-1.  
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Figure IV-1: Oxidation of dextran to introduce aldehydes on IDX nanoparticles 
Sodium meta-periodate (NaIO4) can be used to oxidize dextran, thereby converting vicinal 
diols into two aldehyde functional groups 
129
 (a). This chemistry was applied to dextran-
coated iron oxide nanoparticles (IDX) to introduce surface aldehydes for oxime ligation 
(b). 
The concentration of aldehydes introduced was then measured using a commercially-
obtained fluorimetric detection assay with standard solutions of known aldehyde content. 
1.0 mg/mL (Fe) was introduced into each assay by titrating nanoparticle samples with 
assay buffer and spiking standard solutions with non-oxidized IDX nanoparticles. 
Standards were fit to a 4-parameter sigmoidal curve for interpolation of sample 
concentrations. As seen in Figure IV-2, the concentration of aldehydes measured on 
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nanoparticles increased in correlation with the concentration of oxidant applied during 
oxidation. 
 
Figure IV-2: Measurement of aldehydes on oxidized dextran-coated iron oxide nanoparticles 
Black dots represent aldehyde standard solutions spiked with 1 mg/mL iron from IDX 
nanoparticles. Colored circles represent oxidized IDX (oIDX) samples. Values represent 
average of triplicates +/- SEM. 
The relative numbers of aldehyde functional groups present per nanoparticle in each 
sample were calculated by dividing the measured aldehyde concentration by the 
calculated concentration of nanoparticles in each solution containing 1 mg/mL iron 
(determined spectrophotometrically, see IV.2.2), as tabulated in Table IV-1. 
Table IV-1: Aldehydes on oxidized dextran-coated iron oxide nanoparticles 
Sample Aldehyde Conc. (µM) Aldehydes/NP 
dH2O 7.2 1.0 
500 µM NaIO4 73.7 10.7 
1000 µM NaIO4 184.3 26.7 
1500 µM NaIO4 518.4 75.1 
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IV.3.2. Attempted oxime ligation of FApB2vAoa on aldehyde-bearing iron oxide 
nanoparticles 
To synthesize folate-targeted proteolytic nanobeacons, IDX nanoparticles bearing 
aldehydes from oxidation with 500 µM NaIO4 (“oIDX-500µM”) were reacted with either 
3 or 6 molar equivalents of FApB2vAoa crude peptide (relative to nanoparticles) in the 
presence of a catalytic amount of aniline in accordance with a published technique for 
oxime ligation
130
,  as schematically diagrammed in Figure IV-3. The term “NP++” 
hereafter refers to a number of different proposed nanoparticle constructs, each of which 
is intended to be decorated with peptides bearing both a FA targeting ligand and an 
MMP-cleavable amino acid sequence. 
 
Figure IV-3: Scheme, oxime ligation reaction of FApB2vAoa peptide with oIDX-500uM 
nanoparticles 
 
The resulting reaction mixes were filtered by ultrafiltration in 10 kDa (NMWL) 
centrifugal filter units with collection of the filtrates and concentrates for subsequent 
analyses. To assess the degree of peptide binding to nanoparticles, the UV-visible 
absorbance of the reaction mixes and their separated constituents recovered from 
ultrafiltration were characterized by spectrophotometry and compared with unreacted 
nanoparticles (Figure IV-4a). Reaction mixes and concentrates from both reactions 
possessed absorbance spectra with greater relative absorbance in the spectral regions 
characteristic of the peptide-associated FAM and TAMRA dyes (Figure IV-4b,d), though 
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those of from the reaction with 6 molar equivalents of peptide (“NP6
++”) were of greater 
relative deviation from the oIDX-500µM spectrum than NP3
++
. The absorbance of the 
filtrates was practically negligible, though also indicative of the presence of FAM and 
TAMRA dyes associated with peptide. 
 
Figure IV-4: Absorbance of reactants and recovered reaction mix fractions from oxime ligation of 
FApB2vAoa and oIDX-500uM 
UV-visible absorbance spectra were collected from aqueous solutions of oIDX-500uM 
nanoparticles (a) as well as diluted reaction mixes (b) and concentrates (c) and filtrates (d) 
following centrifugal filtration of reaction mixes through 10 kDa (NMWL) filters. 
In order to quantitatively compare the amount of peptide coupled to nanoparticles by 
oxime ligation reactions, the absorbance spectrum of oIDX-500µM was normalized to 
the absorbance of each sample at 400 nm (a local minimum in absorbance of FAM and 
TAMRA) and subtracted from each sample. Plotted in Figure IV-5, the residual 
absorbance spectra of each reaction mix and concentrate were roughly representative of 
the characteristic peak absorbances of FAM and TAMRA dyes. Predictably, the peptide-
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associated residual absorbance spectra of NP6
++
 reaction mix and concentrate were 
greater in magnitude than those of NP3
++
, corresponding to the relative amounts of 
FApB2vAoa added to the reaction mixes. 
 
Figure IV-5: Peptide-associated absorbance of reaction mix and concentrates from oxime ligation 
Spectra were generated by scaling of oIDX-500uM absorbance spectrum (Figure IV-4a) to 
absorbance of samples  at 400 nm and subtraction from spectra of NPn
++
 reaction mixes 
(Figure IV-4b, left) or concentrates from centrifugal filtration (Figure IV-4d, right). 
Because very little UV-visible absorbance was observed in filtrates from 
ultrafiltration of NP
++
 reaction mixes (Figure IV-4c, above), the reaction mix 
concentrates were compared with concentrates from control solutions composed of non-
oxidized (i.e. non-reactive) IDX nanoparticles, FApB2vAoa, and aniline (“+++ Ctl”) or 
just FApB2vAoa and aniline (“++ Ctl”) to determine whether fluorescence emission 
could be attributed solely to nanoparticle-bound peptides or if unbound peptides in 
solution were contributing to emission intensity. Shown in Figure IV-6, excitation at 495 
nm resulted in emission with intensity maxima at 520 nm and 580 nm from all samples, 
confirming FRET from FApB2vAoa. Emission intensity from excitation at both 495 nm 
and 555 nm was greater in NP6
++
 concentrate than NP3
++
 (Figure IV-6a,c), however the 
intensities from control solutions (Figure IV-6b,d) were comparable to NP3
++
, indicating 
ineffective separation of unbound peptide from nanoparticle products by ultrafiltration. 
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Figure IV-6: Fluorescence of concentrates from oxime ligation 
Fluorescence of oxime ligation product (a,c) and control (b,d) concentrates from NMWL 
10 kDa centrifugal filters with excitation at 495 nm (a,b) or 555 nm (c,d). “+++ Ctl” 
represents sample including FApB2vAoa peptide, aniline, and non-reactive IDX 
nanoparticles. “++ Ctl” represents sample containing FApB2vAoa and aniline only.  
NP6
++
 reaction mix concentrate was therefore precipitated in MeOH, in which 
FApB2vAoa was soluble, and the resulting magnetic nanoparticle pellet collected by 
centrifugation and magnetic attraction. Following resuspension in dH2O, NP6
++
 
nanoparticles were serially diluted for plate reader fluorescence spectroscopy to assess 
whether recovered nanoparticles possessed sufficient peptide decoration for proteolysis 
sensing. Emission spectra from excitation of NP6
++
 at 495 nm and 555 nm (Figure IV-7) 
were characteristic of FAM-TAMRA FRET, however only barely detectable above 
background noise of the instrument. As shown in Figure IV-7c,d, doubling the detector’s 
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emission integration bandwidth from 5 nm to 10 nm increased sensitivity, however even 
the emission signal from undiluted nanoparticle solution remained noisy. 
 
Figure IV-7: Fluorescence emission by NP6
++
 product of oxime ligation (dilution series) 
Fluorescence emission of recovered NP6
++
 product in multiple dilutions was measured via 
a fluorescence plate reader with an emission bandwidth of 5 nm (a,b) or 10 nm (c,d) and 
excitation at 495 nm (a,c) or 555 nm (b,d). 
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IV.3.3. Troubleshooting reaction conditions and catalysts for oxime ligation 
Based upon the insufficient fluorescence emission of NP3
++
 and NP6
++
 characterized 
above, dual-targeted nanoparticle synthesis by oxime ligation was revisited. Wendeler et 
al recently showed that substituted aniline derivatives, specifically p-phenylenediamine 
(pPDA), can offer enhanced catalysis of oxime-based bioconjugations relative to aniline 
across a range of pH, but most notably at pH 7
135
. As such, a series of oxime ligation 
reactions was performed with oIDX-1000uM nanoparticles and FApB2vAoa crude 
peptide in sodium phosphate buffer (pH 6.0), comparing 100 mM aniline and 10 mM 
pPDA as catalysts, as diagrammed in Figure IV-8. Reaction mixes were denoted 
“NPn
++
pPDA” or “NP6
++
An” to indicated the molar equivalents of FApB2vAoa relative to 
nanoparticles and the catalysts used in reaction. Control reactions including no 
nanoparticles or non-oxidized IDX nanoparticles (“No-IDX-Ctl” and “No-Rxn-Ctl,” 
respectively) were conducted in parallel. 
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Figure IV-8: Schema, oxime ligation of FApB2vAoa and oIDX-1000uM with aniline or pPDA as 
catalysts 
 
Following 24 hours of continuous rocking at RT, suspended and soluble products in 
reaction mixes were separated by centrifugation. As diagrammed in Figure IV-9, the 
resulting pellets were washed twice with MeOH to dissolve unbound FApB2vAoa 
peptide and precipitate FeOx-based nanoparticles, pelleting nanoparticles by 
centrifugation and collecting supernatants after each wash for subsequent analyses. 
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Nanoparticle pellets were ultimately resuspended in dH2O prior to dilution for 
absorbance measurements by UV-visible spectrophotometry. 
 
Figure IV-9: Scheme, separation of oxime ligation reactants and products by precipitation and 
centrifugation 
 
In order to determine the distribution of peptide following reactions, each of the 
recovered supernatants and the product solutions from oxime ligations with pPDA and 
aniline catalysts was characterized by UV-visible spectrophotometry. With the exception 
of No-IDX-Ctl (which contained no nanoparticles), all of the product solutions possessed 
absorbance spectra (Figure IV-10) characteristic of IDX nanoparticles, with varying 
degrees of increased absorbance around 495 nm and 550 nm corresponding to peptide-
associated absorbance. The absorbance spectrum of No-IDX-Ctl “product” was 
representative of FApB2vAoa, probably the result of residual peptide in the reaction 
vessel. 
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Figure IV-10: Absorbance of recovered aniline- and pPDA-catalyzed oxime ligation products 
FApB2vAoa peptide was reacted with oIDX-1000uM nanoparticles in the presence of 
pPDA or aniline as catalysts for oxime ligation. “No-Rxn Ctl” contained non-oxidized 
IDX nanoparticles. “No-IDX Ctl” contained peptide and pPDA but no nanoparticles (see 
Figure IV-8). 
Interestingly, upon subtraction of the normalized absorbance spectrum of 
oIDX-1000uM, only the product of NP6
++
An possessed a residual absorbance spectrum 
characteristic of FAM and TAMRA dyes. As plotted in Figure IV-11, for each reaction in 
which FApB2vAoa was exposed to pPDA, the residual absorbance spectra of recovered 
products were somewhat different, decreased absorbance at 560 nm relative to 495 nm 
and greater absorbance in the 400-450 nm range by comparison. This result corroborated 
the observation that the reaction mixes, supernatants, and recovered products of reactions 
containing pPDA exhibited a dark violet hue by visual inspection whereas the aniline-
containing reaction displayed the intensely pink color characteristic of TAMRA. 
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Figure IV-11: Peptide-associated absorbance of recovered aniline- and pPDA-catalyzed oxime 
ligation products 
Spectra represent residual values after subtraction of the absorbance of parental oIDX-
1000 µM nanoparticles scaled to absorbance of samples at 400 nm (as in Figure IV-5). 
Furthermore, the UV-visible absorbance spectra of the supernatants collected from 
the separation of oxime ligation reaction mixes even more clearly demonstrated the 
differences between aniline and pPDA. The NP6
++
An supernatants possessed spectra 
demonstrative of FAM and TAMRA absorbance, with two distinct maxima near 495 nm 
and 560 nm, as seen in Figure IV-12. Supernatants from all reactions containing pPDA, 
however, exhibited a singular broad absorbance peak around 520 nm, uncharacteristic of 
FAM and TAMRA dyes despite the inclusion of FApB2vAoa peptide in the reaction 
mixes. This spectral abnormality suggested that pPDA might be incompatible with 
chemical reactions involving visible-spectrum FRET peptides. 
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Figure IV-12: Absorbance of recovered aniline- and pPDA-catalyzed oxime ligation reaction 
supernatants 
Supernatant 1 (left) was recovered by aspiration following centrifugation of reaction mix 
to pellet precipitated products. Supernatant 2 (right) was recovered by aspiration following 
pellet washing with methanol and subsequent centrifugation. 
To determine whether the products of oxime ligation reactions involving aniline and 
pPDA as a catalysts exhibited the fluorescence properties critically important for optical 
sensing of proteolytic activity, the fluorescence spectra of the recovered nanoparticle 
products from each reaction were recorded by plate reader spectroscopy. As plotted in 
Figure IV-13, excitation at 494 nm resulted in expected FAM emission maximum around 
520 nm but no emission maximum near 580 nm to indicate FRET with TAMRA, as seen 
previously. Greater amounts of FApB2vAoa in reactions corresponded with greater 
emission intensity, though no nanoparticle products emitted signal well above the noise 
of the instrument. Interestingly, greater signal was obtained from the products of 
NP6
++
pPDA than NP6
++
An, despite the reaction mixes possessing equivalent proportions of 
FApB2vAoa, suggesting that pPDA was a more effective catalyst for peptide attachment 
to nanoparticles. However, combined with the peculiar absorbance spectra (above), the 
lack of FRET signal from sensor excitation and the practically absent emission from 
reference (TAMRA) excitation corroborated the incompatibility of pPDA with TAMRA 
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and suggested a problem with this set of oxime ligation products that prohibited use for 
proteolysis sensing applications. 
 
Figure IV-13: Fluorescence of products from aniline- and pPDA-catalyzed oxime ligation 
Traces represent fluorescence emission stimulated by excitation at 494 nm (top) and 555 
nm (bottom). FApB2vAoa peptide was reacted with oIDX-1000uM nanoparticles in the 
presence of pPDA (red, orange, green) or aniline (light blue) as catalysts for oxime 
ligation. “No-Rxn Ctl” contained non-oxidized IDX nanoparticles. “No-IDX Ctl” 
contained peptide and pPDA catalyst but no nanoparticles (see Figure IV-8).  
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IV.3.4. Re-attempt of oxime ligation in organic solvent with fresh aniline catalyst 
and characterization of products 
The aberrant optical properties of NPn
++
pPDA reaction mix components with respect to 
the expected FApB2vAoa spectra, lacking characteristic TAMRA absorbance and FRET, 
effectively prohibited their use as proteolytic nanobeacons. The reaction mix components 
from oxime ligation reactions involving aniline, on the other hand, possessed optical 
spectra representative of FApB2vAoa, although analysis of peptide-associated 
absorbance (Figure IV-11) and fluorescence emission (Figure IV-13) indicated 
insufficient attachment of peptides to nanoparticles. A such, the reaction conditions for 
oxime ligation of oIDX-1000uM nanoparticles with FApB2vAoa using aniline as a 
catalyst were revised as schematically diagrammed in Figure IV-14 to include excess 
peptide and DMSO with 0.1 M sodium acetate buffer (pH 4.5) as the primary solvent 
according to previously successful reactions with non-fluorescent aminooxy-bearing 
peptides and aldehyde-terminated organic dendrons (Scherer and McIntyre, unpublished). 
Aniline was pipetted from a freshly-opened manufacturer’s bottle under inert atmosphere. 
For comparison of final peptide attachment, a control reaction (“No-Rnx Ctl”) containing 
non-oxidized IDX nanoparticles was conducted in parallel.  
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Figure IV-14: Scheme, oxime ligation of FApB2vAoa with oIDX-1000uM in DMSO with fresh 
aniline catalyst 
 
After 5 days of rocking at RT, protected from light, reaction mixes were separated 
into nanoparticle products and supernatants by centrifugation, repeated precipitation in 
MeOH as before (see Figure IV-9), and resuspension in DMSO with sonication to 
recover NP
++
 and No-Rxn Ctl products. The FApB2vAoa peptide-associated absorbance 
of recovered products was calculated following UV-visible spectrophotometry by 
subtracting absorbance spectrum of oIDX-1000uM (scaled to product spectra at 400 nm) 
from product spectra, as detailed earlier (see IV.2.3 and Figure IV-5). Shown in Figure 
IV-15 (green traces), the resulting residual traces were characteristic of FAM and 
TAMRA dye absorbance spectra, representing 31.8% and 18.9% recovery of peptide 
from NP
++
 and No-Rx Ctl reaction mixes, respectively, by TAMRA absorbance (Table 
IV-2). However, following additional washing of the nanoparticle products in MeOH 
with centrifugal or magnetic separation and reconstitution in DMSO, peptide-associated 
absorbance of both NP
++
 and No-Rxn Ctl products decreased (Figure IV-15, red and blue 
traces). 
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Figure IV-15: Peptide-associated absorbance of oxime ligation products decreased with each 
DMSO wash 
FApB2vAoa peptide was reacted with either oIDX-1000 µM (left) or non-oxidized IDX 
nanoparticles (right, control) in the presence of aniline. The iron-subtracted absorbance of 
pelleted products from each reaction condition were calculated following repeated 
nanoparticle precipitations in methanol with centifrugal (green, red) or magnetic pelleting 
(blue) and reconstitution in DMSO with sonication. 
Peptide recovery in nanoparticle product solutions at each phase of washing and 
recovery was calculated from the UV-visible absorbance spectra. The basis for recovery 
was established by measuring the absorbance of the FApB2vAoa reactant solution used 
in each reaction (data not shown) and multiplying by the volume added to reactions. The 
TAMRA-associated absorbance (peak optical density between 550-565 nm) of each 
sample was multiplied by the recovered sample volume, divided by the basis, and 
expressed as a percentage of TAMRA-associated absorbance in the corresponding initial 
reaction mix, as seen in (Table IV-2). Interestingly, MeOH supernatants collected 
subsequent to a previous wash in MeOH but prior to product resuspension in DMSO 
possessed very little TAMRA absorbance compared to MeOH supernatants from 
precipitation of DMSO-suspended products. This suggested that FApB2vAoa peptide 
might be released from association with nanoparticle products by dissolution in DMSO, 
indicative of a non-covalent interaction between peptides and nanoparticles. 
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Table IV-2: TAMRA dye recovery in separated fractions from oxime ligation of FApB2vAoa with 
oIDX-1000uM following multiple separations 
 
 
IV.3.5. Troubleshooting oxime ligation focusing on FApB2vAoa peptide 
After attempting oxime ligation of FApB2vAoa with aldehyde-bearing dextran-
coated iron oxide nanoparticles in several reaction conditions, we hypothesized that 
FApB2vAoa might be prohibited from reacting either because of steric hindrance or 
blocking of requisite functional groups. Due to the known inclusion of unidentified 
chemical adducts in products of SPPS including FApB2vAoa, FApB2vAoa peptide was 
incubated with trypsin to investigate whether the adducts could be modifying the 
aminooxy functional group required for oxime chemistry. At least one set of proteolytic 
cleavage products was expected to result, as diagrammed in Figure IV-16. 
 
Figure IV-16: Scheme, trypsin cleavage of FApB2vAoa 
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LCMS of the cleavage mixture detected ions corresponding to the expected peptide 
fragments from trypsin cleavage of FApB2vAoa between arginine and {peg1} residues as 
depicted in Figure IV-16, above. Ions representative of other possible trypsin cleavage 
sites, expected at the carboxyl sides of arginine or lysine residues except where followed 
immediately by proline, were not prevalent. The mass chromatograms from LCMS of 
trypsin-cleaved FApB2vAoa indicate the presence of the N-terminal cleavage fragment 
without any additional adducts (Figure IV-17a,f). The corresponding C-terminal portion 
of FApB2vAoa, however, was represented by ions with and without adducts of 28 Da and 
40 Da (Figure IV-17b-g), corroborating previous analyses of pB2v peptide indicating 
attachment of adducts within the last four C-terminal residues (see III.3.2). 
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Figure IV-17: LCMS chromatograms and detected masses of cleavage products including C-
terminal adducts following trypsin cleavage of FApB2vAoa 
Doubly-charged ions with m/z of 1040.48 (a), 458.21 (b), 452.21 (c), and 438.21 (d) 
corresponding to trypsin-cleaved fragments of FApB2vAoa corresponding to expected 
ions with and without adducts (f) eluted separately and were detected. Total ion counts 
following reversed phase liquid chromatography are shown (e). A representative trace 
indicating the double charge of ion with M/z 458.21 is shown (g). 
To directly determine whether the FApB2vAoa could form oxime bonds as intended, 
unpurified FApB2vAoa peptide from SPPS was reacted with 4-formylbenzoic acid, a 
small molecule with an aldehyde functional group and a carboxyl group attached to a 
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benzene ring, using the same reaction conditions attempted with FApB2vAoa and oIDX-
1000uM nanoparticles, as represented in Figure IV-18. 
 
Figure IV-18: Scheme, reaction of FApB2vAoa with 4-formylbenzoic acid 
 
The reaction mix and crude FApB2vAoa peptide starting material were analyzed 
separately by ESI+ MS for comparison of molecular weights to determine whether the 
reaction had modified the peptide by oxime ligation. Shown in Figure IV-19, ions 
representing the triply- and quadruply-charged states of chemical species with the 
intended mass of FApB2vAoa as well as those with additions of 40 Da, 67 Da, and 107 
Da adducts were detected in the crude peptide mixture. An ion 129 Da smaller than 
FApB2vAoa corresponding to an omission of the DprAoa residue was also apparent, 
introducing an obvious reason for lack of reactivity. Interestingly, some of the ions 
present in the peptide mixture were also detected in the reaction mix, whereas others 
were absent but corresponded with another ion peak increased by 132 Da, the expected 
mass addition from oxime ligation with 4-formylbenzoic acid. Importantly, FApB2vAoa 
ions with 40 Da or 107 Da additions or a 129 Da subtraction were found in both the crude 
peptide and reaction mix samples, indicating no modification of these peptide structures 
in the reaction. Conversely, FApB2vAoa ions with the expected mass from SPPS with 
and without 67 Da adducts were not found in reaction mix, but ions with the expected 
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mass of the oxime ligation product with and without 67 Da adduct were detected, 
suggesting successful reaction of these peptide structures with 4-formylbenzoic acid. 
 
Figure IV-19: ESI+ mass spectra of unpurified FApB2vAoa and reaction mix following oxime 
ligation with 4-formylbenzoic acid 
Dashed arrows and red text indicate ions detected in the unreacted FApB2vAoa sample 
(red trace, bottom) as well as the reaction mix (green trace, top). Adducts of +40, +67, and 
+107 Da were detected in the triply (+3H) and quadruply (+4H) charged states. 
Subtraction of 129 Da from the expected masses corresponds to the absence of C-terminal 
DprAoa residue in the synthetic peptide. 
IV.3.6. Nanobeacon synthesis via Steglich esterification 
In parallel with attempts to troubleshoot and optimize oxime ligation, alternative 
chemistries for C-terminal attachment of peptides to nanoparticles were explored, 
including a few different reactions requiring a carboxylic acid functional group. For 
example, Auzély-Velty et al demonstrated the use of Steglich esterification to introduce a 
modified amino acid residue into a starch polymer, wherein a reaction of carboxyl of the 
amino acid with the primary and secondary alcohols in the starch polymer was mediated 
by the carbodiimide DIC and catalyzed by DMAP, as shown in Figure IV-20. 
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Figure IV-20: Scheme, Steglich esterification reaction to modify a starch polymer with a carboxyl-
containing mock amino acid residue
148
. 
 
Because the dextran coating of IDX nanoparticles consists of lengthy starch polymers 
with an abundance of secondary alcohols, Steglich esterification of peptides with IDX 
nanoparticles was attempted. For this purpose, a carboxyl-terminated FRET peptide 
based on the structure of pB2v with an additional {peg1} spacer, “pB2vp-cooh” 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg1}G-cooh], was 
synthesized by SPPS (refer to Appendix A for detailed structure). The N-terminus of 
pB2vp-cooh was acetylated on resin to yield “AcpB2vp-cooh” and the resulting 
unpurified peptide characterized by LCMS. The crude peptide mixture was found to be 
composed of a minority product with the expected mass and a majority product 42 Da 
larger than AcpB2vp-cooh (data not shown), the same size adduct that was found 
previously on AcpB2vAoa (see III.3.6). Because adducts of the same mass were found on 
these two peptides with different C-termini, modification of the carboxylic acid group in 
AcpB2vp-cooh was not suspected. As such, crude AcpB2vp-cooh peptide mixture was 
reacted overnight with IDX nanoparticles, DIC, and DMAP, all in DMSO, as 
schematically diagrammed in Figure IV-21. 
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Figure IV-21: Scheme, Steglich esterification reaction of AcpB2vp-cooh peptide with dextran-
coated iron oxide nanoparticles (IDX) 
 
Magnetic nanoparticles were precipitated from the Steglich esterification reaction mix 
by pipetting the reaction mix into ice cold methanol on a magnetic separator device as 
described previously (see IV.2.5). Peptide attachment to recovered nanoparticles was 
characterized by UV-visible spectrophotometry as described previously (see IV.2.3). As 
made apparent by overlaying the absorbance spectra of reaction mix (Figure IV-22a) and 
recovered nanoparticles (Figure IV-22b) with the spectrum of unreacted IDX 
nanoparticles scaled to each sample’s absorbance at 400 nm, the reaction mix exhibited 
additional absorbance in visible range characteristic of the peptide-associated dyes, FAM 
and TAMRA. The recovered magnetic nanoparticles (“Product” in Figure IV-22b, 
below), did not, as its absorbance spectrum was indistinguishable that of IDX 
nanoparticles, indicating negligible attachment of pB2vp-cooh to nanoparticles. 
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Figure IV-22: Absorbance of reaction mix components from attempted Steglich esterification of 
AcpB2vp-cooh and IDX nanoparticles 
Absorbance of diluted reaction mix (a) and magnetically recovered products of reaction 
(b) are overlaid with scaled absorbance of parental IDX nanoparticles (purple lines) scaled 
to absorbance of samples at 400 nm. 
The recoveries of peptide in each component of separated reaction mix were 
calculated from the results of spectrophotometry, as described earlier (see IV.3.4 and 
Table IV-2), using the peptide-associated (IDX subtracted) absorbance of TAMRA dye in 
the reaction mix as a basis (Table IV-3). Using TAMRA absorbance as a surrogate 
measure, approximately 2% of the peptide added to reaction mix was recovered with 
magnetic nanoparticles, or about 0.1 peptides per nanoparticle on average out of a 
theoretical maximum of 5 peptides per nanoparticle in the reaction mix. 
Table IV-3: Calculated peptide recovery from magnetic separation of Steglich esterification 
reaction of AcpB2vp-cooh and IDX nanoparticles 
Recovered Separation Fraction Recovery 
Reaction Mix (IDX Subtracted) 100% 
Supernatant 1 92% 
Supernatant 2 2% 
Product (IDX Subtracted) 2% 
 
IV.3.7. Nanobeacon synthesis via EDAC coupling 
Due to the evident lack of sufficient binding of peptides to iron oxide nanoparticles 
using oxime ligation or Steglich esterification with peptides produced by SPPS, another 
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coupling scheme was developed. To eliminate blocking of functional groups on peptides 
from SPPS or nanoparticle surfaces as a possible cause of non-reactivity, carboxyl-
terminated peptides and amine-decorated quantum dot nanoparticles from commercial 
sources were reacted via a well-studied mechanism of amide bond formation
129
. For this 
reaction, the 2-color MMP14 substrate, Peptide 13c, and quantum dots decorated with 
PEG-amine, “Qdot(605)NH2,” were mixed in the presence of EDAC as a mediator of 
carboxyl-to-amine bioconjugation, as schematically diagrammed in Figure IV-23. Peptide 
13c was used in excesses of 100- to 2000-fold relative to quantum dots to allow detection 
of peptide-nanoparticle conjugation even at low coupling efficiencies. Control reactions 
replacing either peptide or EDAC with solvent were conducted in parallel. 
 
Figure IV-23: Scheme, carbodiimide (EDAC) coupling of Peptide 13c and PEG-NH2 functionalized 
quantum dots 
 
Following reactions, qualitative assessment of peptide binding to quantum dots was 
attempted by measuring the electrophoretic mobility of nanoparticles in 1% agarose gels. 
As seen in Figure IV-24a, quantum dots migrated toward the cathode at approximately 
equivalent rates for all reaction conditions except that containing 1000:500:1 molar ratios 
of peptide:EDAC:Qdot(605)NH2. Because only one reaction condition appeared to result 
in retardation of quantum dots, electrophoresis was repeated comparing the previously 
assessed samples with another reaction mix containing 2000:1500:1 molar ratios to 
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determine whether a trend could be established. Interestingly, in each gel, quantum dots 
from the reaction mix omitting EDAC appeared to be partially confined to the sample 
wells. A qualitative determination of peptides binding to quantum dots could not be 
made, though, because there was no clear difference in electrophorectic mobility between 
unreacted quantum dots and those from reaction mixes, as seen in Figure IV-24b. 
 
Figure IV-24: Agarose gel electrophoresis of Qdot(605)NH2 and reaction mixes following attempted 
carbodiimide (EDAC) coupling with Peptide 13c 
Nanoparticle mixtures diluted in sodium borate buffer were pipette in duplicate (a) or 
singly (b) into wells of freshly cast 1% agarose gels. Bands indicated UV-stimulated 
fluorescence of Qdots. No Peptide and No EDAC Controls are equivalent to 0:100:1 and 
100:0:1 peptide:EDAC:Qdot ratios, respectively. 
To provide an alternative means for measuring the attachment of fluorescent peptides 
to nanoparticles, Peptide 13c was mixed overnight with generation 4 PAMAM 
dendrimers (“PAMAM-G4”) and EDAC, as diagrammed in Figure IV-25, to facilitate 
carbodiimide-mediated carboxyl-to-amine amide bond formation. A control mixture 
containing only solvent in place of EDAC (“No Rxn”) was also prepared to provide a 
comparison with a solution in which no covalent attachment of peptides to PAMAM was 
expected to occur. 
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Figure IV-25: Scheme, carbodiimide (EDAC) coupling of Peptide 13c and PAMAM-G4 
 
To separate PAMAM-based macromolecules from unbound reactants in solution 
following reactions, reaction mixes were diluted in buffer and reconcentrated by repeated 
ultrafiltration in YM-3 (MWCO 3,000) and YM-10 (MWCO 10,000) centrifugal filter 
devices. All constituent fractions of reaction mixes recovered from ultrafiltration were 
analyzed by UV-visible spectrophotometry to allow quantitative determination of the 
distribution of peptide in each fraction and the amount of peptide attached to PAMAM 
nanoparticles in each reaction. As shown in Figure IV-26, the absorbance spectra of the 
reaction mixes and collected retentates from ultrafiltration thereof exhibited peaks 
corresponding to the peptide-associated dyes, as expected. Calculating peptide recovery 
from the TAMRA-associated absorbance and volumes of recovered solutions, the 
retentates from the first separation (“YM-3 Retentate 1,” below) represented 
approximately 19% of the peptide added to reaction mixes, or about 0.4 peptides per 
PAMAM-G4 (assuming 90% recovery of PAMAM in retentates), regardless of EDAC 
inclusion in each reaction. Similarly, the final effluents and retentates of YM-3 
ultrafiltration were practically no different between reaction mixes with and without 
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EDAC. As such, no quantitative or qualitative discernment of peptide attachment to 
nanoparticles could be attributed to covalent amide bonding. 
 
Figure IV-26: UV-visible absorbance of reaction mix components from EDAC coupling of Peptide 
13c and PAMAM-G4 
Peptide 13c was reacted with PAMAM-G4 either with (red) or without (blue) EDAC 
carbodiimide coupling reagent. Reaction mix aliquots (a) were collected prior to YM-3 
ultrafiltration. YM-3 Retentates 2 (c) represent repeated ultrafiltration of retentates from 
initial YM-3 ultrafiltration (b). TAMRA-associate absorbance was used to calculate 
peptide recovery in each fraction (d).
IV.3.8. Synthesis and characterization of pB2vp5C-cooh 
We hypothesized that the lack of empirical evidence for covalent bonding of FRET-
equipped MMP substrate peptides to different types of nanoparticles using various 
coupling chemistries could be attributed to steric hindrance of the reactive functional 
groups on peptides due to the proximity of bulky peptide constituents to the C-terminus 
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and/or unfavorable conformation of peptides owing to hydrophobic interactions. To 
address these concerns, a peptide based on pB2v with a relatively long hydrophilic spacer 
and a cysteine residue at the C-terminus, “pB2vp5C-cooh” 
[Fmoc-{peg1}K(fam){peg1}RPLGLWAR{peg1}K(tamra){peg5}C-cooh], was 
synthesized by SPPS (refer to Appendix A for detailed structure). This peptide was 
deprotected at the N-terminus and folated on resin according to the established standard 
protocol for folation (see III.2.7) to generate “FApB2vp5C-cooh.” 
After final deprotection, cleavage from solid support resin, and recovery by 
precipitation in ice cold Et2O, crude FApB2vp5C-cooh peptide was characterized by 
ESI+ MS to determine the molecular weights of recovered peptide products. Unlike 
previous results from peptides produced by SPPS, the ions most abundant by far in the 
mass spectrum of crude FApB2vp5C-cooh (Figure IV-27) represented multiple charge 
states of a parent ion with the expected mass of the peptide without any modifications. 
 
Figure IV-27: ESI+ mass spectrum of unpurified FApB2vp5C-cooh 
The most abundant mass peaks represent the triply (1034.81, M+3H) and quadruply 
(776.34 M+4H) charged states of the expected FApB2vp5C-cooh peptide from SPPS. 
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The relative purity of crude FApB2vp5C-cooh peptide mixture from SPPS was 
further investigated by LCMS. While the resulting chromatogram of total ions counted 
(Figure IV-28) displayed multiple peaks, the first two  peaks represented low molecular 
weight ions not likely to be peptide products of SPPS and the peak of greatest area was 
characterized by a mass spectrum similar to Figure IV-27, above, indicative of the 
expected structure of FApB2vp5C-cooh (data not shown).  
 
Figure IV-28: LCMS of unpurified FApB2vp5C-cooh  
Trace represents total ion count in ESI+ mode following reversed-phase liquid 
chromatography of crude FApB2vp5C-cooh from SPPS. Arrow indicates the most 
abundant peak containing ions with the expected molecular weight of the intended peptide. 
The intended optical properties of unpurified FApB2vp5C-cooh were confirmed by 
UV-visible spectrophotometry and plate reader fluorescence spectroscopy. As seen in 
Figure IV-29a, the crude peptide possessed visible-spectrum absorbance maxima near 
495 nm and 560 nm, characteristic of FAM and TAMRA dyes, respectively. Excitation of 
FApB2vp5C-cooh at 555 nm resulted fluorescence emission near 580 nm, also 
representative of TAMRA dye, as plotted in Figure IV-29b. Most importantly, excitation 
at 494 nm resulted in fluorescence emission with a local maximum around 520 nm, 
characteristic of FAM, but an even greater maximum around 580 nm, suggesting better 
than 50% FRET efficiency between FAM and TAMRA. 
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Figure IV-29: Optical properties of FApB2vp5C-cooh peptide 
Absorbance (a) and fluorescence (b) spectra of unpurified FApB2vp5C-cooh peptide. 
To validate FApB2vp5C-cooh as an optical sensor of MMP-associated proteolysis, 
the FRET switch of unpurified FApB2vp5C-cooh upon cleavage by MMPs (2, 9, or 14) 
was measured. As plotted in Figure IV-30, a greater than 10-fold increase in sensor 
(FAM) fluorescence emission intensity was generated within 60 minutes of incubation 
with each MMP while continuing to trend upward. The increasing trend continued 
through approximately 10 hours of uncovered incubation at 37 °C to give 23-, 24-, and 
28-fold increases in FApB2vp5C-cooh sensor fluorescence generated by incubation with 
MMP2, MMP14, and MMP9, respectively (data not shown). MMPs used in this 
experiment were not characterized for active enzyme content. 
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Figure IV-30: FRET switch assay of FApB2vp5C-cooh peptide with MMPs 
Sensor fluorescence amplification of FApB2vp5C-cooh upon treatment with MMPs 2, 9, 
and 14 to cleave peptide substrate. Control samples (“Buffer”, blue diamonds) contained 
an only assay buffer in lieu of enzyme. Values represent average of triplicates. Error bars 
not shown (SEM; small enough to be obscured by trace markers). 
IV.3.9. Synthesis of nanobeacons via reaction of FApB2vp5C-cooh with amine-
bearing iron oxide nanoparticles and heterobifunctional linkers 
With the MMP-sensing capability of FApB2vp5C-cooh confirmed, a nanoparticle 
with surface chemistry amenable to bioconjugation involving the C-terminal cysteine 
residue was required for synthesis of proteolytic nanobeacons. Iron oxide nanoparticles 
remained an attractive option for nanoparticle cores owing to their ease of recovery by 
magnetic attraction and the additional imaging modalities they potentially enable, such as 
MRI contrast and histological staining with Prussian blue. Primary amines provided an 
adaptable chemistry for bioconjugation with cysteine, as either carbodiimides or any of 
several commercially available heterobifunctional linkers can mediate covalent bonding 
of the two 
129
. 
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As such, APTES-coated superparamagnetic iron oxide nanoparticles (“FeOx-NH2”) 
were synthesized by thermal decomposition of iron pentacarbonyl [Fe(CO)5] in oleic acid 
followed by ligand exchange of APTES for oleic acid by Charleson S. Bell of the Giorgio 
Laboratory (Dept. of Biomedical Engineering, Vanderbilt University, Nashville, TN, 
USA). The average particle diameter determined by transmission electron microscopy 
(TEM) was approximately 17 nm. The presence of surface amines was confirmed by 
qualitative Ninhydrin test (data not shown, see III.2.4 for general method). 
Synthesis of folate-targeted proteolytic nanobeacons was attempted by reacting 
FApB2vp5C-cooh peptide and FeOx-NH2 nanoparticles with either Sulfo-SMPB or SIA, 
two heterobifunctional linkers with amine-reactive succinimidyl groups and sulfhydryl-
reactive maleimide or iodoacetyl groups, respectively. Schematically diagrammed in 
Figure IV-31, FeOx-NH2 were first “activated” by reaction with SIA or Sulfo-SMPB 
while FApB2vp5C-cooh was pre-treated with TCEP to reduce and thereby eliminate any 
disulfide bonds that may have formed in DMSO solution. Activated nanoparticles and 
reduced peptide solution were then mixed for approximately 21 hours before a solution of 
mPEG-SH(1k) was added to each reaction to PEGylate any unreacted SIA or Sulfo-
SMPB sites, affording FeOx-based “NP++SIA” and “NP
++
SMPB.” 
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Figure IV-31: Scheme, preparation of FeOx-based NP
++
 nanobeacons  
Reactions of FeOx-NH2 with FApB2vp5C-cooh mediated by amine- and –sulfhydryl-
reactive heterobifunctional crosslinkers SIA and Sulfo-SMPB. 
The magnetic nanoparticle products of FeOx-based proteolytic nanobeacon synthesis 
reactions were pelleted by magnetic attraction and the supernatants collected for 
subsequent analysis. DMSO was added to pellets and magnetic collection repeated, as 
represented in Figure IV-32. 
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Figure IV-32: Scheme, magnetic separation and recovery of reaction mix components following 
FeOx-based NP
++
 synthesis 
 
To determine the extent of reaction, the UV-visible absorbance spectra of the 
recovered component solutions from magnetic separation of reaction mixes were 
recorded. The absorbance spectra of the magnetically recovered products of syntheses 
were unobtainable due to rapid flocculation of suspended particulates in DMSO. Several 
solvents, including water, ethanol, anhydrous DMSO, and chloroform were introduced by 
solvent exchange to improve the stability of the colloidal suspensions, but none were 
successful insofar as stabilizing suspensions long enough to obtain absorbance spectra. 
The supernatants collected from the initial magnetic separation of reaction mix 
components from each reaction mix (“Supnt 1”, above) exhibited visible absorbance 
spectra characteristic of FApB2vp5C-cooh, as seen in Figure IV-33. The subsequently 
collected supernatants from the washing of magnetically recovered reaction mix 
components (“Supnt 2,” above), however, where characterized by negligible peptide-
associated absorbance. 
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Figure IV-33: Absorbance of FeOx-based NP
++
 reaction mix components recovered from magnetic 
separation. 
Components of reaction mixes from FApB2vp5C-cooh and FeOx-NH2 with SIA or Sulfo-
SMPB were collected following reactions and subsequent magnetic separation. A diluted 
aliquot of the reduced FApB2vp5C-cooh reactant used in reactions is shown in dark blue. 
Supernatants 1 (red, green) were collected after pelleting paramagnetic constituents 
magnetically. Supernatants 2 (purple, light blue) were collected following a DMSO 
resuspension and magnetic pelleting. 
Similar to previous assessments of peptide attachment to nanoparticles using UV-
visible absorbance (see IV.3.4, IV.3.6, IV.3.7), peptide recovery was determined by 
TAMRA-associated absorbance in supernatant samples relative to that in the reaction 
mix. Representative of peptide recovery, the first supernatant from NP
++
SIA synthesis 
exhibited 56% of the TAMRA absorbance in the corresponding reaction mix. The first 
supernatant from NP
++
SMPB similarly indicated recovery of 55% of the peptide initially 
added to the synthesis reaction. As indicated above, the supernatants collected following 
a wash of magnetic nanoparticles with DMSO possessed negligible peptide-associated 
absorbance, while measurement of absorbance from magnetically recovered products was 
not possible. By inference, though, because 55-56% of the peptide-associated TAMRA 
absorbance from reaction mixes was attributed to recovered supernatants, 44-45% 
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coupling of FApB2vp5C-cooh to FeOx nanoparticles (or approximately 225 peptides per 
nanoparticle) was suspected. 
To further investigate FApB2vp5C-cooh peptide attachment to FeOx nanoparticles, 
fluorescence emission spectra of magnetically recovered NP
++
SIA and NP
++
SMPB 
nanoparticles were recorded by plate reader fluorescence spectroscopy. As shown in 
Figure IV-34a, FeOx-based NP
++
SIA and NP
++
SMPB nanoparticles fluoresced weakly upon 
excitation at 494 nm, exhibiting noisy emission spectra with maxima near 580 nm, 
indicative of either TAMRA fluorescence or FRET between FAM and TAMRA. 
Unexpectedly, emission intensity maxima near 520 nm were almost unobservable. 
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Figure IV-34: Fluorescence and FRET properties of FeOx-based NP
++
SIA and NP
++
SMPB. 
Sensor (FAM) fluorescence emission of magnetically-recovered products from reaction of 
FApB2vp5C-cooh with FeOx-NH2 compared to starting nanoparticles (a). Sensor (FAM) 
fluorescence emission over time upon incubation of NP
++
SIA (b) or NP
++
SMPB (c) with 
MMP-14. Blank-subtracted FAM (d) and TAMRA (e) fluorescence emission of iron-
depleted supernatants following incubation with MMP14 or buffer. Values represent mean 
of triplicates +/-SEM (b-e). 
To test the hypothesis that broad absorbance in the UV-visible range by FeOx 
nanoparticles could be interfering with excitation and emission of the peptide-associated 
fluorophores, thereby limiting detection of nanobeacon fluorescence, NP
++
SIA and 
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NP
++
SMPB were incubated with or without MMP14 in proteolysis buffer and monitored for 
FAM fluorescence by plate reader fluorescence spectroscopy over 1 hour, during which 
flocculated aggregates formed in assay wells. Despite the previously demonstrated FRET 
switch of FApB2vp5C-cooh with MMP14 (Figure IV-30), incubation of nanoparticle 
solutions with MMP14 did not result in any significant increase in sensor (FAM) 
fluorescence, as shown in Figure IV-34b,c. To determine whether depletion of iron from 
solutions could result in increased FAM fluorescence emission by proteolytically released 
peptide fragments, the FAM- and TAMRA-associated emission intensities of the assay 
sample supernatants were subsequently measured. While the FAM intensities of 
supernatants from samples treated with MMP14 were greater than those from samples 
containing only assay buffer, as shown in Figure IV-34d, the overall background-
subtracted fluorescence intensities represented weak fluorescence, near the limit of 
detection of the instrument. The TAMRA fluorescence of supernatants (Figure IV-34e) 
did not exhibit as large a relative difference between MMP14 and assay buffer 
conditions, although the absolute magnitude of TAMRA emission was greater than FAM 
emission in all supernatants. Due to the lack of demonstrable FRET switch or sensor 
fluorescence in iron-depleted supernatants, FeOx-based NP
++
SIA and NP
++
SMPB could not 
be validated for use as proteolytic nanobeacons. 
IV.3.10. Synthesis, purification, and characterization of folate-targeted proteolytic 
nanobeacons from pB2vp5C-cooh and PAMAM-G4 dendrimers 
To facilitate optical assessment of FApB2vp5C-cooh peptide attachment to 
nanoparticles in proteolytic nanobeacon synthesis reactions without the interfering UV-
visible absorbance from iron, PAMAM-G4 dendrimers were decorated with 
FApB2vp5C-cooh peptide using SIA, Sulfo-SMPB, or EDAC to mediate covalent bond 
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formation between cysteine residues on peptides and primary amines on dendrimers. As 
schematically diagrammed in Figure IV-35, PAMAM-G4 dendrimers, nominally 
possessing 64 primary amines each, were prepared by first reacting with PEG5000-NHS 
to improve water solubility. Aliquots of PEGylated dendrimers (“PAMAM4(PEG5k)2”) 
were then activated with SIA or Sulfo-SMPB to generate sulfhydryl-reactive sites on 
PAMAM-G4, while FApB2vp5C-cooh peptide was reduced with β-mercaptoethanol to 
eliminate disulfide dimers that may have formed due to oxidation in solution. 
Approximately 5 molar equivalents of reduced peptide relative to dendrimers was mixed 
with either activated PAMAM4(PEG5k)2 or with PAMAM4(PEG5k)2 and EDAC to 
couple peptides to dendrimers. Following overnight reactions, mPEG-SH (1kDa) was 
added to the reaction mixes including heterobifunctional linkers SIA or Sulfo-SMPB to 
convert any remaining sulfhydryl-reactive groups on dendrimer branch termini. The 
nanoparticle products of reactions were deemed “NP++SIA,” “NP
++
SMPB,” or “NP
++
EDAC” to 
represent intended folate-targeting and MMP cleavability as well as the mediator of 
peptide attachment to nanoparticle cores. 
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Figure IV-35: Scheme, synthesis of PAMAM-based NP
++
EDAC, NP
++
SIA, and NP
++
SMPB from 
FApB2vp5C-cooh and PAMAM-G4 dendrimer 
 
After completion of PAMAM-G4-based NP
++
 synthesis reactions, reaction mixes 
were diluted in buffer containing 20% ethanol and reconcentrated by ultrafiltration in 
YM-10 (MWCO 10,000) centrifugal filter devices, as described above (see IV.3.7). 
Initial retentates were diluted and reconcentrated a second time with collection of all 
solutions to allow spectrophotometric quantitation of peptide recovery in each component 
of separated reaction mixes. Shown in Figure IV-36, the UV-visible absorbance spectra 
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of all collected solutions diluted in PBS (pH 7.1) were indicative of FAM and TAMRA, 
possessing absorbance maxima near 495 nm and 560 nm. 
 
Figure IV-36: Absorbance of recovered PAMAM-based NP
++
 reaction mix components following 
ultrafiltration. 
Absorbance of reaction mixes (blue), effluents (red, green) and retentates (purple, 
“Product”) following YM-10 ultrafiltration of coupling of FApB2vp5C-cooh and 
PAMAM-G4 via EDAC (a), Sulfo-SMPB (b), or SIA (c). 
FApB2vp5C-cooh peptide recovery in final ultrafiltration retentates (“product” in 
Figure IV-36 and Table IV-4) and effluents were determined by TAMRA-associated 
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absorbance of each component of reaction mixes. Coupling of peptide with EDAC and 
Sulfo-SMPB appeared to be more efficient than with SIA, as indicated by 77%, 75%, or 
48% recovery in each product, respectively, as seen in Table IV-4. Given the 
stoichiometry of the reactions, these recoveries represented approximate averages of 3.9 
peptides per dendrimer in NP
++
EDAC, 3.8 in NP
++
SMPB, and 2.4 in NP
++
SIA. Substantial and 
varied TAMRA-associated absorbance in ultrafiltration effluents suggested effective 
transport of FApB2vp5C-cooh through filters to separate PAMAM-bound from free 
peptides.  
Table IV-4: Calculated peptide recovery in PAMAM-based NP++ reaction mix components 
 
% Peptide Recovery (TAMRA dye) 
Sample NP++EDAC NP
++
SMPB NP
++
SIA 
Effluent 1 14% 17% 36% 
Effluent 2 9% 8% 16% 
Product 77% 75% 48% 
 
To validate PAMAM-based NP
++
 nanoparticles for use as proteolytic nanobeacons, 
capable of sensing MMP activity, NP
++
EDAC, NP
++
SMPB, and NP
++
SIA were mixed with 
MMP9 and monitored for FRET switch in comparison with the constituent FApB2vp5C-
cooh peptide by plate reader fluorescence spectroscopy. EDTA was included in a control 
sample with FApB2vp5C-cooh and MMP9 to inhibit metalloproteinase activity. Sensor 
(FAM) fluorescence emission intensity of the peptide and all NP
++
 products increased 
roughly linearly over 60 minutes of exposure to MMP9, as shown in Figure IV-37. No 
FRET switch was observed in any sample not containing MMP9. Inclusion of EDTA 
completely abrogated FRET switch from FApB2vp5C-cooh peptide (Figure IV-37a,b). 
After 60 minutes, the relative FRET switch of NP
++
EDAC was greatest of all samples, 
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represented by a greater than 12-fold increase in FAM fluorescence emission (Figure 
IV-37d). NP
++
SMPB and NP
++
SIA each also exhibited FRET switches greater than 10-fold 
after 60 minutes with MMP9. 
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Figure IV-37: FRET switch assay of FApB2vp5C-cooh and PAMAM-based NP++ nanobeacons 
with MMP9 
Sensor fluorescence of FApB2vp5C-cooh peptide (a-b), NP
++
EDAC (c-d), NP
++
SMPB (e-f), 
and NP
++
SIA (g-h) was measured in real time during incubation with MMP9. Green 
triangles (a-b) indicate inhibition of MMP9 activity by inclusion of EDTA. Values 
represent average of triplicates. 
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Sensor fluorescence of all samples mixed with MMP9 continued to increase for 
approximately 10 hours before sharply decreasing, presumably due to evaporation of 
sample solutions. NP
++
EDAC, which possessed the greatest relative FApB2vp5C-cooh 
peptide recovery from nanobeacon synthesis (Table IV-4, above), exhibited the greatest 
maximum FRET switch after 10 hours with a greater than 61-fold increase in FAM 
emission, as shown in Figure IV-38. Maximum FRET switch was greater for each NP
++
 
proteolytic nanobeacon than the constituent FApB2vp5C-cooh peptide. The fluorescence 
emission intensity of the reference fluorophore (TAMRA) in each sample also increased 
over time (data not shown). As a result, the maximum FRET switch of NP
++
EDAC after 10 
hours corresponded to an increase in the sensor-to-reference emission ratio (S/R) of 9.4-
fold (data not shown). 
 
Figure IV-38: Maximum FRET switch of FApB2vp5C-cooh and PAMAM-based NP++ 
nanobeacons with MMP9 
FApB2vp5C-cooh and NP
++
EDAC, NP
++
SMPB, and NP
++
SIA synthesized on PAMAM-G4 
were incubated with or without MMP9 in proteolysis buffer. Chart reflects maximum fold-
change in sensor fluorescence emission intensity after approximately 10 hours of 
incubation. Values represent average of triplicates. Error bars: SEM. 
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IV.3.11. Pilot assessment of MMP- and folate-dependent uptake of proteolytic 
nanobeacons in vitro 
To validate proteolytic nanobeacons in vitro with endogenous MMPs and to test the 
impacts of folate targeting and/or MMP cleavage on cellular uptake of proteloytic 
nanobeacons, MDA-MB-231 human breast cancer cells were incubated with media 
containing either intact or MMP14 pre-cleaved NP
++
EDAC nanobeacons, with or without 
the addition of folic acid to compete for folate receptors on cell membranes. Following 4 
hours of exposure in chamber slide wells, treatment media were collected and cells were 
washed with fresh PBS prior to imaging by fluorescence microscopy to visualize sensor 
(FAM) and reference (TAMRA) fluorescence belonging to proteolytic nanobeacons and 
products of nanobeacon cleavage. The FRET switch of NP
++
EDAC by recombinant 
MMP14 in cell culture medium was confirmed by plate reader fluorescence spectroscopy 
(data not shown). As seen in Figure IV-39, both sensor and reference fluorescence were 
most prominent in cells treated with intact NP
++
EDAC without free folic acid competition 
(Figure IV-39a-d). Interestingly, fluorescence in the sensor channel was found 
intracellularly in both diffuse and punctate patterns, whereas reference fluorescence was 
punctate only. Cells in no other treatment conditions exhibited diffuse fluorescence in the 
sensor channel. Neither sensor nor reference fluorescence was observed in cells treated 
with intact NP
++
EDAC and free folic acid (Figure IV-39e-h). Fluorescence puncta in both 
the sensor and reference channels were found in cells treated with pre-cleaved NP
++
EDAC  
in the absence of free folic acid (Figure IV-39i-l), however treatment with pre-cleaved 
nanobeacons in combination with folic acid resulted in the observation of no intracellular 
fluorescence (Figure IV-39m-p). 
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Figure IV-39: Fluorescence microscopy of cell uptake of NP
++
EDAC by MB231 cells. 
MDA-MB-231 cells incubated in folate-free medium containing NP
++
EDAC (a-p). The 
additions to each set of culture wells are indicated on the left. NP
++
EDAC was added either 
unmodified (a-h) or after pre-incubation with MMP14. Competing folic acid was included 
(e-h, m-p) or omitted (a-d, i-l) from media during incubation with NP
++
EDAC. The non-
fluorescent no-treatment controls (q-t) were incubated in medium only. Scale bar: 10 µm. 
To further quantitate intracellular fluorescence as a measure of cell uptake of 
nanobeacons, MDA-MB-231 cells were harvested from chamber slides following 
fluorescence microscopy (above) and analyzed by flow cytometry with 488 nm 
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excitation. Emission was recorded using filters appropriate for FAM and TAMRA 
emission, the latter resulting either from minimal excitation of TAMRA at 488 nm or 
FRET from FAM. As shown in Figure IV-40, both FAM and TAMRA fluorescence 
emission intensities were about an order of magnitude greater than control in cells treated 
with NP
++
EDAC proteolytic nanobeacons in the absence of free folic acid. Cells treated 
with intact nanobeacons fluoresced more than cells treated with beacons pre-incubated 
with MMP14 in both emission filters, except when free folic acid was included in 
treatment media, in which cases cellular fluorescence was no different than controls that 
were incubated without nanobeacons regardless of proteolytic cleavage. 
 
Figure IV-40: Flow cytometry of MDA-MB231 cells following treatment with NP
++
EDAC. 
+/-MMP14 indicates whether or not cell culture media containing NP
++
EDAC were treated 
overnight with MMP14 prior to cell treatment. +/-FA indicates the inclusion or omission 
of folic acid during cell incubation with NP
++
EDAC. No treatment represents incubation of 
cells with incubation medium only. 
Binary gates for FAM and TAMRA fluorescence emission were imposed to calculate 
the relative number of cells from each treatment condition that were positive for 
nanobeacon-associated fluorescence. As tabulated in Table IV-5, while less than 1% of 
control cells were positive for FAM or TAMRA, more than 96% of cells treated with 
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intact NP
++
EDAC folate-targeted proteolytic nanobeacons without free folic acid were 
positive. More than 70% of cells exposed to pre-cleaved nanobeacons in the absence of 
free folic acid also fluoresced above thresholds for FAM or TAMRA. The vast majority 
of similarly treated cells that were co-incubated with free folic acid to compete for folate 
receptors, however, were negative according to the same gates. Taken together with the 
fluorescence microscopy of cells, cellular association of NP
++
EDAC appeared to be mostly 
dependent upon folate-targeting. 
Table IV-5: Gated detection of FAM and TAMRA/FRET fluorescence by flow cytometry 
following NP
++
EDAC uptake experiment with MDA-MB231 cells  
    
Live Cells 
Sample NP
++
EDAC MMP14 FA FAM+ (%) TAMRA/FRET+ (%) 
No Treatment  - - - 0.2  0.9 
No pretreat, No FA  + - - 96.1 97.8 
No pretreat, FA  + - + 1.5 3.4 
MMP14 Pretreat, No FA  + + - 70.1 80.6 
MMP14 Pretreat, FA  + + + 1.2 2.3 
 
IV.4. DISCUSSION AND CONCLUSIONS 
The research presented in this chapter focused on the synthesis and characterization 
of folate-targeted proteolytic nanobeacons from the constituent beacon peptides and 
different types of nanoparticles. As discussed below, the initially proposed synthesis 
scheme employing oxime ligation of FRET-equipped MMP substrate peptides with FeOx 
nanoparticles proved unsuccessful in the production of nanobeacons with measurable 
optical properties for MMP-dependent imaging and delivery applications. Several 
attempts at alternative syntheses based upon published bioconjugation techniques also 
resulted in unsuitable nanoparticles, though providing insights into the complexities 
beacon peptide attachment to nanoparticles. Ultimately, proof-of-concept was 
accomplished by synthesizing folate-targeted proteolytic nanobeacons using peptides 
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with hydrophilic PEG5 spacer tails and amine-terminated organic PAMAM dendrimers. 
The resulting nanoparticles were shown to possess all of the requisite optical and 
biochemical characteristics necessary for testing of the hypothesis that combined 
targeting of nanoparticle payloads to folate receptors and proteolysis by MMPs improves 
selective delivery to solid tumor cells. 
Development and troubleshooting of conditions for oxime ligation of the beacon 
peptides developed in the previous chapters with dextran-coated iron oxide (IDX) 
nanoparticles provided several insights that informed the successful synthesis of 
proteolytic nanobeacons. To facilitate this type of bioconjugation with peptides 
possessing an aminooxy functional group, nanoparticles presenting carbonyl (ketone or 
aldehyde) groups were required. As indicated by Figure IV-2, introduction of aldehydes 
on the surfaces of water-soluble IDX nanoparticles was achieved by oxidation with 
sodium meta-periodate as reported previously
129,151,152
 and could be detected by 
modification of a commercial assay for aldehyde concentration in solutions. The number 
of aldehydes detected per IDX nanoparticle (Table IV-1) correlated with increasing 
concentration of periodate applied up to 2000 µM, above which IDX nanoparticles 
rapidly flocculated (data not shown). Oxidation by 500-1000 µM sodium meta-periodate 
over 1 hour was determined to be optimal for maximum introduction of aldehydes 
without causing noticeable flocculation. 
In the pilot attempt to synthesize folate-targeted proteolytic nanobeacons from 
peptides produced by SPPS, unpurified FApB2vAoa peptide mixture was reacted with 
oxidized IDX nanoparticles (oIDX-500µM) and 100 µM aniline for nucleophilic catalysis 
of the reaction
130
. Approximately 3 molar equivalents or 6 molar equivalents of 
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FApB2vAoa relative to nanoparticles (chosen to be less than the calculated 10.7 
aldehydes per nanoparticle on oIDX-500µM) were added in two separate reactions to 
allow assessment of relative conjugation efficiency in each reaction (abbreviated NP3
++
 
and NP6
++
, respectively). UV-visible spectrophotometry was used following 
ultrafiltration to quantitatively compare the amount of peptides bound to nanoparticles 
based on the characteristic absorbances of FAM and TAMRA fluorophores incorporated 
in FApB2vAoa. As seen in Figure IV-4, recovered reaction mixes and concentrates from 
ultrafiltration of the reactions possessed absorbance spectra shaped differently than the 
parental oIDX-500µM nanoparticles, especially in the 400-600 nm wavelength range 
where FAM and TAMRA absorb maximally. The filtrates, on the other hand absorbed 
very little in the same range, indicating negligible iron and peptide concentrations. 
Scaling and subtraction of the oIDX-500µM absorbance spectrum from the reaction 
mixes and ultrafiltration concentrates resulted in residual spectra (Figure IV-5) 
resembling the absorption of the peptide-associated dyes, confirming FApB2vAoa 
content in the reaction mixes and suggesting recovery of peptides with nanoparticles 
retained during ultrafiltration. However, the observation of very little UV-visible 
absorbance in the filtrates (Figure IV-4c) prompted comparison of the reaction mix 
concentrates with non-reactive control solutions to which ultrafiltration was also applied. 
Shown in Figure IV-6, the fluorescence emission intensities corresponding to excitation 
of FAM and TAMRA dyes were greater in the NP6
++
 concentrate than NP3
++
 concentrate, 
reflective of the difference in the amount of FApB2vAoa peptide added to the reaction 
mixes. Yet the nearly equivalent emission intensities of NP3
++
 concentrate and the control 
concentrates indicated that the majority of the fluorescence signal from NP3
++
 could not 
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be attributed to covalently attached peptides. The very faintly detectable fluorescence 
emission from the NP6
++
 concentrate following a wash with MeOH (Figure IV-7), in 
which FApB2vAoa is soluble but IDX nanoparticles are not, further corroborated the 
suggestion that peptides were not covalently attached and could be removed by solvation. 
Given the lack of peptide-associated absorption in filtrates, the similarity of NP3
++
 
concentrate fluorescence emission intensity to non-reactive control solutions, and the 
observation that the ultrafiltration devices were stained following centrifugation (data not 
shown), FApB2vAoa peptides were not efficiently bioconjugated to oxidized IDX 
particles in the aforementioned reactions nor did they traverse the filter membranes of the 
ultrafiltration device as expected. Furthermore, due to aggregation and challenging 
recovery of iron-containing particles in the devices, ultrafiltration was determined to be 
unsuitable for the separation of IDX-based nanoparticles and unbound FApB2vAoa. 
To explore conditions for improving the efficiency of peptide coupling with surface 
aldehydes on oxidized IDX nanoparticles, FApB2vAoa crude peptide mixture was mixed 
with oIDX-1000µM nanoparticles and either aniline or pPDA, a substituted aniline 
derivative that has been reported to provide an increased rate of oxime catalysis relative 
to aniline
135
. Characterization of the centrifugally separated particulate products of these 
reactions by UV-visible spectrophotometry (Figure IV-10) yielded unexpected results. 
Shown in Figure IV-11, the peptide-associated (oIDX-1000µM subtracted) absorbance 
spectra of all samples that contained pPDA in their respective reaction mixtures 
(NPn
++
pPDA, No-Rxn Ctl) were not distinctly representative of FAM and TAMRA 
absorbance. The spectrum of NP6
++
An, from the reaction employing aniline as the catalyst, 
did exhibit the absorbance maxima characteristic of the dyes, as expected. This 
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observation was more obviously portrayed in the absorbance spectra of the recovered 
supernatants from particulate recovery by centrifugation (Figure IV-12), where the 
supernatants of NP6
++
An possessed the two absorbance peaks corresponding FAM and 
TAMRA in unbound FApB2vAoa and all other samples possessed only one broad 
absorbance peak corresponding to neither dye. As seen in Figure IV-13, the FAM-
associated fluorescence emission intensities of NPn
++
pPDA recovered particles were all 
greater than that of NP6
++
An and correlated with the relative amount of FApB2vAoa 
added to reaction mixtures, however exhibited almost no detectable TAMRA-associated 
fluorescence emission. Taken together with the absorbance spectra, these data suggest 
that while pPDA is likely a more effective catalyst of oxime ligation in the reaction 
conditions tested, it alters the optical properties of TAMRA. Reactions employing pPDA 
as a nucleophilic catalyst of oxime ligation were therefore not repeated, as the optical 
sensing of proteolysis by proteolytic nanobeacons made from the peptides developed in 
the preceding chapters is dependent upon FRET between FAM and TAMRA. 
Modifications of the reaction conditions including solvent system, buffer, and reagent 
quality for aniline-catalyzed oxime ligation were also attempted with the aim of 
providing suitable reaction conditions for covalent attachment of FApB2vAoa peptides to 
oxidized IDX nanoparticles. Reaction of crude FApB2vAoa and oIDX-1000µM in 
DMSO with 0.1 M sodium acetate (pH 4.5) was performed in consistency with the 
conditions previously used by our laboratory for bioconjugation of aminooxy terminated 
peptides with aldehyde terminated dendrons (Scherer and McIntrye, unpublished data). 
Aniline was sourced from a freshly opened, nitrogen flushed manufacturer’s bottle for 
optimum quality. IDX-based nanoparticles were recovered following reaction by repeated 
204 
 
precipitation in MeOH and centrifugation, as with the syntheses above. The peptide-
associated absorbance spectra of initially recovered nanoparticles, shown in Figure 
IV-15, was characteristic of FAM and TAMRA as expected and indicated approximately 
32% recovery of the peptide added to the reaction mix in the recovered nanoparticle 
sample (see Table IV-2). However, by the same measurement the nanoparticle sample 
recovered from a control reaction that included non-oxidized IDX nanoparticles instead 
of oIDX-1000µM also possessed 19% of the peptide added to its reaction mixture, 
despite the previous finding of less than 1 aldehyde per IDX nanoparticle versus 
approximately 27 aldehydes per oIDX-1000µM (see Table IV-1). The absorbances of 
these recovered particle samples at 400 nm and 560 nm corresponds to 5.8 peptides per 
oIDX-1000µM nanoparticle and 3.0 peptides per IDX nanoparticle. 
To determine whether the observation of FApB2vAoa-associated absorption in 
particulate samples could be attributed to non-covalent inclusion of peptides (e.g. 
entrapment during precipitation and centrifugation or intercalation in the dextran coating 
of nanoparticles), the recovered magnetic nanoparticles were washed in MeOH and 
resuspended in DMSO two additional times, once with recovery by centrifugation and 
subsequently with recovery by magnetic attraction alone. As indicated in Table IV-2, the 
calculated recovery of the initial TAMRA absorbance in each type of nanoparticle 
solution decreased proportionally to one another through each wash and resuspension 
cycle. Calculations based on iron-associated and TAMRA-associated absorbance after the 
third recovery correspond to 3.1 and 1.2 peptides per nanoparticle for oIDX-1000µM and 
IDX nanoparticles, respectively. Interestingly, the repeated MeOH washes of the 
nanoparticle products without resuspension in DMSO and sonication preceding (Supnt 2, 
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Supnt 4) did not result in substantial recovery of unbound peptides, suggesting that 
suspension in DMSO and/or sonication led to the incremental release of peptides from 
nanoparticle suspensions. This observation corroborates the notion that FApB2vAoa 
peptides may have been trapped during phase separations or otherwise non-covalently 
intercalated with IDX-based nanoparticles, as the concentration gradient in a solvent 
capable of suspending both the nanoparticles and unbound peptides (DMSO) may have 
driven an equilibrium-based release of peptides. The difference in TAMRA-associated 
absorptivity of nanoparticles from the second wash-recovery cycle and the third such 
cycle represented approximately a 50% reduction in the fraction of initial peptide 
recovered for both oIDX-1000µM and IDX nanoparticles. No further washing of 
recovered nanoparticle products was performed, as the reactions had resulted in 15% 
efficiency of FApB2vAoa attachment to oIDX-1000µM nanoparticles at best, and further 
release of peptides was anticipated. 
Because troubleshooting of reaction conditions for oxime ligation and application of 
conditions previously demonstrated to be robust with commercially obtained peptides did 
not result in effective bioconjugation, the characteristics of FApB2vAoa from SPPS were 
revisited. We hypothesized that the unidentified adducts (40 Da, 67 Da) in peptides 
synthesized with DprAoa as the C-terminal residue could be inhibiting reaction of 
peptides with aldehydes on nanoparticles, presumably by blocking the required aminooxy 
group on peptides. As shown in Figure IV-17, LCMS analysis of the mixture resulting 
from trypsin cleavage of FApB2vAoa indicated the inclusion of the adduct on the C-
terminal fragment representing the last four residues of FApB2vAoa, 
[h2n-{peg1}K(tamra)G{Dpr(Aoa)}-conh2], confirming the possibility of attachment to the 
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aminooxy. To directly assess whether FApB2vAoa could form oxime bonds with 
aldehydes, FApB2vAoa crude peptide mixture from SPPS was mixed with aniline and a 
simpler aldehyde-presenting molecule, 4-formylbenzoic acid. Comparison of the mass 
spectra obtained by ESI+ MS of the crude peptide mixture and the reaction mix was 
informative. As seen in Figure IV-19, several ions corresponding to the expected M/z of 
FApB2vAoa with either mass additions of 40 Da or 107 Da or a mass subtraction of 129 
Da were detected in both the starting material and the reaction mix, indicating no reaction 
of these chemical species with the aldehyde. Interestingly, the subtraction of 129 Da 
corresponds to the omission of the C-terminal Dpr(Aoa) residue from the structure of 
FApB2vAoa, and no ion with M/z representative of a 129 Da subtraction as well as a 40 
Da addition was detected. Furthermore, ions with M/z representative of the expected 
structure of FApB2vAoa, with or without a 67 Da adduct, were found in the crude 
peptide mixture but not in the reaction mix. Rather, concordant ions with M/z 
representing the expected mass addition of 132 Da from reaction with 4-formylbenzoic 
acid were detected in mass spectrum of the reaction mix, suggesting that the intended 
FApB2vAoa molecule did react with the aldehyde and that the 67 Da adduct did not 
interfere. The presence of an ion with M/z representative of the peptide omitting 129 Da 
but possessing a 67 Da adduct in both samples indicates that the omission of 129 Da was 
sufficient to block reaction with the aldehyde, corroborating the identity of the omission 
as Dpr(Aoa). No ions representative of a peptide omitting Dpr(Aoa) but including 
adducts of 40 Da or 107 Da were detected, suggesting that the 107 Da adduct is likely a 
combination of the 40 Da and 67 Da adducts and that the 40 Da adduct on other 
structures was likely attached to the Dpr(Aoa) residue. 40 Da is conspicuously the 
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expected MW addition if the aminooxy group had reacted with acetone, however the 
peptide should not have been exposed to substantial concentrations of acetone at any time 
during synthesis or subsequent workup. Nonetheless, taken together with the 
inefficiencies of FApB2vAoa oxime ligation reactions with much larger nanoparticles, 
these data indicate three distinct but possibly overlapping causes for lack of peptide-
nanoparticle bioconjugation by oxime formation: (1) lack of an aminooxy functional 
group due to omission of Dpr(Aoa) in some proportion of peptides from SPPS, (2) 
blocking of oxime formation due to an unidentified 40 Da adduct on the Dpr(Aoa) 
residue, and/or (3) steric hindrance of the reactive site by TAMRA dye and relatively 
large nanoparticles. 
Due to the possible inhibition of oxime-based bioconjugation of peptides and 
nanoparticles by the aforementioned complications related to the Dpr(Aoa) residue, 
alternative reaction schemes for covalent attachment were pursued in parallel. These 
strategies relied on the well-characterized and often used reactions of carboxylic acid 
groups with primary amines mediated by carbodiimides
129
. While this approach is 
suitable for pB2v-based peptides from SPPS, it limits the adaptability of MMP substrate 
peptides produced by SPPS by requiring that all primary amines (i.e. the N-terminus and 
all lysine side chains) be either protected or functionalized at the time of peptide 
bioconjugation to nanoparticles. Nonetheless, attempts at nanobeacon synthesis using 
carboxyl-terminated peptides and aminated nanoparticles were instructive. 
 Carbodiimide-mediated synthesis of nanobeacons was first attempted by reacting a 
carboxy-terminated pB2v-based peptide (AcpB2vp-cooh, see Appendix A) with IDX 
nanoparticles and DIC, reproducing reported conditions for the attachment of an amino 
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acid analogue to starch polymers similar to dextran by Steglich esterification
148
. As 
shown in Figure IV-22 and Table IV-3, analysis of the magnetically recovered reaction 
mix components by UV-visible spectrophotometry indicated recovery of 2% or less of 
the peptide added to the reaction mix, corresponding to about 0.1 peptides per 
nanoparticle. AcpB2vp-cooh crude peptide mixture did possess a majority product with a 
42 Da adduct characterized by LCMS (data not shown), however because an adduct of 
the same size was detected previously in AcpB2vAoa, attachment to the carboxylic acid 
functional group was not suspected. The expected mass addition from acetylation is also 
42 Da, suggesting that the reaction used for acetylation in solid phase may have imparted 
two acetyl groups to each intended peptide during synthesis. 
To eliminate the blocking of functional groups as a possible cause of non-reactivity, 
carboxyl-terminated peptides and amine-decorated nanoparticles synthesized and 
characterized by commercial vendors were reacted in various conditions for 
carbodiimide-mediated amide bond formation. The 2-color (FAM/TAMRA) MMP14 
substrate peptide, Peptide 13c, was reacted with Qdot(605)NH2 nanoparticles and EDAC 
in various proportions. The electrophoretic mobilities of the Qdots in the resulting 
reaction mixes were compared with unreacted Qdots and control solutions. As shown in 
Figure IV-24a, Qdots from reaction with 1000-fold excess of Peptide 13c and 500-fold 
excess of EDAC exhibited a trend towards retardation of migration toward the cathode. 
The tendency of the bands to curve after enough time had elapsed to induce migration of 
the Qdots confounded interpretation of this gel, though. A repeat electrophoresis 
experiment including a sample of a reaction mix including even greater excesses of 
Peptide 13c and EDAC relative to Qdots (Figure IV-24b) did not confirm the trend of 
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Qdot electrophoretic retardation following reactions. Quizically, samples from a control 
mixture including Peptide 13c but not EDAC appeared to contain a population of Qdots 
that were trapped in the loading wells of the 1% agarose gel for an unknown reason. 
Separate, visibly pink bands in samples containing 1000-fold or greater excesses of 
Peptide 13c over Qdots were observed to migrate towards the anode, likely indicative of 
migration of unbound peptides. Unfortunately, not even qualitative evidence of carboxyl-
terminated peptide conjugation to Qdot(605)NH2 nanoparticles could not be gleaned from 
these experiments. 
To quantitatively assess peptide attachment to nanoparticles, a similar reaction was 
performed with Peptide 13c and organic PAMAM dendrimers using EDAC as the 
carbodiimide mediator of amide bond formation. The use of these reactants enabled both 
separation of unbound peptides from nanoparticles by ultrafiltration and direct 
measurement of peptide content in recovered solutions by UV-visible spectrophotometry 
because PAMAM dendrimers possess negligible visible-spectrum absorbance. A control 
solution containing Peptide 13c and PAMAM in amounts equivalent to the reaction mix 
but omitting EDAC (“No Rxn”) was prepared and incubated in parallel with the reaction. 
The UV-visible absorbance spectra recorded for the reaction mix and the control (Figure 
IV-26) confirmed equivalent additions of Peptide 13c to each solution with absorbance 
maxima characteristic of FAM and TAMRA dyes. However, the spectra recorded for 
diluted solutions of nanoparticles retained during ultrafiltration were unexpectedly also 
nearly identical in absorptivity. If EDAC had mediated covalent attachment of Peptide 
13c to the terminal primary amines of PAMAM dendrimers, as expected, one should 
have observed much greater peptide-associate absorption from the products of the 
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reaction than from the control. Rather, in both cases the absorbance at 560 nm 
corresponded to about 0.3-0.4 peptides per nanoparticle (assuming 90% recovery of 
peptides from ultrafiltration – McIntyre, unpublished data), or about 16-19% recovery of 
the peptide added to reaction mixes. As such, EDAC-mediated covalent attachment of 
peptides to PAMAM dendrimers was not demonstrated. 
The lack of evident covalent attachment of FRET-equipped MMP substrate peptides 
to nanoparticles from various reaction schema employing different functional groups and 
different types of nanoparticles suggested a systemic problem in our attempts at 
bioconjugation. We hypothesized that steric hindrance of the reactive site was the 
primary impedance to effective attachment chemistry. Given our previous findings 
regarding the effects of steric hindrance of the MMP cleavage site and hydrophobicity of 
spacer moieties in substrate peptides (see II.4), synthesis of a pB2v-based peptide with 
the inclusion of a lengthier, hydrophilic PEG5 spacer isolating a C-terminal cysteine 
residue (pB2vp5C-cooh) was synthesized by SPPS. Cysteine was selected as the C-
terminal residue for its versatility in bioconjugation reactions, as it presents both a 
sulfhydryl and a carboxylic acid for participation in various types of covalent attachment 
chemistry. Building on the optimized synthesis of pB2v (see III.3.6), great care was taken 
to ensure attachment of the initial PEG5 residue to Fmoc-Cys(Trt)-Wang resin and 
termination of uncoupled amines following this coupling to block the yield of peptides 
omitting PEG5. As a result, mass spectrometry characterization of unpurified peptide 
mixture following folation, final deprotection, and detachment from the solid support 
resin (Figure IV-27 and Figure IV-28) indicated a majority of ions with M/z 
representative of the expected structure of FApB2vp5C-cooh. Unlike previous syntheses 
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of folated peptides by SPPS, this majority did not correspond to unintended peptide 
structures including adducts or omitting residues. As seen in Figure IV-29, FApB2vp5C-
cooh possessed an absorbance spectrum with maxima around 495 nm and 560 nm, 
indicative of FAM and TAMRA dye incorporation. Stimulation of fluorescence by 
excitation at 555 nm and 495 nm resulted in emissions characteristic of TAMRA and 
FRET between FAM and TAMRA, respectively, confirming the desired optical 
properties of FApB2vp5C-cooh. Finally, a rapid FRET switch was readily observed from 
this peptide upon proteolysis by MMPs, as demonstrated in Figure IV-30 by 10-fold to 
16-fold increases in FAM emission intensity after exposure to MMPs (2, 9, or 14) for 60 
minutes that continued to trend upward for up to 10 hours. Altogether, validation of the 
optical properties and MMP-cleavability of FApB2vp5C-cooh by spectroscopy and 
corroboration of its molecular structure by mass spectrometry confirmed that 
FApB2vp5C-cooh possessed all the attributes necessary for constructing folate-targeted 
proteolytic nanobeacons and testing our overall hypotheses. 
Upon validation of FApB2vp5C-cooh, synthesis of proteolytic nanobeacons using 
FeOx-based nanoparticles was revisited. Several synthesis schemes and mediators enable 
bioconjugation of sulfhydryl and carboxylic acid functional groups of cysteine with 
primary amines
24,37,129,153
. Therefore FeOx nanoparticles with APTES surface decoration, 
FeOx-NH2, were synthesized by Charleson S. Bell of the Giorgio Laboratory and 
characterized by qualitative Ninhydrin assay to confirm availability of primary amines 
(data not shown). Synthesis of complete nanobeacons from FApB2vp5C-cooh peptide 
and FeOx-NH2 nanoparticles was attempted with mediating of covalent bonding by 
heterobifunctional linkers SIA or Sulfo-SMPB, as diagrammed in Figure IV-31. 
212 
 
Recovery of nanoparticle products by magnetic attraction and characterization of reaction 
extent by UV-visible spectrophotometry mirrored previous experiments. Shown in Figure 
IV-33, the absorbance spectra of the nanoparticle-depleted initial supernatants from 
separated reaction mixes were clearly representative of peptide with dual maxima in the 
visible portion of the electromagnetic spectrum. These maxima were not observed in 
supernatants from a DMSO wash of the recovered nanoparticles, though, suggesting that 
nearly complete removal of unbound FApB2vp5C-cooh from nanoparticles was achieved 
by the first separation. Unfortunately, reliable UV-visible absorbance spectra of the 
recovered NP
++
x nanoparticles could not be recorded due to rapid flocculation of particles 
in many solvents. However, because the TAMRA-associated absorptivity of the collected 
supernatants represented only 55-56% of the peptide added to reaction mixes, we inferred 
that the reactions may have proceeded to a modest extent, attaching 44-45% of starting 
peptide to nanoparticles (220-225 peptides per nanoparticle). As can be seen in Figure 
IV-34, excitation of these FeOx-based NP
++
x nanoparticles at 494 nm resulted in emission 
spectra with maxima around 520 nm and 580 nm corresponding to FAM and TAMRA 
dyes, however this emission was only slightly more intense than the background of the 
non-decorated FeOx-NH2 nanoparticles and insufficient to be recorded without 
substantial contributions of noise to the signals. These emission intensities would be 
insufficient for optical sensing of proteolytic activity, but could be the result of either 
poor conjugation efficiency or optical interference, the latter of which might be remedied 
upon separation of cleaved peptide fragments from nanoparticle cores, especially in 
microscopy experiments. With the hypothesis that the relatively great UV-visible 
extinction of FeOx might be interfering with excitation and/or emission of FAM and 
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TAMRA, if present, MMP14-induced FRET switch assays were conducted with 
fluorescence measurements before and after nanoparticle depletion of samples. No 
increase in FAM fluorescence emission intensity of either FeOx-based NP
++
x suspension 
was associated with proteolysis by MMP14, as shown in Figure IV-34b-c. Interestingly, 
the MMP14-associated increases in fluorescence emission intensity in nanoparticle-
depleted samples were greater for FAM emission than TAMRA emission in each sample 
(Figure IV-34d-e), perhaps indicative of FRET disruption, but the overall emissions were 
again scarcely an order of magnitude greater in intensity than the noise of the instrument. 
Whether or not the bioconjugation reactions proceeded sufficiently to attach 
FApB2vp5C-cooh to FeOx-NH2 nanoparticles, MMP-associated FRET switch could not 
be observed from the resulting product suspensions, rendering them unsuitable for use as 
proteolytic nanobeacons. 
Given the above evidence suggesting possible attachment of peptides to aminated 
FeOx nanoparticles but the application-limiting optical and solubility properties of the 
recovered product suspensions, a proof-of-concept synthesis of nanobeacons using 
nanoparticles transparent to visible-spectrum light was pursued. PAMAM-G4 
dendrimers, though somewhat smaller than the ideal range for selective accumulation in 
solid tumors in vivo via the EPR effect, provided the requisite poly-amine surface and 
visible-spectrum transparency for this synthesis. As diagrammed in Figure IV-35, 
FApB2vp5C-cooh crude peptide mixture was mixed with PEGylated PAMAM-G4 
separate reactions employing three different mediators of covalent attachment. SIA and 
Sulfo-SMPB were applied to facilitate reaction with the cysteine sulfhydryl on the 
peptide and amines on PAMAM-G4, while the carbodiimide EDAC was used to generate 
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amine-reactive intermediates from the carboxyl termini of peptides for amide bond 
formation. As with previously attempted PAMAM-based syntheses, unbound peptides 
were separated from nanoparticles by ultrafiltration and all solutions recovered for 
analysis by UV-visible spectrophotometry. Calculated from the spectra in Figure IV-36, 
the FApB2vp5C-cooh peptide recoveries in Table IV-4 are consistent with attachment of 
peptides to PAMAM-G4 to varying extents. Despite the ability of peptides to traverse the 
filtration membrane as demonstrated by differing intensities of peptide-associated 
absorption in the effluent solutions, 48-77% of the peptide added to each reaction mix 
was recovered in the final retentate solutions. According to the absorbance measurements 
and calculations, EDAC and Sulfo-SMPB mediation of bioconjugation were comparable 
and both superior to SIA with respect to the amount of peptide attached to nanoparticles. 
While the UV-visible absorbance spectra shown in Figure IV-36 indicated 
incorporation of the peptide-associated FAM and TAMRA dyes in recovered PAMAM-
based NP
++
x nanoparticle solutions, FRET switch assays with MMP9 (Figure IV-37) 
validated the functional properties of these prospective proteolytic nanobeacons. 
NP
++
EDAC, NP
++
SMPB, and NP
++
SIA solutions each exhibited a 10-12-fold increase in FAM 
fluorescence emission intensity with a still-increasing trend after 60 minutes of 
incubation with MMP9, constituting the first ever sensing of proteolytic activity by 
folate-targeted proteolytic nanobeacons. The relative FRET switches of all nanoparticles 
solutions were greater than that of FApB2vp5C-cooh peptide alone, possibly due to 
additional intramolecular quenching of FAM by multiple proximal peptides prior to 
proteolysis. As depicted in Figure IV-38, the disparity in the maximum FRET switches 
obtained after up to 10 hours incubation was even greater. The TAMRA (reference) 
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emission intensity of each solution also increased during incubation, though less rapidly, 
such that the 61-fold increase in the FAM emission intensity of NP
++
EDAC corresponded 
to an approximately 9.4-fold increase in S/R ratio. Nonetheless, these relative increases in 
sensor emission and S/R ratio of each nanoparticle solution in response to proteolysis by 
MMP9 were sufficient for sensing MMP activation of nanobeacons, especially using 
fluorescence microscopy. 
To validate these nanoparticles as proof-of-concept folate-targeted proteolytic 
nanobeacons in vitro, MDA-MB-231 human metastatic breast cancer cells known to 
express folate receptor and MMPs (see Appendix C) were incubated with either intact or 
MMP14 pre-treated NP
++
EDAC nanoparticles, with or without addition of folic acid to 
treatment media to compete for cell membrane-anchored folate receptors. This 
experimental design allowed us to confirm susceptibility of NP
++
EDAC to cleavage by 
endogenously expressed MMPs as well as to elucidate the effects of folate targeting and 
MMP cleavage on cellular internalization of nanobeacons and/or enzymatically released 
peptide fragments carrying FAM. Bright field and fluorescence microscopy of cells after 
4 hours of treatment and exchange of treatment media for PBS (Figure IV-39) indicated 
that folic acid competition was the most influential factor affecting cell uptake of 
nanobeacons. Fluorescence in both the FAM and TAMRA channels was found 
intracellularly when folic acid was not added to treatment media, but almost no 
fluorescent signal above background was detectable inside cells exposed to free folic acid 
in addition to nanobeacons. As shown in Figure IV-40 and Table IV-5, quantitation of 
cellular fluorescence by flow cytometry of cells recovered following microscopy 
corroborated these observations. 
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Interestingly, FAM fluorescence was both punctate and diffuse in cells treated with 
intact NP
++
EDAC in the absence of competing folic acid (Figure IV-39a-d), whereas only 
punctate FAM fluorescence was observed in cells incubated with pre-cleaved 
nanobeacons (Figure IV-39i-l). Intracellular TAMRA fluorescence was only observed to 
be punctate and in all cases accompanied by FAM, corroborating the suggestion that 
fluorescence puncta in both channels represent intact peptides or nanobeacons. 
Concordantly, the diffuse intracellular FAM fluorescence could indicate liberated peptide 
fragments inclusive of FAM but not TAMRA, as intended following nanobeacon 
proteolysis by MMPs. However, the absence of diffuse FAM fluorescence in cells treated 
with pre-cleaved NP
++
EDAC confounds this suggestion, as the treatment media should 
have contained a much greater proportion of folate-targeted peptide fragments 
supposedly represented by diffuse staining. Furthermore, in the absence of competing 
folic acid, the overall intracellular FAM and TAMRA fluorescence emissions were more 
intense in cells incubated with intact nanobeacons, as shown in Figure IV-40 and Table 
IV-5. 
While additional experiments are needed to elucidate the reasons for these 
observations, one explanation could be that the multivalent receptor binding mode of 
intact nanobeacons results in more efficient association of FAM-carrying nanobeacons 
with cell surfaces than the monovalent ligand-receptor binding by folate conjugates 
released from cleaved nanobeacons. The pB2v-based substrate peptide tethering FAM to 
nanobeacons is cleavable by membrane-bound MMP14 as well as secreted MMPs, 
concentrations of which are often elevated pericellularly around malignant cells, 
particularly tumor cells actively invading through surrounding ECM
11,42,110,121,122,154
. 
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Rather than leading to rapid uptake of intact nanoparticles, folate targeting may 
counterintuitively augment extracellular proteolysis of proteolytic nanobeacons by 
increasing the overall avidity of nanobeacons for folate receptors displayed on cell 
membranes, thereby concentrating them in the vicinity of active MMPs. 
It is important to emphasize that these observations were made in vitro with only one 
time interval applied for treatment. A 3-dimensional, heterogeneous tumor 
microenvironment in vivo may present additional physical and chemical barriers to 
cellular internalization of nanobeacons, such that the temporal relationship between 
extracellular proteolysis and receptor-dependent association of folate-targeted proteolytic 
nanobeacons with cells could be very different. Conceivably, due to slower diffusion 
through ECM among other factors, folation could have little impact on the degree to 
which proteolytic nanobeacons are cleaved extracellularly in vivo. Nonetheless, selective 
delivery to tumor cells may result from this scenario as well, resulting from the intended 
release of monovalent folate conjugates capable of more rapid diffusion throughout the 
ECM only in the MMP-rich microenvironment of a tumor. Alternatively, if the 
fluorescence distributions observed in cells are unrelated to proteolysis of nanobeacons, it 
is also possible that folate-mediated internalization of intact folate-targeted proteolytic 
nanobeacons may occur rapidly enough that sufficient time for extracellular proteolysis is 
not allowed. The diffuse FAM fluorescence observed in MDA-MB-231 cells treated with 
NP
++
EDAC nanoparticles indicates that regardless of the mechanisms, some proportion of 
the sensor moiety was found in the cytoplasm, the aim of delivery for many diagnostic 
and therapeutic compounds. 
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While additional experiments are necessary to elucidate the mechanisms and kinetics 
of delivery and the intracellular fate of such nanoparticles, the troubleshooting presented 
in this chapter has culminated in the synthesis and characterization of PAMAM-based 
nanobeacons that are folate-targeted, FRET-equipped, MMP-responsive, and internalized 
by tumor cells. Folate-targeted proteolytic nanobeacons synthesized from 
FApB2vp5C-cooh peptides and PAMAM-G4 dendrimers were cleaved by MMPs and 
internalized in MDA-MB-231 breast cancer cells via a folate-dependent mechanism. We 
have demonstrated by the syntheses and characterizations above that synthesis of folate-
targeted proteolytic nanobeacons is feasible and that the proof-of concept nanoparticles 
produced may be used to test the hypothesis that our design for dually-targeted 
nanobeacons allows selective, imageable delivery to tumor cells. 
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CHAPTER V 
 SUMMARY AND FUTURE DIRECTIONS 
V.1. SUMMARY OF CONCLUSIONS 
The research detailed in this dissertation culminated in the synthesis, characterization, 
and preliminary in vitro validation of FTPNBs for the detection of MMP activity and 
delivery to tumor cells. FTPNBs constitute folate-targeted, MMP-cleavable nanobeacons 
equipped with visible-spectrum fluorophores that enable a dramatic optical switch upon 
proteolysis for the detection of MMP activity. Throughout the design, troubleshooting, 
and optimization of the synthetic and analytical techniques required, several important 
insights were gained that should inform future work in the field of cancer nanotechnology 
and optical theranostics. 
Complete solid phase synthesis employing standard Fmoc-amino acids, unusual 
amino acid analogues, folic acid, and HCTU provided a robust and adaptable system for 
the production of substrate peptides possessing all of the characteristics required for 
FTPNBs: attachment to FRET-paired sensor and reference fluorophores on opposing 
sides of an MMP-cleavable peptide bond, N-terminal attachment to folic acid, and 
unhindered chemical functional groups at the C-terminus for bioconjugation with 
nanoparticle cores. Key developments and demonstrations in the synthesis of these 
specialized peptides include: 
 attachment of paired fluorophores directly to the substrate peptide for FRET 
quenching with reproducible efficiency (II.3.2), 
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 lengthening of the intramolecular spacing between fluorophores using flexible, 
hydrophilic PEG1 spacers to enhance cleavage by MMPs that likely results from 
alleviation of steric hindrance of the MMP cleavage (P1-P1’) site by the bulky 
fluorophores (II.3.4), 
 demonstrated optical non-interference and biological non-toxicity of small 
(40-67 Da), unidentified adducts incorporated during peptide workup (III.3.2), 
 optimization of Fmoc-SPPS employing triple-coupling of 
Fmoc-Lys(5/6-FAM)-OH and Fmoc-Arg(Pbf)-OH to improve yield of the 
intended peptide products (III.3.6), 
 robust and economical bioconjugation of folic acid as a targeting ligand or acetyl 
as a non-reactive terminus to peptides in solid phase (III.3.3), 
 non-interference of folic acid conjugation with fluorescence, FRET, or MMP-
associated substrate proteolysis (III.3.6), 
 inclusion of a flexible, hydrophilic, intermediate-length PEG5 spacer separating a 
C-terminal cysteine residue provided for efficient bioconjugation of peptides to 
reactive functional groups on nanoparticle cores; the linker is postulated to 
alleviate potential steric hindrance of the coupling reaction (IV.2.10), 
 and successful conjugation of folate-targeted, FRET-equipped, MMP-cleavable 
substrate peptides to PAMAM nanoparticles utilizing the carboxyl or sulfhydryl 
functional groups of the C-terminal cysteine with appropriate mediators for 
covalent attachment to primary amines (IV.2.12). 
Other pertinent observations were made during the course of this work that may 
inform the further development of diagnostic nanoparticles. For example, two different 
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reagents (2% hydrazine solution and p-phenylene diamine) were found to modify 
TAMRA dye such that its optical properties became unsuitable for use as the quenching 
reference fluorophore in FTPNBs. In applications where the characteristic optical 
properties of TAMRA dye are essential, exposure to these chemicals should be avoided, 
e.g. by altering the sequence of synthesis operations or by chemically protecting 
TAMRA.  
Several factors may have contributed to alack of detectable attachment of aminooxy-
functionalized pB2vAoa peptides with aldehyde-bearing oIDX nanoparticles. These 
include unintended omission of the Dpr(Boc-Aoa) residue during SPPS, blocking of the 
Aoa residue by an unidentified 40 Da adduct, and steric hindrance of the reactive site. 
Oxime ligation is nonetheless a useful chemoselective method and could be applicable 
for development of peptide-decorated nanoparticle probes. This may prove especially 
important in the development of NIR-emitting FTPNBs, as NIR dyes are often 
incompatible with the repeatedly applied acid-base deprotection chemistry employed in 
SPPS. The orthogonality of oxime ligation to amine- and thiol-based bioconjugations 
allows SPPS and bioconjugation of peptides prior to attachment of NIR dyes, sparing 
them the harsh conditions of deprotection chemistry. Our laboratory previously has had 
success employing this strategy to produce NIR-emitting proteolytic beacons (Scherer et 
al, unpublished). In future syntheses designed for oxime ligation of peptides with 
nanoparticles or surfaces, one should take care to verify the presence and reactivity of the 
aminooxy functional group and adequate spacing and solubility to minimize potential 
steric hindrance of the reaction. 
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Though there was evidence suggesting some conjugation of peptides to amine-
terminated FeOx nanoparticles using SIA or Sulfo-SMPB heterobifunctional linkers (see 
IV.2.11), the resulting nanoparticles could not be characterized by absorbance and did not 
exhibit the expected fluorescence properties. In addition to the rapid flocculation of these 
nanoparticles, the broad UV-visible absorbance of FeOx interfered with optical 
characterization. FeOx nanoparticles as cores of FTPNBs would provide benefits such as 
simplified purification by magnetic separation and additional imaging modalities 
including MRI for tracking biodistribution. Since others have reported the preparation of 
fluorescent FeOx-based nanoparticles decorated with fluorescein
141,143,155,156
, further 
studies into the development of FeOx-based FTPNBs are merited. 
V.2. SIGNIFICANCE AND FUTURE DIRECTIONS 
The results and conclusions presented in this dissertation are directly applicable to the 
fields of cancer imaging and drug delivery. Detailed above are the best practices, 
potential pitfalls, and troubleshooting strategies gleaned from the design, synthesis, and 
characterization of multiply-targeted, multifunctional nanoparticles for delivery to solid 
tumors. These insights should prove valuable in the development and application of 
future diagnostic and therapeutic macromolecules for cancer research and treatment. 
FTPNBs evolve a fluorescent optical switch upon proteolytic activation, the source of 
which is the sensor fluorophore that may subsequently be captured in a tumor cell via a 
selective, receptor-mediated endocytic mechanism resulting from folate targeting. 
Sensor-equipped molecules liberated by proteolysis from other macromolecules lacking a 
targeting ligand, solubility switch, or other mechanism for immobilization may rapidly 
diffuse out of a tumor or return to circulation. As such, FTPNBs constitute a contribution 
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toward developing imaging agents useful for analysis of tumor response to therapy, 
particularly for disease-specific MMPI treatment where quantitative measurements of 
efficacy have been historically lacking
18,19
. While other imaging agents have been 
developed, e.g. MMPSense
26
, no one agent has overcome all of the challenges associated 
with clinical assignment/assessment of tumor-associated protease activity by specific 
protease family members in humans. Ability to selectively image MMP activity in tumors 
using nanoparticle-mediated delivery of enzyme-selective proteolysis sensors could 
breathe new life into the interest in MMPs as therapeutic targets in cancer. 
FTPNBs developed in this work may also aid in elucidating the mechanisms that 
determine the intracellular fate of folate-targeted constructs for engineered delivery to 
tumor cells and overcoming previously unidentified challenges. Whereas many targeting 
ligands are internalized and trafficked to lysosomes for degradation, folates may be 
internalized via at least two receptor-mediated routes, one of which directs vesicles to 
recycling centers where FA may or may not be released from FR before FR is recycled to 
the cell surface
48,66,67
. The dependence of the intracellular fate of FA-linked particles on 
multiplicity of FA-FR binding was recently examined, wherein it was shown that folates 
binding singly were trafficked to mildly acidic (mean pH 6.8-6.95) endosomes whereas 
particles binding multiple FRs simultaneously were found in lysosomal compartments 
(mean pH less than 5.0)
48,70
. 
This could be a critical insight that defines a previously unidentified challenge that 
many recently developed folate-targeted therapeutic approaches have faced, especially 
those based on multivalent nanoparticles. For example, Majoros et al developed a 
dendrimer-based nanoparticle multiply decorated on its surface with FA, a fluorescein-
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based fluorescent dye (FITC), and paclitaxel (PXL), a toxic drug that interrupts mitosis in 
dividing cells. Despite demonstrating the effective targeting of FR-positive KB cells by 
the nanoparticles, flow cytometry also revealed less than 25% death in targeted cells 
despite administering 100 nM drug-equipped nanoparticles, the equivalent of 400 nM 
PXL. Nanoparticle concentrations greater than this were toxic to all cells, regardless of 
FR status
57
. It is important to note that unlike FTPNBs, the FA, dye, and PXL conjugated 
to the nanoparticle in that study were each covalently attached directly to the dendrimer 
on separate branch termini and all by non-cleavable molecular linkers. FTPNBs may 
overcome this challenge by deploying monovalent folate conjugates only in a permissive, 
MMP-rich microenvironment such as a solid tumor. Further experiments testing cellular 
internalization of FTPNBs in conjunction with monitoring of intracellular vesicles using 
reagents such as LysoTracker dyes could be used to elucidate the intracellular fate of 
FTPNBs and the folate conjugates released from them by proteolysis. 
With slight modifications to the nanoparticles developed in this work, applying the 
insights detailed above, FTPNBs could provide invaluable developments in the fields of 
cancer imaging and theranostics. As alluded to above, the oxime ligation chemistry could 
be combined with conventional amide bond-forming and thiol bond-forming 
bioconjugations to enable incorporation of NIR dyes or therapeutic molecules on beacon 
peptides following SPPS. NIR fluorescence permits in vivo optical imaging not possible 
with other fluorophores mostly due to the absorption of lower-wavelength light by 
hemoglobin and absorption of higher-wavelength light by water outside the NIR 
window
157
. Furthermore, synthesis of NIR-equipped FTPNBs employing FeOx-based 
nanoparticle cores in place of PAMAM dendrimers would enable multimodal in vivo 
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imaging using fluorescence as well as MRI. One can envision tracking of nanoparticle 
accumulation and biodistribution by MRI and assessment of MMP activation by optical 
imaging. If surgical resection is possible, one could also then quantify tumor and organ 
accumulation of nanoparticles by Prussian blue staining for iron as well as intracellular 
delivery of folate conjugates by fluorescence microscopy. If some of the constituent 
peptides comprising FTPNBs are conjugated with a therapeutic molecule in place of the 
sensor fluorophore, the resulting nanoparticle becomes a true theranostic agent, one that 
simultaneously delivers both imaging and therapeutic compounds. The optical fluorescent 
signal generated upon activation by MMPs would then be a surrogate measure of drug 
delivery. This strategy has been shown effective in our laboratory by attaching PXL as a 
pro-drug, which then exerts the full potential of its cyotoxicity following proteolytic 
activation
109
. 
The protocols and optimized methods outlined in the preceding chapters are 
anticipated to have applications well beyond cancer research. The techniques that were 
developed herein for the synthesis of MMP-cleavable beacon peptides and FTPNBs are 
highly adaptable to development of substrates for other proteases and enzyme families, 
attachment of other targeting ligands, and conjugation to other types of nanoparticles. 
Peptides and nanobeacons with efficient FRET quenching and consequent optical 
fluorescence switch enable robust interrogation of protease activity in vitro, ex vivo, and 
potentially in vivo. Mammalian degradomes constitute a massive category within their 
respective proteomes
126
, and proteases alone are thought to comprise 1.7% of the human 
genome, representing the second largest enzyme family
8
. Indeed, over 570 individual 
proteases have been identified in the human proteome and linked to over 114 different 
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hereditary diseases
126
. It is the hope of the author that the methods and results 
documented in this dissertation may be applied to the research of a plethora of protease-
dependent biological processes and disease states and to the development of future 
diagnostic and therapeutic approaches. 
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APPENDIX A 
 PEPTIDE STRUCTURES 
Name/Identifier  Amino Acid/Residue Sequence  Page 
Peptide #13      fitc{Ahx}RIGF  *  LRTA{Ahx}C-cooh  228 
Peptide #14  fitc{Ahx}PLA  *  XWAR{Ahx}C-cooh 228 
Weiss  Ac-CSGESSN  *  LFVL{Ahx}-conh2 229 
Mucha/Weiss Hybrid  Ac-KWSLN  *  LFVLC-cooh 229 
Ahx-Hybrid Ac-K{Ahx}WSLN  *  LFVL{Ahx}C-cooh 229 
Broad2 h2n-RPLG  *  LWARC-cooh  230 
TMR-Broad2-FL (TB2F) tamra-RPLG  *  LWARC(fam)-cooh  230 
FL-Broad2-TMR (FB2T) fam-RPLG  *  LWARC(tamra)-cooh  231 
Peptide 13c  tamra-RIGF  *  LRTRK(fitc)R-cooh 232 
Peptide 13e  tamra-SGRIGF  *  LRTAK(fitc)R-conh2 232 
Peptide 13g  tamra-{Ahx}SGRIGF  *  LRTAK(fitc)R-conh2 233 
Peptide 13i  Dab-SGRIGF  *  LRTAK(fitc)R-conh2 233 
Ahx-Broad2 h2n-{Ahx}RPLG  *  LWAR{Ahx}C-cooh  234 
Ahx-Broad2-vis fam-{Ahx}RPLG  *  LWAR{Ahx}C(tamra)-cooh  234 
M9 h2n-{Ahx}AVRW  *  LLTA{Ahx}C-cooh  235 
M9-Folate (M9F) fa-K{Ahx}AVRW  *  LLTA{Ahx}C-cooh  235 
GG-Broad2-vis Ac-GGK(fam)GGRPLG  *  LWARGGK(tamra)G-cooh  236 
FA-GG-Broad2-vis fa-GGK(fam)GGRPLG  *  LWARGGK(tamra)G-cooh  237 
peg-Broad2-vis (pB2v) h2n-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra)G-cooh  238 
PEPDAB1001 Dab-GPLG  *  MRGC(fitc)-conh2 239 
pB2vAoa h2n-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra)G{DprAoa}-cooh  240 
FApB2vAoa fa-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra)G{DprAoa}-cooh  241 
AcpB2vAoa Ac-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra)G{DprAoa}-cooh  242 
pB2vp-cooh h2n-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra){peg1}G-cooh  243 
AcpB2vp-cooh Ac-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra){peg1}G-cooh  243 
pB2vp5C-cooh h2n-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra){peg5}C-cooh  244 
FApB2vp5C-cooh FA-{peg1}K(fam){peg1}RPLG  *  LWAR{peg1}K(tamra){peg5}C-cooh  245 
  
* designates scissile bond / MMP cleavage  
 
Note: Standard amino acid side chains are pictured hereafter as conventional neutral 
residues for simplicity. Due to handling with concentrated TFA, the arginine side chains 
of peptides produced by SPPS probably carried +1 charge corresponding to protonation. 
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APPENDIX B 
 MEASUREMENT OF PEPTIDE CLEAVAGE EFFICIENCY BY MMPs 
The relative efficiencies of enzymatic cleavage of peptides by MMPs were compared 
by calculating the specificity constants (kcat/Km), as follows: 
eem
cat
CF
M
K
k
 , 
where M is the initial rate of fluorescence increase, Fe is the maximum fluorescence 
increase for a particular enzyme-substrate pair and Ce is the concentration of active 
enzyme
116
. These parameters were indirectly measured by fluorescent FRET switch assay 
(see II.2.3) of peptides with MMPs, as depicted in Figure B-1. 
 
Figure B-1: Calculation of enzyme-substrate specificity constant by FRET switch assay 
A representative FRET switch assay used to determine the relative efficiency of enzymatic 
cleavage of PEPDAB1001 peptide by MMPs. The fluorescence emission developed by 
MMP2-dependent cleavage is used as an example to indicate the parameters used in 
calculations. 
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While M and Fe were directly observable from this assay, the concentrations of active 
MMPs (Ce) had to be determined separately. For this determination, an active site 
titration assay was performed by incubating MMPs and broadly MMP-cleavable 
PEPDAB1001 peptide (see Appendix A) in a FRET switch assay with serially diluted 
GM6001. GM6001 is a broad-spectrum tight-binding inhibitor of MMPs. Active MMP 
concentrations were then calculated by fitting data to the Morrison equation: 
    









  ]][[4][][][][
2
1
][ 0
2
,0,00 IEKIEKIEESAV appiappi  
where V is the observed rate of fluorescence increase, SA is the specific activity of the 
MMP, [E0] is the active MMP concentration, [I] is the GM6001 concentration and Ki,app 
is the apparent inhibition constant
158
. An example of the assay and curve-fitting for 
proteolysis of PEPDAB1001 in the presence of GM6001 to determine the active 
concentration of a stock of MMP14 is shown in Figure B-2. 
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Figure B-2: Determination of MMP14 stock concentration by inhibitor titration assay (ITA). 
PEPDAB1001 peptide was incubated with MMP14 and various concentrations of 
GM6001 to measure the initial rate of fluorescence increase (A). Initial linear rates of 
fluorescence increase were plotted against inhibitor concentration (B) and fit to the 
Morrison equation (blue trace) to calculate the effective inhibition constant (Ki) and active 
enzyme concentration (E0 x 80) based on dilution of a purchased stock of MMP14. 
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APPENDIX C 
 PREPARATION AND CHARACTERIZATION OF CELL LINES AND 
CONTRUCTS FOR BIOLOGICAL EXPERIMENTS 
Several human and mouse breast cancer cell lines were characterized using common 
molecular biology techniques to assess their usefulness for in vitro and in vivo tumor 
models to facilitate testing of the targeting mechanisms employed by FTPNBs. As a first 
step, expression of the folate receptor gene, FOLR1, was assessed using reverse 
transcription polymerase chain reaction (RT-PCR), as shown in Figure C-1. 
 
Figure C-1: Qualitative FOLR1 expression by human and mouse breast cancer cell lines. 
An expected 569-bp amplicon from the mouse FOLR1 gene was amplified from mouse 
breast cancer cell lines (4T1, 17L3C, and R221A) by RT-PCR using: 
TTGTTGCTCCTGGTGATG, forward primer; and CTGAGCTTGTAGGAGTGA, 
reverse primer. An expected 360-bp amplicon from the human FORL1 gene was amplified 
from human breast cancer cell line MDA-MB-231 using: 
TGGGTGGCTGTAGTAGGGGAG, forward primer; and 
CAGGGGCACGTTCAGTACC, reverse primer
159
. A water-only (no cDNA) PCR 
reaction was performed in parallel as a negative control. A mouse FOLR1 cDNA from 
Sino Biological (Beijing, CN) was used as a positive control. 100 bp DNA Ladder from 
Life Technologies (Carlsbad, CA, USA) was used to estimate the sizes of DNA oligomers. 
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4T1 mouse breast cancer cells and MDA-MB-468 human breast cancer cells have 
been reported to express negligible amounts of FRα54,160 but substantial levels of MMPs 
including MMP14
161,162
. These cells presented the potential to develop models allowing 
testing of folate- and MMP-targeting separately and jointly by manipulating expression 
of FOLR1 or MMPs. Quantitative RealTime PCR (qPCR) experiments were performed 
on MB-468 cells in addition to the cell lines introduced above to assess relative 
expression of the FORL1 and MMP14 genes. Interestingly, these experiments confirmed 
reported results from 4T1 cells, but indicated that MB-468 cells expressed much more 
FOLR1 than MB-231 cells and much less MMP14, as shown in Figure C-2. 
 
Figure C-2: Relative expression of FOLR1 and MMP14 in human and mouse breast cancer cells 
RealTime PCR was performed using Quantitect Primer Assays from Qiagen (Valencia, 
CA, USA) to calculate the relative expression of the FOLR1 and MMP14 genes in 
selected human (A) and mouse (B) breast cancer cell lines. Expression levels were 
normalized to GAPDH and compared against MB231 (human cells) or FVB mouse kidney 
tissue lysates (mouse cells). Values represent average of duplicates. 
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Based upon the above results demonstrating high expression of MMP14 but low-to-
negligible expression of FRα in 4T1 cells, construction of a manipulated variant of 4T1 
cells expressing exogenous FRα was attempted in order to develop an experimental 
condition for testing dual-targeted FTPNBs. Briefly, a full-length mouse FOLR1 cDNA 
clone was obtained from Sino Biologicals (Beijing, CN). This clone was amplified by 
RT-PCR and validated by restriction enzyme digestion, gel electrophoresis, and 
sequencing by the Vanderbilt DNA Sequencing Core (data not shown). Mouse FOLR1 
cDNA was then used in the Gateway® Cloning System from Life Technologies 
(Carlsbad, CA, USA) according to supplier instructions to develop a mammalian 
transfection vector. First, the cDNA was inserted into a pDONR™ 201 entry vector used 
in the Gateway® system. E. coli bacteria were transformed with the entry vector and 
grown on kanamycin-supplemented agar plates to select for cells expressing the vector. 
The pDONR™ entry vector was extracted from the selected E. coli cells and used in an 
L/R recombination reaction with a pcDNA™ 6.2/V5-DEST Gateway® destination vector 
according to supplier instructions to construct a mammalian expression vector. 
Competent bacteria were then transformed with the expression vector and grown on 
kanamycin-supplemented agar for selection. Individual clones were selected by streaking 
and expanded in ampicillin-supplemented LB broth. Plasmid DNA was extracted from 
expanded clonal populations using Plasmid DNA MidiPrep Kits from Life Technologies 
(Carlsbad, CA, USA) and sequenced by the Vanderbilt DNA Sequencing Core using the 
T7 promoter. A clone producing the appropriate expression vector for transfection of 
mammalian cells was selected based on this sequencing, as shown in Figure C-3. 
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Figure C-3: Sequencing of mouse FOLR1 expression clone and encoded peptide product 
A Gateway® expression vector extracted from E.coli grown in ampicillin-supplemented 
LB broth was sequenced by the Vanderbilt DNA Sequencing Core using the T7 promoter. 
The protein coding sequence from the plasmid and the encoded protein are highlighted in 
yellow. The encoded protein is homologous with the reported sequence of protein encoded 
by the mouse FOLR1 gene (highlighted in green). 
Next, transfection of 4T1 cells was attempted using the mouse FOLR1 expression 
vector validated above. This plasmid was incorporated into transfection complexes and 
used for transfection using either Lipofectamine® 2000 (Life Technologies, Carlsbad, 
CA, USA) or SuperFect® (Qiagen, Valencia, CA, USA) according to the suppliers’ 
instructions. Unfortunately, expansion of 4T1 cell culture colonies that remained adherent 
more than 24 hours subsequent to transfection was not observed. Anecdotally, some cells 
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appeared to remain viable, but did not remain adherent, seeming to become more like 
suspension-tolerant cells. To validate successful transfection, 293 human embryonic 
kidney cells with transiently transfected with the mouse FOLR1 expression vector or a 
COP-GFP vector, or both vectors simultaneously using Lipofectamine® 2000. As seen in 
Figure C-4, transient transfection of 293 cells using COP-GFP and mouse FOLR1 
together was confirmed by fluorescence microscopy. However, subsequent analysis by 
qPCR did not detect mouse FOLR1 expression in wild type or transfected 293 cells (data 
not shown). As such, further attempts at transfection of 4T1 cells with mouse FORL1 
were not made. 
 
Figure C-4: Transient transfection of 293 cells with COP-GPF and mouse FOLR1 
293 human embryonic kidney cells well transiently transfected with expression vectors for 
COP-GFP and mouse FOLR1 using Lipofectamine® 2000 reagent. Cells were imaged 
following transfection and overnight culture in growth medium using bright field and a 
green fluorescence filter on an EVOS FL inverted fluorescence microscope (Advanced 
Microscopy Group, Mill Creek, WA, USA). Scale bar: 400 µm.  
Because the attempts at transfection of low FR-expressing 4T1 cells with mouse 
FOLR1 did not generate a stable construct for experiments on folate targeted compounds, 
MDA-MB-468 human breast cancer cells were reassessed. In addition to MMP 
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expression, Figure C-2 above demonstrates relatively high FR expression by MB-468 
cells in our laboratory that is contrary to previous reports
160
. Hence, MB-468 cells 
presented another option for constructing cells with different experimental conditions for 
folate targeting experiments by knocking down this FR expression. However, before 
proceeding to manipulate gene expression by these cells, the previous reports of MMP 
expression levels
161
 were also investigated. Shown in Figure C-5, MB-468 cells 
expressed a substantial amount of MMP7 and much lower levels of MMP2 and MMP9, 
recapitulating the results reported by Giambernardi et al
161
 with the exception of MMP14 
expression. 
 
Figure C-5: Expression of selected MMPs by MDA-MB-468 cells 
The expression of MMPs 2, 3, 7, 9, 13, and 14 by MDA-MB-468 cells was qualitatively 
assessed by RT-PCR using the DNA oligo primers and reaction conditions reported by 
Giambernardi et al
161
. With the exception of a lack of MMP14 expression, these results 
corroborate the reported findings for MMP expression. 
Because relatively high expression of MMP14 by MB-468 cells has been reported
161
 
and my earlier qPCR experiments detected MMP14 expression by MB-468 cells (Figure 
C-2), RT-PCR analysis was repeated using different primers and MDA-MB-231 cells as 
a positive control. In this experiment, MMP14 expression by both MB-231 and MB-468 
cell lines was confirmed, as seen in Figure C-6. 
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Figure C-6: MMP14 expression by MDA-MB-231 and MDA-MB-468 cell lines 
Expression of MMP14 by MDA-MB-231 and MDA-MB-468 metastatic breast cancer 
cells lines was qualitatively assessed by RT-PCR using primers from the Human MMP14 
Quantitect Primer Assay (Qiagen, Valencia, CA, USA). Negative control reactions were 
performed in parallel using either MB-468 RNA or molecular biology grade water in place 
of a cDNA template. 
With the expression of FRα and MMPs by MB-468 cells confirmed, a strategy was 
developed to manipulate MB-468 cells to provide different experimental conditions for 
folate targeting experiments. FR-knockdown cells were constructed by infecting MB-468 
cells with lentiviral particles containing vectors encoding short hairpin ribonucleic acid 
(shRNA) sequences designed to interfere with FOLR1 expression. Mission® shRNA 
lentiviral transduction particles targeting human FOLR1 knockdown were obtained from 
Sigma Aldrich (St. Louis, MO, USA). Particles encoding three different targeted shRNA 
sequences were used to infect MB-468 cells according to the supplier’s instructions: 
i. #343: CCGGCCCACTGTTCTGTGCAATGAACTCGAGTTCATTGCACA-
GAACAGTGGGTTTTTG 
ii. #344: CGGGCTTCTCAATGTCTGCATGAACTCGAGTTCATGCAGAC-
ATTGAGAAGCTTTTTG 
iii. #347: CGGGTGAGCAATGGTGGGAAGATTCTCGAGAATCTTCCCAC-
CATTGCTCACTTTTTG 
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Following lentiviral transduction, infected cells were grown in RPMI-1640 cell 
culture medium (Life Technologies, Carlsbad, CA, USA) supplemented with 5-10% fetal 
bovine serum (FBS) and  0.5 µg/mL puromycin to select for cells expressing the shRNA 
knockdown vectors.  
It was also desirable to develop a condition in which the expression of FR by cells 
was increased above endogenous levels. FR expression and/or folate binding capacity of 
some cells has been shown to be increased by incubating cells in folate-deficient 
media
61,163
. For example, the folic acid binding capacity of M109 murine lung carcinoma 
cells was reportedly increased by as much as 20-80-fold after as little as 24 hours in 
folate-deficient  RPMI-1640 medium
61
. Recapitulating these studies, MB-468 cells were 
grown in RPMI-1640 and folate-deficient RPMI-1640 media supplemented with 5-10% 
FBS in parallel. 
The expression of FOLR1 and protein levels of FRα in parental and manipulated MB-
468 cells were subsequently characterized by qPCR and Western blotting to assess the 
degree of gene and protein knockdown (see Figure C-7). Cells expressing targeted 
shRNAs expressed the FORL1 gene at levels 40-75% lower than cells infected with a 
nonspecific control shRNA. FRα protein levels in lysates from MB-468 cells infected 
with targeted shRNAs were lower than levels in parental cell lysates. Conversely, cells 
grown in folate-deficient RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) 
exhibited increased levels of FRα protein. 
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Figure C-7: Knockdown of FRα expression in MDA-MB-468 cells by shRNA 
MB-468 cells were infected using lentiviral transduction particles carrying vectors for the 
expression of shRNA directed against the expression of the FOLR1 gene. A non-specific 
shRNA (shCtl) was used in parallel as a negative control for knockdown effects.  
(A): Quantitative assessment of gene expression by RealTime PCR indicates 40-75% 
knockdown of gene expression by MB-468 cells infected with targeted shRNAs. Values 
represent average of triplicates. Error bars: standard deviation. (B): FRα protein levels in 
lysates from MB-468 cells infected with targeted shRNAs were lower than levels in 
parental cell lysates. MB-468 cells grown in folate-deficient RPMI-1640 medium (Life 
Technologies, Carlsbad, CA, USA) exhibited increased levels of FRα protein. Cell lysate 
samples were standardized to total protein content as measured by BCA assay. FRα 
protein was stained using a rabbit anti-FR polyclonal antibody obtained from AbCam 
(Cambridge, MA, USA). 
FRα is a GPI-anchored recycling receptor that is internalized by cells along with any 
bound ligands (i.e. FA or folates). Previous studies have shown that the high affinity of 
FA for FR and the rate of internalization of ligand-bound receptors is largely unaffected 
by FA conjugation to other molecules
136,164
. However, the rate of receptor recycling may 
vary considerable between different cell types, a factor that may greatly influence the 
capacity for folate-mediated drug delivery to a particular cell type and may even 
determine what frequency of dosing is most efficient
136
. Folate binding capacity has 
previously been reported using radiolabeled ligand assays that require special handling 
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and safety equipment
61,136,163
.  I developed an alternative measure of folate binding 
capacity using a comparatively more economical strategy employing indirect flow 
cytometry to measure the amount of FRα present on the surface of cells. Briefly, cells 
were harvested from subconfluent cultures using enzyme-free cell dissociation buffer 
(Life Technologies, Carlsbad, CA, USA), rinsed and resuspended in AutoMACs buffer 
(Miltenyi Biotec, San Diego, CA, USA) containing 3% bovine serum albumin (BSA) and 
kept on ice during all subsequent steps leading to analysis by flow cytometry. After 
blocking using a rat anti-CD16/32 (Fcγ III/II) antibody, cells were either labeled with a 
rabbit anti-FR polyclonal antibody (AbCam, Cambridge, MA, USA) or washed in 
AutoMACs to provide no-primary controls for secondary antibody staining. For detection 
by the cytometer, cells were then labeled with a FITC-labeled goat anti-rabbit secondary 
antibody. Cell suspensions were filtered through 70 µm cell separating filters and then 
counted using a BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA). 
The effect of growth in folate-deficient medium on cell surface FRα levels of several 
cell lines was assessed using this assay. As demonstrated in Figure C-8, surface 
expression of FRα was measurable in these cell lines. Furthermore, the average 
fluorescence intensities of these cell lines increased subsequent to growth in folate 
deficient media. With optimization, these techniques for manipulating and measuring the 
folate binding capacity of cells should prove useful in the design and implementation of 
experimental tumor models with folate-targeted molecules such as FTPNBs. 
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Figure C-8: Folate binding capacity of cell lines increases after growth in folate-deficient medium 
FRα levels on the surfaces of MDA-MB468 human breast cancer (A), B16 mouse 
melanoma (B), Lewis rat lung carcinoma (LLC)(C), and R221A mouse breast cancer cells 
(D) were assessed by indirect flow cytometry after growth in standard or low FA RPMI-
1640 cell culture media. Control reactions substituting buffer only for anti-FR antibodies 
were performed in parallel to control for nonspecific fluorescence. 
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